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ABSTRACT
The aim of this study was to investigate the role of the adipokine visfatin as a possible
molecular mediator between obesity and prostate cancer.
Visfatin, an adipokine that is elevated in obesity and has many proposed roles and has
been linked to a variety of cancers. No data pertaining to the role of visfatin in prostate
cancer existed and this was an area that this study looked to address. It is suggested
that obesity is a significant risk factor for prostate cancer; in particular, aggressive
disease and adipokines have been investigated as a link for this hypothesis.
This study presents novel data demonstrating the expression of visfatin in the LNCaP
and PC3 cell lines as well as in benign and cancerous prostate tissue at both mRNA
and protein level. Furthermore visfatin is shown to have functional roles in auto-
regulation and promoting increased cell proliferation in PC3 cells and also showed
further effects with respect to cell migration across a wound. These data gave promise
to develop the study further and evaluate potential mechanisms of action including
common second messenger systems such as MAPK and also other oncologically
multifunctional molecules in the forms of MMP-2/-9. We then demonstrated that visfatin
up-regulated MAPK phosphorylation and MMP mRNA/protein expression and more
importantly MMP-2/-9 zymographic activity. This provided possible mechanisms by
which visfatin may mediate a role for obesity driven aggressive prostate cancer.
The study then looked to evaluate NMN (the byproduct of visfatin catalysed
biosynthetic activity), as well as the visfatin inhibitor FK866 which is being evaluated as
chemotherapeutic agent. Unsurprisingly NMN and FK866 had opposing actions on
proliferation and FK866 was naturally proapoptotic. NMN was able to rescue the effect
of FK866 on PC3 cell apoptosis. Prior studies have shown that NMN did not affect
oncogenes however NMN was found to significantly reduce BAX mRNA expression in
PC3 cells.
The findings are consistent with other studies linking visfatin with cancer states. These
novel data indicate roles for visfatin in prostate cancer and possible mechanisms linking
obesity and prostate cancer.
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CHAPTER 1
GENERAL INTRODUCTION
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CHAPTER 1 GENERAL INTRODUCTION
THE PROSTATE GLAND
ANATOMY AND HISTOLOGY
The embryological origin of the prostate gland is from the urogenital sinus and its
development in foetal life is driven by androgens. It is part of the male reproductive
system and its major role involves the synthesis and storage of seminal fluid.
Anatomically it is located deep in the pelvis surrounding the proximal urethra at the
base of the bladder and is anterior to the rectum. 70% of the gland is primarily
composed of glandular elements with the remaining 30% being made of fibromuscular
stroma. The fibromuscular stroma is continuous with the prostatic capsule and is
composed of collagen and large amounts of smooth muscle (Wein 2007).
Tubuloalveolar glands make up the majority of the glandular element of the prostate
and are lined with simple columnar epithelium. McNeal (McNeal 1981) divided the
prostate into 3 distinct zones based on the glandular components; location, embryonic
origin and differing pathological lesions.
 The transitional zone is endodermal in origin and surrounds the pre-prostatic
(proximal) and prostatic (distal) urethra. It accounts for 5-10% of the prostatic
glandular tissue and is the region where the majority of benign prostatic
hyperplasia (BPH) arises. Approximately 20% of prostate cancer (CaP) arises
from this zone.
 The central zone is a cone shaped region arising circumferentially from around
the openings of the ejaculatory ducts. Embryologically speaking it is of Wolffian
21
duct origin and comprises 25% of the prostatic glandular tissue; this area is
immunohistochemically distinct from the remaining prostate gland and is
relatively resistant to disease contributing to only 1-5% of CaP.
 The peripheral zone makes up the bulk (70%) of the prostatic glandular tissue,
covering the posterior and lateral aspects of the gland. This zone is mesodermal
with respect to its embryological origin and is the area where the majority of
prostatic adenocarcinomas arise.
Each zone consists of ducts and acini lined by an epithelial bi-layer of basal cells, which
lies beneath the secretory luminal cells, and mingles with neuro-endocrine cells. Basal
cells are typically androgen receptor (AR) negative and consist of self-renewing stem
cells that differentiate into transit amplifying (TA) cells, also AR-negative and are of
limited proliferative capacity. The TA cells then clonally expand, differentiate and move
up from the basal to luminal layer where they again differentiate to form mature AR-
positive luminal cells that are non-proliferative (Litvinov, De Marzo et al. 2003; Uzgare,
Xu et al. 2004; Uzgare and Isaacs 2005).
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Figure 1.1 Diagram showing the anatomical location of the p
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Figure 1.3 Schematic diagram showing the zonal anatomy of the prostate gland
(adapted from Lavoipierre (2000)).
NORMAL PHYSIOLOGY
Multiple factors such as steroid hormones, endocrine and peptide growth factors,
extracellular matrix factors and epithelial-stromal cell interactions regulate normal
prostatic growth. These interactions are complex and still incompletely understood and
are still being investigated. The pioneering work by Charles Huggins in the 1930’s
demonstrating that castration or oestrogen administration resulted in prostate glandular
atrophy, which could be reversed by the administration of androgen (Huggins 1940)
has laid the foundation for androgen studies in CaP.
ANDROGENS
Testicular Leydig cells are responsible for the production of testosterone under the
control of the hypothalamo-pituitary-testicular axis and account for the bulk (95%) of
circulating androgens; the remaining 5% of androgens are produced by the adrenal
glands and peripheral conversion of oestrogen by aromatase. Testosterone is mostly
bound by sex-hormone binding globulins (SHBGs) and circulates in the plasma and
Transition zone
Peripheral
zone
Central zone
SEMINAL
VESICLE
VAS
DEFERENS
JUNCTION OF PROXIMAL
AND DISTAL URETHRA
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only free testosterone is available for transport into prostate cells by diffusion.
Androgens are essential to the normal development of the prostate gland during
embryonic development. It is dihydrotestosterone (DHT) which is produced from the
metabolic conversion of foetal testosterone by 5α-reductase (located within the 
urogenital sinus) which drives prostate growth in the foetus.
Testosterone is integral in the post-natal maintenance of normal secretory functions of
the prostate gland.
Although testosterone is capable of direct ligand binding to the androgen receptor, 90%
is converted to the predominant prostatic isoform, DHT, by 5α reductase type II (5αR-II) 
within the prostate. In the secretory epithelial cells within which testosterone is able to
directly bind via the androgen receptor, 5αR-II does not appear to be present but is 
present in the basal epithelium and stromal cells. This being said, it does appear that a
fraction of the DHT produced by the epithelial and stromal cells is able to diffuse into
adjacent secretory epithelial cells and exert a paracrine effect resulting in AR activation.
It should be noted that DHT has a much higher affinity for the AR than its precursor
testosterone and is therefore a more potent androgen. Androgen binding to the AR
results in translocation of the receptor to the cell nucleus where the androgen-AR
complex binds to specific DNA binding sites promoting the transcription of various
genes and eventually protein synthesis. Therefore, the AR serves a central role in the
mediation of androgen responses (Isaacs and Isaacs 2004).
By removing the androgen stimulus from prostatic cells an inactivation of androgen
dependent genes results such as prostate specific antigen (PSA) but also key genes
involved with apoptosis (Kyprianou and Isaacs 1989). Despite the afore-mentioned
importance of androgens for normal prostate development there is no current evidence
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that they have direct carcinogenic properties on the prostate despite the fact that
androgens are well known to regulate many growth factors and their receptors. In the
clinical setting it has been demonstrated that androgen therapy does not lead to an
increased risk of CaP (Isbarn, Pinthus et al. 2009).
The traditional paradigm of the androgen receptor pathway as described above, results
in a significant delay between ligand binding and the effect. It has however now been
shown that androgens can exert a more rapid action via reported membrane receptors
that have been detected in CaP tissue (Stathopoulos, Dambaki et al. 2003). Once
bound by androgen these membrane receptors cause a rapid induction of calcium
mobilisation, resulting in cell signalling pathway activation and alteration in the actin
cytoskeleton mediated by PI-3K activation and accompanied by the downstream
upregulation of the Rho small GTPases Cdc42, Rac1, RhoA and RhoB (Lieberherr and
Grosse 1994; Lyng, Jones et al. 2000; Papakonstanti, Kampa et al. 2003). The same
group also showed the greater expression of these androgen membrane receptors in
cancerous vs. benign prostate tissue (Stathopoulos, Dambaki et al. 2003). The
activation of the membrane receptors has also been shown to have further effects
pertaining to apoptosis induction and concomitant reduction in cell proliferation as well
as cell motility and adhesion (Hatzoglou, Kampa et al. 2005); the effects observed as a
result of activation of these membrane receptors appear to be independent of the
nuclear androgen receptor in both nuclear androgen receptor positive and negative cell
lines.
On review of the literature membrane androgen receptors have been identified and it is
suggested that they play a significant role in apoptotic control via modulation of the
actin cytoskeleton and downstream pathways. The physiological role in CaP remains
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unclear however the experimental response to testosterone show significant potential
for a clinical use based on the following:
 membrane AR is selectively over-expressed in high grade CaP compared to
samples benign prostate hyperplasia patients or healthy subjects (Stathopoulos,
Dambaki et al. 2003).
 membrane AR ligands (testosterone-BSA conjugates) induced apoptosis of prostate
cancer cells in vitro and in vivo (Hatzoglou, Kampa et al. 2005; Kampa, Kogia et al.
2006).
 membrane AR induced apoptosis is independent of nuclear AR status and is still
ongoing in the presence of anti-androgens (Hatzoglou, Kampa et al. 2005; Kampa,
Kogia et al. 2006).
 Lastly, membrane AR activation potentiates paclitaxel action in hormone sensitive
and refractory cell lines and derived xenografts in animals (Kampa, Kogia et al.
2006)
These rapid acting membrane receptors are still the subject of much investigation
however further investigation will prove important as they may provide an angle for
future CaP treatment targets.
STROMAL-EPITHELIAL INTERACTIONS
Fibromuscular stroma within the prostate is made up of AR-positive smooth muscle
cells and fibroblasts. When stimulated by androgens they release various growth
factors including basic fibroblast growth factor (bFGF), epidermal growth factor (EGF),
transforming growth factor-β (TGF- β) and insulin-like growth factor (IGF) that exert 
paracrine effects on neighbouring epithelial cells. The above-mentioned proteins bind to
their receptors on the TA cells and are participants in cell cycle regulation. The survival
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of the AR-positive luminal cells is still dependent on these factors although they do not
undergo proliferation in response to androgen-stimulated growth factors. Binding of
androgens to the AR in the luminal cells, however, suppresses their proliferation and
instead induces differentiation thus regulating their production of various secretory
proteins including PSA (Litvinov, De Marzo et al. 2003; Uzgare, Xu et al. 2004; Uzgare
and Isaacs 2005).
CARCINOMA OF THE PROSTATE (CAP)
EPIDEMIOLOGY
CaP is the commonest non-cutaneous malignancy in men and the second leading
cause of cancer-related death worldwide, accounting for almost 10% of all cancers in
men (Parkin, Bray et al. 2001). From the year 2000, CaP became the most frequently
diagnosed cancer in men in the U.K, with over 24,000 new diagnoses, with the cancer
specific mortality rate reaching 35 per 100,000 in 2001 (Melia 2005). There are marked
differences between the incidence of clinically significant disease worldwide however
incidental non-clinically relevant disease is still equal. Canada has one of the highest
incidence rates and this follows with many western countries including the USA and
UK. There are even significant variations between northern and southern countries
within Europe, with CaP incidence and mortality being highest in England and Wales,
and lowest in Mediterranean countries (Quinn and Babb 2002). The incidences of CaP
are increasing, across the world including countries like Japan, China and India, which
historically have reported the lowest rates (Melia 2005).
The increased incidence amongst the developed countries is attributable to several
factors. The routine examination of transurethral prostatectomy (TURP) histology
specimens with improved techniques and rationalised sampling is one such reason and
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another being the longer life expectancy of men. The use of serum analysis for PSA as
a marker for CaP has also a role to play in the increased incidence particularly in the
more developed countries and this is being heavily studied at present with major
studies both in Europe and North America (Eckersberger, Finkelstein et al. 2009).
Despite our improved ability to detect CaP in the context of an aging population the
global increases in CaP incidence suggests that environmental factors are contributing
to the pathogenesis of this disease and one cannot simply attribute increased incidence
to increased detection.
AETIOLOGY
The specific causes of CaP are unknown. There are many established risk factors
associated with the development of cancers and CaP is no exception; age, ethnicity
and family history/genetic factors are al implicated. However, there is increasing
evidence for the role of other factors such as diet, lifestyle, endogenous hormone
profile and obesity in the aetiology of the CaP (Venkateswaran and Klotz 2010)
AGE
CaP is a disease that increases in prevalence with old age. Over 75% of new cases are
diagnosed in men over the age of 65 years. Gann (Gann 2002) has studied age-
specific incidence and shown that CaP risk begins to rise sharply after the age of 55
and peaks at age 70-74 years. It should be noted that there has been a recent increase
in the incidence within the age group of 50-59 and it can be speculated that this rise
may well be secondary to the increased use of PSA as an opportunistic screening tool.
ETHNICITY
The highest incidence of CaP is within African American men in the U.S.A. This group
has a 60% increased risk of developing CaP, a 2 fold increased risk of developing
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distant disease and twice the mortality relative to Caucasians (Hoffman, Gilliland et al.
2001; Jemal, Murray et al. 2003). Countries such as Japan and China have relatively
low rates of CaP within the native population. The reason for this is multi-factorial and
the genetic role as well as diet and socioeconomic status have been put forward.
GENETIC FACTORS
Less than 10% of all CaPs are hereditary. The two main characteristics of hereditary
CaP are young age of onset, multiple affected first degree relatives and the increased
risk is thought to be due to autosomal dominance of rare but highly penetrant genes
(Carter, Beaty et al. 1992). Genes such as HPC1, HPCX, and HPC2/ELAC2 have
been identified as hereditary CaP genes and they have been found to have genetic
locus heterogenecity making them a difficult topic to study.
There are also several low-penetrance genes which can not only alter the way
individuals respond to both environmental factors but can also interact with other
genes.  Two examples of this include vitamin D  polymorphisms and 5α-reductase type 
2 gene polymorphisms. Both are associated with increased CaP risk and the latter may
allow a greater conversion of testosterone to DHT by enhancing the degree of
enzymatic activity within the prostate.
ENDOGENOUS HORMONE PROFILE
Higher levels of circulating androgen levels in African-American men as compared to
white men (Ross, Bernstein et al. 1986), have been suggested as the cause for their
higher incidence of CaP based on the fact that CaP is dependent on androgen growth.
Although this would make a compelling hypothesis, there is still much debate about the
relationship between circulating androgens and intra-prostatic androgen levels.
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IGF-1 levels, which have been shown to have mitogenic and anti-apoptotic effects, are
positively correlated with CaP risk (Chan, Stampfer et al. 1998).
DIET
Diet has been long postulated as a risk factor for CaP and especially given the
geographical variation in incidence in CaP. One of the best examples of dietary
difference is the high calorie and saturated fat diet found in the West. In vitro studies
have shown that high saturated fat levels are stimulatory to prostate cell growth
compared to a slower growth of androgen sensitive cells that are exposed to low levels
of saturated fat (Wang, Corr et al. 1995; Pandalai, Pilat et al. 1996; Ngo, Barnard et al.
2004). Cohort studies in the most part have shown no significant association between
dietary fat intake and CaP (Mills, Beeson et al. 1989; Hsing, McLaughlin et al. 1990;
Schuurman, van den Brandt et al. 1999), some, however, have found a link between
animal fat consumption and CaP risk (Gann, Hennekens et al. 1994; Le Marchand,
Kolonel et al. 1994). Postulated mechanisms by which dietary fat may be implicated in
CaP are: alteration of serum androgens, IGF-1 levels and free radical or pro-
inflammatory fatty acid metabolite production (Sonn, Aronson et al. 2005).
The differences in the dietary consumption of soy products particularly in Asian as
compared to Western countries may explain the significant difference in CaP incidence
between these geographical areas. Soy contains high levels of phyto-oestrogens
(isoflavones) which have weak oestrogenic activity which are suggested to have anti-
carcinogenic properties (Adlercreutz 2002).
Elevated dietary calcium has been suggested as a risk factor for CaP (Chan,
Giovannucci et al. 1998; Giovannucci, Rimm et al. 1998). The elevated calcium levels
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are thought to suppress the levels of vitamin D metabolite 1,25-dihydroxy vitamin D
which has anti-proliferative effects (Barreto, Schwartz et al. 2000).
TUMOURIGENESIS: CELL PROLIFERATION, THE CELL CYCLE,
APOPTOSIS AND FACTORS CONTROLLING THEIR REGULATION (BCL-2,
BAX, MCL-1, BCL2-L1, IGF-R)
Tumourigenesis is a product of dysregulated or deregulated cellular proliferation. This
deregulation is the complex product of several successive genetic events that gradually
lead to tumour formation. There is a delicate balance between growth factors and
apoptotic agents in the regulation of prostate growth (Reynolds and Kyprianou 2006). It
is disruption at this level which leads to the loss of apoptosis and the over-expression of
factors promoting cell survival and proliferation and subsequent tumour development.
Once cell proliferation is uncontrolled, prostate cancer progression is associated with a
variety of growth factors and their respective signaling pathways (Djakiew 2000).
Growth factors can be categorized into three distinct groups: traditional growth factors
i.e. those that increase cell proliferation e.g. Insulin-like growth factor-1 (IGF-1);
negative growth factors i.e. those which inhibit cell proliferation/induce apoptosis e.g.
transforming growth factor-β (TGF-β), and angiogenic factors e.g. fibroblast growth
factor (FGF).
The human cell cycle broadly consists of four stages: The first three stages combined
can be grouped together under the umbrella term of ‘interphase’. This encompasses
G1 (gap 1) i.e. the phase when the cell prepares to duplicate its DNA in preparation for
cell division; S-phase (synthesis phase) i.e. when the cell duplicates its DNA; G2 (gap
2) i.e. when the cell prepares to divide; The final phase is M-phase during which the cell
actually divides and undergoes mitosis; cells that are quiescent are said to be in the G0
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phase (Garrett 2001). Disruption of the cell cycle inhibits potential apoptosis which
normally takes place if the cycle is arrested (Norbury and Zhivotovsky 2004). This
disruption can allow mutations to be transferred to the daughter cells.
2 potential points of control in the cell cycle which are the G1S and G2M check points,
and, can be controlled by a sequence of various positive and negative proteins (Garrett
2001). As well as understanding the cell cycle, it is important to evaluate the apoptotic
mechanisms as it is another key process which can be altered resulting in
tumourogenesis.
APOPTOSIS AND ITS REGULATION
Apoptosis relates to programmed cell death. Apoptosis can be triggered by a multitude
of stimuli either intrinsic or extrinsic to the cell, e.g. by ligation of cell surface receptors,
by DNA damage, treatment with cytotoxic drugs, or by developmental death signals
(Norbury and Zhivotovsky 2004). These diverse signals appear to eventually activate a
common cell death pathway leading to programmed cell death or apoptosis.
One of the mechanisms of extrinsic induced apoptosis is the activation of
transmembrane death receptors for the ligands of CD95/tumor necrosis factor family
via multiprotein complexes and activation of the cysteine aspartyl proteases (caspases)
cascade (Ashkenazi and Dixit 1998).
The mitochondria can not only amplify the above process from extrinsic stimuli but also
initiate or propagate the death signals intrinsically from stimuli such as DNA damage,
oxidative stress and starvation (Kaufmann and Earnshaw 2000). The majority of
mechanisms involve the disruption of the mitochondrial inner transmembrane potential
(Dy) as well as the so called permeability transition (PT), this in turn leads to the
opening of the permeability transition pore (PTP) complex which is located in the
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mitochondrial membrane. This also triggers the corresponding release of apoptogenic
proteins such as cytochrome c and apoptosis inducing factor (AIF) which can in turn
activate caspases. The release of caspases and cytochrome c from the mitochondrial
intermembrane space into the cytosol after PTP formation is a crucial event inducing
apoptotic cell death (Loeffler and Kroemer 2000). Alternatively mechanisms involving
factors released from mitochondria can lead to programmed cell death (Green and
Reed 1998).
A distinct evolutionary advantage is gained with apoptosis only allowing undamaged
cells to be replicated and is normally triggered when the cells are unable to arrest the
cell cycle or institute DNA repair. However, aberrant apoptotic regulatory mechanisms
that allow damaged cells to continue replicating are a hallmark of cancer development
and progression.
A key apoptotic regulator is TGF-β. In the normal prostate, TGF-β has been shown to 
inhibit epithelial cell proliferation and promote apoptosis i.e. acts like a tumour
suppressor (Bello-DeOcampo and Tindall 2003)..
TGF-β has paracrine like activity upon its release from prostatic stromal cells leading to 
the inhibition of prostatic cell growth via apoptosis (Wu, Sun et al. 2001; Bhowmick,
Coad et al. 2004). TGF-β stimulates a multiple downstream targets – all of which have 
antiproliferative or apoptotic effects (Reynolds and Kyprianou 2006). TGF-β receptor 
activation leads to the transcription of BAX, a proapoptotic factor and deactivation of
BCL-2, (see below). Thus inhibition of this negative growth factor could lead to
tumourigenesis.
Two further examples of classic apoptotic regulators are p53 and BCL-2, and these
have been proved to have abnormal function and expression in prostate cancer
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progression and the subsequent progression to hormone resistance (Quinn, Henshall
et al. 2005).
Tumour suppressor genes and oncogenes are both involved in manipulating the above
processes. Tumour suppressor genes are normal genes that allow the cell to enter G0
phase and allow DNA repair, or arrest the cell cycle and carry out apoptosis. Mutations
or inactivation in tumour suppressor genes allow development of tumours. Several
different tumour suppressor genes have been identified and some of them include p53,
BRCA1, BRCA2 (Oesterreich and Fuqua 1999)
An key difference between oncogenes and tumour suppressor genes is that oncogenes
result from the activation (turning on) of proto-oncogenes. Oncogenes encode proteins
that can affect cell proliferations and apoptosis or potentially both.
The BCL family has been previously documented to be involved with prostate
carcinogenesis.
BCL-2
The BCL-2 gene family encodes a group of proteins directly involved in regulating
apoptosis. They can be either proapoptotic (BCL-2, BCL2-L1 MCL-1) or antiapoptotic
(BAX, BAK, BCL-xS, BAD, BID) (Adams and Cory 1998). Reed demonstrated that it
was the selective and competitive dimerisation between pairs of pro- and antiapoptotic
family members that inferred how the cell will behave following stimuli (Reed 1994).
BCL-2 is not expressed in the normal prostate however the BCL family of genes are
commonly expressed in both primary and metastatic CaP (Hughes, Murphy et al.
2005). BCL-2 is one of the oncogenes implicated in the progression to the androgen-
independent CaP as well as high grade disease (McDonnell, Troncoso et al. 1992). The
adipokine adiponectin has been shown to have anti-apoptotic and cytoprotective effects
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on human neuroblastoma cells via regulation of BCL-2 (and BAX) expression (Jung,
Lee et al. 2006; Jung, Lee et al. 2006). It is therefore of note that adipokines can have
varying effects on BCL-2 expression and by inference oncogene manipulation
depending on the cell type. It has also been discovered that adiponectin and leptin
interact to modulate the oncogenes p53 and BCL-2 and hence proliferation in PC3 cell
lines (Mistry, Digby et al. 2008). Further proof of this concept is noted in that leptin
alters the BCL-2:BAX ratio in pancreatic beta cells and thus inhibits apoptosis (Brown
and Dunmore 2007). For this reason I sought to identify if visfatin affects multiple
members of the BCL-2 family. Multiple oncogenes are continually being discovered.
Many growth factors have been described. Below I use IGF-1 to illustrate an example
of growth factors influence on cellular proliferation.
One of the most commonly reported changes associated with CaP are the changes in
endocrine growth factor loops. In the advanced stages of prostate cancer, insulin-like
growth factor-1 receptor (IGF-1R), and other GFRs have been frequently shown to be
over-expressed, and an interaction of these receptors has been increasingly elucidated
(Papatsoris, Karamouzis et al. 2005). IGF-1R has also been reported as a novel
oncogene in recent times (Werner and Bruchim 2009).
Low levels of IGF-1 production can be demonstrated in nearly all cells (Reynolds and
Kyprianou 2006). IGF-1 ligand binding to its corresponding receptor activates signaling
pathways that contribute to nearly 50% of cell growth and proliferation (Baserga,
Peruzzi et al. 2003).
Androgen stimulation leads to IGF-1 production with a resultant paracrine effect on the
surrounding prostatic epithelial cells, leading to increased proliferation (Moschos and
Mantzoros 2002; Bogdanos, Karamanolakis et al. 2003). In healthy cells, the IGF-1
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pathway is regulated by IGF binding proteins (IGFBPs) (Grimberg and Cohen 2000).
The downstream targets of the IGF-1 signaling axis ultimately promote cell survival.
A positive correlation between plasma IGF-1 levels and CaP progression has drawn the
conclusion that IGF-1 is an aetiological factor in CaP (Stattin, Rinaldi et al. 2004)
MITOGEN-ACTIVATED PROTEIN KINASES (MAPK) ERK 1/2 AND P38
As summarized in Figure 1.4 a multitude of growth factors, cytokines, and proto-
oncogene products impart stimuli through the activation of the small G protein Ras and
subsequently of the MAPK network which result in large proportion of key cellular
operations for example proliferation, apoptosis and differentiation. Three of the major
MAPK include the extracellular-signal regulated kinase (ERK; p42/44 MAPK), p38
MAPK and c-jun N-terminal kinase (JNK; stress activated protein kinase-1 SAPK1).
Figure 1.4 Diagram showing the potential second messenger pathways involved. From
Papatsoris 2007, (Papatsoris, Karamouzis et al. 2007)
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One key observation is that MAPK activity has been demonstrated to be implicated with
progression of disease to the more aggressive and advanced hormone-independent
state (Uzgare and Isaacs 2004; Oka, Chatani et al. 2005). Importantly, it has been
reported that the effect of phosphorylated ERK (pERK) on prostate cancer cells is to
enhance proliferation or mitogenesis and is therefore inversely related to apoptosis
(Cross TG 2002). It is also possible that the relative activation of ERK1 and ERK2 can
have differing effects on prostate carcinogenesis. These observations highlight the
importance of ERK activation in this model of disease.
p38 MAPK is mainly activated via external stimuli which in this case would be
represented by exogenous visfatin and has been broadly associated with induction of
apoptosis (Cross TG 2002). There is however also evidence that activation of p38 may
cause increases in cell proliferation in prostate cancer in response to external stimuli,
and that its over-expression is implicated in increased cell proliferation (Ricote, Garcia-
Tunon et al. 2006). It has been suggested that it is the ratio of p-ERK to p-p38 MAPK
that may be useful in identifying the action of CaP or other solid tumours in vivo
(Aguirre-Ghiso, Estrada et al. 2003).
ANGIOGENESIS AND DISEASE PROGRESSION
Angiogenesis is the process of developing new blood vessels and is interplay between
a variety of activators and inhibitors. Angiogenesis thought to be driven by a hypoxic
stimuli and this leads to activation of endothelial-cell proliferation and migration via
tyrosine kinase ligands (Carmeliet 2000) e.g. vascular endothelial growth factor
(VEGF), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF) and
epidermal growth factor (EGF). These are counterbalanced by the inhibitors endostatin
and angiostatin. Overall it is a balance between the activators and inhibitors of
angiogenesis that dictate whether an endothelial cell will become angiogenic.
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It has been shown that CaP express VEGF-A and this is a significant mechanism in the
disease progression (Yu, Jain et al. 2010). Along with the balance of angiogenic factors
and neovascularisation allowing nutrient delivery to invading tumour, the metastatic
potential of a tumour is also dependent on features such as degradation of extracellular
matrix. Matrix metalloproteinases are a group of agents that are involved in the
degradation of the basement membranes. A positive correlation between tumour
progression and the expression of the MMPs in tumours has been demonstrated
human and animal studies (Stetler-Stevenson 1996; Ellerbroek and Stack 1999). The
activity of MMPs is regulated by natural inhibitors called tissue inhibitors of matrix
metalloproteinases (TIMP). MMP-2 is inhibited by TIMP-2/-4, while MMP-9 is inhibited
by TIMP-1 (Schaefer, Han et al. 1997; Bee, Barnes et al. 2000). An imbalance between
these two groups of proteins has been shown to be linked with a variety of different
tumours, including prostate (Boag and Young 1994).
MATRIX METALLOPROTEINASES (MMPS)
Matrix metalloproteinases in particular MMP-2 and -9 (gelatinases) are proteases that
are involved in the breakdown of the extracellular matrix (ECM) under both
physiological and pathological conditions (Saarialho-Kere, Chang et al. 1992; Adya,
Tan et al. 2008). More specifically, they degrade type IV collagen, the major structural
component of basement membranes and are crucial to the process of cell migration,
invasion and metastasis. Both MMP -2 and -9 are known to be highly expressed in
prostate cancer tissue (Wilson, Gallagher et al. 2004) and circulating levels of MMP-2
and -9 have also been correlated with bone metastases and tumour grade in prostate
cancer patients (Incorvaia, Badalamenti et al. 2007). A dysregulation of MMP biology
can lead to a wide range of pathologies including tumour neovascularisation,
aneurysms, atherosclerosis, rheumatoid arthritis etc (Woessner 1998).
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Dysregulation of MMP activity can have a role in cancer development and progression
but it is thought that early expression in a tumour related environment is involved in
ECM remodelling which in turn leads to the release of ECM along with membrane-
bound growth factors to alter the environment in a fashion which allows the tumour to
thrive. MMP-2 and MMP-9, are also known to be key in the regulation of angiogenesis
(van Hinsbergh, Engelse et al. 2006), which is a well known component of tumour
progression and metastasis. This angiogenic process can arise early prior to any
malignant transformation, and has been demonstrated by increased vessel density
seen in precancerous lesions (Hanahan and Folkman 1996). The gelatinases have
been shown to also activate growth factors, cytokines, and degradation/activation of
inhibitors of angiogenesis. For example, MMP-9 can cause the onset of tumour
angiogenesis as well as its oppression via the same proteolytic process (Hamano,
Zeisberg et al. 2003). In conjunction with this process the gelatinases, which as
mentioned above can degrade basement membrane components, allow tumor cells to
invade into surrounding tissue. MMPs can contribute to the tumour advancement in
several ways and at a variety of stages; they can remove sites of adhesion and aid cell
migration, expose novel binding sites, and can directly release chemo-attractants from
the ECM (McCawley and Matrisian 2001).
Visfatin has been demonstrated to up-regulate MMP activity in other systems (Adya,
Tan et al. 2008). MMPs are upregulated by various stimuli, one of which includes
vascular endothelial growth factor (VEGF) (Wang and Keiser 1998). VEGF, a
homodimeric glycoprotein, plays an important role in vasculogenesis (Wang and Keiser
1998) and thus an important part of neoplastic growth in supplying oxygen to enlarging
solid tumours. With the aforementioned, this study sought to study the possible
interplay between visfatin and the pro-angiogenic MMP molecules.
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PATHOGENESIS
95% of CaP are adenocarcinomas arising from either the prostatic ductal or acinar
epithelial cells. The remaining 5% of cancers include sarcomas and local invasion by
transitional cell carcinoma (TCC) of the bladder. 70% of cancers arise in the peripheral
zone with 25% arise from the transitional zone and the remainder in the central zone
(McNeal, Redwine et al. 1988); CaP is a multifocal disease with more than 85% of
prostate adenocarcinomas demonstrating this characteristic. CaP is graded using the
Gleason scoring system (Gleason 1966). The Gleason grading system uses a H&E-
stain to describe the histological pattern of carcinoma cells. Specifically, the method
uses low magnification and characterizes the extent of glandular differentiation and the
pattern of growth of the tumor in the prostatic stroma. Five grades were described and
these were illustrated in a drawing by Dr Gleason (Figure 1.5). The grading system
generates a score from 2 to 10. This is calculated by observing the most common
pattern i.e. the primary grade pattern and adding this to the second most common
pattern i.e. the secondary grade pattern.
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Figure 1.5 Gleason Grading system diagram as drawn by Gleason (Gleason 1966)
The prostate gland has no histological capsule and CaP spread is initially along the
course of the autonomic nerves and this is classed as perineural invasion. Local
spread can involve any of the surrounding structures (fig 1.1) such as the seminal
vesicles, prostatic urethra, corpora of the penis and trigone of the bladder although
there is also lymphatic and haematogenous spread to the axial skeleton.
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The multistep or multi-hit hypothesis is a well documented process by which a normal
prostate cell differentiates into a cancerous phenotype. These steps result in the
production of several autocrine growth factors by the CaP cells via AR signalling (Gao,
Arnold et al. 2001). Thus, androgens act in an autocrine manner regulating proliferation
and survival in androgen-sensitive CaP cells (Litvinov, De Marzo et al. 2003),
conversely in healthy normal prostate tissue there is a paracrine, stromal cell
dependent androgen pathway (Uzgare and Isaacs 2005). This androgen response was
the basis for Huggins theory of castration as method of treatment in prostate cancer
(Huggins 1941).
Following the treatment of CaP with anti-androgen therapy all tumours will inevitably
become hormone refractory tumours or androgen-independent CaP. This phenomenon
is hypothesized to occur through the mutations to independent cell clones as opposed
to de-differentiation of the cells. This mechanism has not been elucidated to date but a
progression of the multi-hit hypothesis leading to the accumulation of several mutations
that confer advantage to this androgen insensitive cell type has been suggested
(Uzgare and Isaacs 2005). Frequent genetic changes associated with CaP include
somatic loss of alleles on chromosomes 8, 16 and 18; inactivation of PTEN and p53
tumour suppressor genes (chromosomes 10q and 17p, respectively); activation of c-
myc and bcl-2 proto-oncogenes.
TREATMENT
Treatment for CaP has evolved over the years and varies dependent on the stage,
grade and physiological status of the patient concerned. Local low grade disease can
be managed by ‘Active Surveillance’ protocols as well as other more aggressive
strategies such as radical prostatectomy (healthy men with a life expectancy of more
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than 10 years), external beam radiotherapy, brachytherapy, cryotherapy and high-
intensity focused ultrasound (HIFU).
Once CaP has progressed locally or a patient has distant metastasis, whereby
treatments such as surgery or radiotherapy can no longer offer a curative option,
androgen deprivation becomes the next line of treatment.
The genesis of androgen ablation therapy was primarily thanks to work done by
Huggins and Hodges in 1941 when they reported a good response to castration or
oestrogen therapy with respect to acid and alkaline phosphatase levels (Huggins 1941).
There are several methods that can be employed to cause androgen deprivation
ranging from surgical castration to medical hormone manipulation using; LHRH
agonists, antiandrogens as well as 5-α reductase inhibitors.  Medical manipulation of 
androgen status results in a reduction of PSA and clinical improvement in more than
70% of patients however due to the often advanced stage of disease in this cohort of
patients and progression to the ‘androgen independent’ growth phase the majority of
patients will die within 5 years (Group 2000).
Treatment options for patients reaching this stage of the disease are limited to palliative
as well as cytotoxic options and other limited benefit therapy.
OBESITY AND CAP
Obesity, the most significant and growing public health concern, has reached epidemic
proportions with a prevalence of 60% or more in some Western societies (Simon 2005).
Obesity is well established as a risk factor for type 2 diabetes, cardiovascular disease
and cancer. More specifically, visceral obesity is associated with insulin resistance,
hyperinsulinaemia and prothrombotic/proinflammatory states as well as cancer.
44
(Kershaw and Flier 2004). The state of obesity and metabolic dysregulation and its
associated conditions; type 2 diabetes, dyslipidaemia, atherosclerosis and others, is
termed ‘metabolic syndrome’ (DeFronzo and Ferrannini 1991). Metabolic syndrome is
thought to be becoming endemic in populations with a ‘western’ diet and lifestyle,
insulin resistance appears to play a central role but its mechanisms are still not fully
understood (Ford, Giles et al. 2002).
Multiple studies have been undertaken to try and identify not only if obesity is a risk
factor for prostate cancer but also to try and identify whether it plays a specific role in
disease progression. With respect to the association between obesity and CaP various
studies have been performed. The results for the most part have been inconsistent
(Ngo, Barnard et al. 2004) and this may be due to the varying criteria that are used
between studies (for example body mass index (BMI) vs. waist to hip ratio (WHR)) . von
Hafe et al introduced the concept that visceral fat accumulation as identified on CT
scan is a specific risk factor for CaP (von Hafe, Pina et al. 2004).
Both tumour aggressiveness and mortality from prostate cancer correlate positively with
body mass index (BMI) (Andersson, Wolk et al. 1997; Calle, Rodriguez et al. 2003).
Several studies have also now identified obesity and in particular visceral obesity as a
risk factor for prostate cancer (von Hafe, Pina et al. 2004; Freedland, Wen et al. 2008)
with evidence suggesting that obesity increases the aggressiveness of the disease
(Freedland, Giovannucci et al. 2006; Freedland and Platz 2007). It is therefore
reasonably hypothesised that instead of an absolute increase in prostate cancer risk
obesity is a risk factor for progression of the so termed latent or clinically insignificant
disease group to clinically significant and metastatic CaP (Yip, Heber et al. 1999;
Stattin, Soderberg et al. 2001). A meta-analysis has demonstrated a significant positive
45
correlation with an increased BMI finding a 5% increased risk of prostate cancer per 5
unit rise in BMI (MacInnis and English 2006).
Obesity and the metabolic syndrome have been linked as risk factors to various
cancers which include in particular hormone-dependent cancers such as breast,
endometrial and prostate (Kelesidis, Kelesidis et al. 2006). There are multiple
hypothesized mechanisms for these associations.
One such mechanism is that obesity influences sex steroids, insulin and IGF-1
pathways which are all implicated in the cancer biology (Kaaks and Lukanova 2001).
There are multiple reports on the inverse relationship between serum insulin and
steroid hormone binding globulin (SHBG) levels (Plymate, Hoop et al. 1990; Strain,
Zumoff et al. 1994; Pasquali, Casimirri et al. 1995; Katsuki, Sumida et al. 1996), and
further more it has been demonstrated in hepatoma cells that insulin inhibits SHBG
production (Plymate, Matej et al. 1988). With a reduction in serum SHBG there is an
increase in the level of unbound and therefore active androgen and subsequent risk in
the development of androgen dependent cancers. With regards to the risk of CaP, an
increase in peripheral aromatization of androgens to oestrogens may also be a
contributory factor to this association. Chronic inflammation is also associated with
obesity and there is an increase in the levels of acute phase reactants e.g. tumour
necrosis factor alpha (TNF-α) and activation of pro-inflammatory signalling (Weisberg, 
McCann et al. 2003; Wellen and Hotamisligil 2003). It is well documented in the
literature that chronic inflammation of the prostate is a risk factor for CaP and thus adds
a further possible link between obesity and CaP (Palapattu, Sutcliffe et al. 2005;
MacLennan, Eisenberg et al. 2006).
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White adipose tissue accumulation is a key step in the development of obesity and has
now been well documented as a metabolically active organ rather than a simple store
for energy (Kershaw and Flier 2004). Not only is adipose tissue a site for the
metabolism of androgens but is also the site for the production of multiple biologically
active peptides now termed ‘Adipokines’. (Matsuzawa, Funahashi et al. 1999). Although
termed adipokines these peptides are produced by numerous other cell types in
addition to adipocytes such as stromal cells, macrophages and connective tissue cells,
which may also contribute to adipose tissue mass (Frayn, Karpe et al. 2003; Fain,
Madan et al. 2004). They may function at local (autocrine/paracrine) and systemic
(endocrine) levels, and act as regulators of energy homeostasis as well as contributing
to inflammatory and immune processes. Adiponectin and leptin are almost exclusively
produced by adipocytes and are the most abundantly circulating adipokines; others
include cytokines and growth factors such as tumour necrosis factor-alpha (TNF-α), 
interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and visfatin/PBEF
(Wozniak, Gee et al. 2009).
Serum adipokines have been positively correlated with visceral fat and BMI (Mistry,
Digby et al. 2007; Ritchie and Connell 2007), and their influence on cell biology
(including apoptosis, proliferation and angiogenesis) is under constant study. CaP cells
cultured in the presence of adipocytes demonstrated altered proliferation,
differentiation, growth and cytokine expression (Tokuda, Satoh et al. 2003), and lends
further support that locally produced and circulating adipokines may be important in the
CaP.
Thus, visceral obesity appears to have good rationale as a risk factor for the
development of aggressive CaP. Adipokines, represent a potential molecular
mechanism for this hypothesis. In particular the paracrine effects of adipokines may be
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of relevance in cases of locally advanced CaP where extra-prostatic extension and
invasion into the retropubic fat pad occurs, thus resulting in the direct exposure of
cancer cells to high concentrations of adipokines (Onuma, Bub et al. 2003).
ADIPOKINES AND PROSTATE CANCER
There has been a significant amount of research into the potential roles that adipokines
may play in prostate carcinogenesis, and cancer in general. Two adipokines that have
received the great interest with respect to prostate cancer are leptin and adiponectin.
LEPTIN
Leptin is a 16 kDa adipokine first described by Zhang et al. in 1994 (Zhang, Proenca et
al. 1994). It is primarily produced by adipocytes of white adipose tissue but also to a
lesser extent in other tissues such as the stomach, skeletal tissue and placenta (Zhang,
Proenca et al. 1994). Total body fat concentrations are positively correlated with
circulating leptin concentrations and serum leptin is known to be elevated in obese
individuals (Considine, Sinha et al. 1996). Leptin has been documented to have many
functions including; regulation of satiety (Heini, Lara-Castro et al. 1998), energy
homeostasis (Jequier 2002), neuroendocrine physiology (Ahima, Prabakaran et al.
1996), and it is also speculated to be important in the development and maintenance of
reproductive tissues, including the prostate (Nazian and Cameron 1999).
There have been epidemiological studies evaluating the relationship between obesity,
circulating leptin levels and prostate cancer which have been inconclusive. A case
control study by Lagiou et al. aimed to evaluate the hypothesis that prostate cancer
was correlated with circulating leptin levels. The group failed to identify a significant
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difference in serum leptin levels between men with prostate cancer and matched
healthy controls (Lagiou, Signorello et al. 1998). Conversely a similar study by Chang
et al found after adjusting for variables such as age, testosterone levels and BMI, men
with high-volume disease had elevated leptin concentrations (Chang, Hursting et al.
2001). Lim et al has shown that the expressed degree of leptin is higher in CaP tissue
than in BPH tissue and the group surmised that leptin possibly has an influence on the
occurrence of CaP. These positive findings were also corroborated by Stattin et al. in a
nested case-reference study confirming an association between moderately elevated
leptin concentrations and later development of prostate cancer (Stattin, Soderberg et al.
2001). It should be noted that the above studies were all limited by sample size and in
particular both the studies by Kim et al and Lagiou et al had small numbers of obese
patients included. Another small study by Saglam et al suggested a positive correlation
between serum leptin levels, PSA and Gleason score in CaP patients (Saglam, Aydur
et al. 2003).
In summary the literature suggests that there may be a correlation between leptin
levels, both in serum and tissue, and CaP. The studies need to be reviewed with
caution in particular in view of small sample sizes.
In vitro studies have been performed and tend to support a role for leptin in CaP. In
androgen-independent prostate cancer cell lines leptin has been shown to increase
cellular proliferation (Onuma, Bub et al. 2003). Leptin promotes vascular endothelial
cell proliferation and angiogenesis in-vitro and these effects appear to be both direct
and indirect (Bouloumie, Drexler et al. 1998; Sierra-Honigmann, Nath et al. 1998;
Onuma, Bub et al. 2003). These effects occur via induction of VEGF, transforming
growth factor- (TGF)-β1 and basic fibroblast growth factor (bFGF) (Frankenberry, 
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Somasundar et al. 2004) and it is of importance as these processes are thought to be
crucial factors in cancer progression and invasion.
A variety of second messenger systems have been shown to be involved following
leptin treatment in vitro such as phosphatidyl-inositol 3-kinase (PI3-K) and c-Jun NH2-
terminal kinase (JNK) (Onuma, Bub et al. 2003; Somasundar, Frankenberry et al.
2004). These pathways are of significant interest as they are involved with prostate
carcinogenesis and malignant transformation, but also in obesity and the pathology of
type 2 diabetes (Miyazaki, Bub et al. 2005).
In conclusion the evidence suggests that leptin may well be a factor in CaP although
the evidence is predominantly based on small case controlled studies and in vitro
evidence. Further large scale studies are required to determine if there are significant
correlations between serum leptin concentrations and CaP and in-vivo studies would
help discern whether a significant role in the pathophysiology of CaP exists.
ADIPONECTIN
Adiponectin is also called 30-kDa adipocyte complement-related protein (Acrp30),
adipoQ, APM-1 or gelatin-binding protein-28 (GBP28) (Kelesidis, Kelesidis et al. 2006).
It is the most abundantly circulating adipokine (Kadowaki and Yamauchi 2005).
Circulating levels of adiponectin have been shown to be negatively correlated with
obesity (especially central), body mass index, visceral fat accumulation and insulin
resistance (Chandran, Phillips et al. 2003). Reductions in plasma adiponectin levels
have also been observed in diseases closely related obesity e.g. type 2 diabetes,
cardiovascular disease, hypertension and metabolic syndrome; and furthermore
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adiponectin has been shown to improve these disorders (Kadowaki and Yamauchi
2005).
A small case controlled study has demonstrated that adiponectin levels were
significantly lower in patients with prostate cancer, compared to patients with BPH or
controls (Goktas, Yilmaz et al. 2005). The same study also showed a negative
association between plasma adiponectin concentrations and Gleason score as well as
stage of prostate cancer. Reduced serum adiponectin levels has also been associated
with an increased risk of other hormone-dependent cancers such as breast and
endometrial (Kelesidis, Kelesidis et al. 2006), and also alarmingly and increased risk of
aggressive disease (Miyoshi, Funahashi et al. 2003; Petridou, Mantzoros et al. 2003;
Mantzoros, Petridou et al. 2004).
Miyazaki et al demonstrated the presence of adiponectin receptors in the LNCaP-FGC
(fast growing colony), DU145, and PC-3 prostate cancer cell lines (Miyazaki, Bub et al.
2005). Adiponectin was also shown to activate the JNK and activator of transcription 3
(STAT3) as common downstream effectors (Miyazaki, Bub et al. 2005). Both JNK and
STAT3 play crucial roles in regulating cell proliferation, differentiation, and apoptosis in
particular in relation to tumour-genesis (Davis 2000; Levy and Darnell 2002). Mistry et
al has also demonstrated the protein distribution of adiponectin receptors both
cancerous and benign prostate tissue (Mistry, Digby et al. 2006). The same study also
identified that androgens, oestrogen, TNF-α, leptin, and adiponectin, regulate the 
adiponectin receptors in the LNCaP and PC3 cell lines in a cell specific manner. It is
important to note that all of the aforementioned display altered levels in obesity states
and are implicated in CaP.
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The above findings have demonstrated an early insight into the potential effects and
associations of adiponectin in CaP pathology. Further studies are needed to clarify
whether adiponectin is significantly associated with prostate cancer biology. It is of
great interest and importance that Mistry et al have shown that leptin and adiponectin
interact in prostate cancer cell lines to modulate the tumour suppressor and oncogenes
p-53 and BCL-2. This highlights the notion that in-vitro studies of one cytokine in
isolation need to be interpreted with caution as there is far more likely to be a complex
interaction of physiological factors in the true in-vivo setting.
VISFATIN
Visfatin (also known as Pre-B cell colony enhancing factor/PBEF and nicotinamide
phosphoribosyltransferase - Nampt) is a 52kDa protein highly expressed in visceral
adipose tissue, and in other tissues such as liver, muscle and bone marrow cells.
Circulating visfatin levels have been shown to be increased proportionally with visceral
fat accumulation (Sandeep, Velmurugan et al. 2007) and pro-inflammatory states
(Moschen, Kaser et al. 2007). Since its discovery visfatin has been shown to have a
role in multiple cellular processes, such as inflammation and sepsis, and has been
reported to have anti-apoptotic effects (Jia, Li et al. 2004). It is of interest that in
mammals visfatin has been compartmentalised into intracellular and extracellular
(Revollo, Grimm et al. 2007). Thus far the biosynthetic properties of the intracellular
form has been well supported by biochemical and structural analysis, yet the functional
significance of circulating or extracellular visfatin has yet to be delineated. For the
purpose of the thesis the nomenclature used will remain as visfatin. Circulating visfatin
plasma concentrations as well as visceral adipose tissue visfatin mRNA expression
have been positively correlated with measures of obesity and visceral fat accumulation
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(Berndt, Kloting et al. 2005). Visfatin plasma concentrations have also been shown to
be markedly elevated in obese subjects (0.037 +/- 0.008 mcg/ml), compared with
controls (0.001 +/- 0.000 mcg/ml) (Haider, Schindler et al. 2006)
STRUCTURE OF VISFATIN
The gene, PBEF1, which encodes visfatin was initially detected from a human
peripheral blood lymphocyte cDNA library (Samal, Sun et al. 1994). The gene is located
on the long arm of chromosome 7 between 7q22.1 and 7q31.33 (Jia, Li et al. 2004) and
encodes a polypeptide of 491 amino acids corresponding to a molecular mass of
52kDa (National Center for Biotechnology Information accession number AAA17884).
Visfatin lacks a signal sequence in its primary structure and also lacks a caspase I
cleavage site (Rongvaux, Shea et al. 2002). The crystal structure of visfatin has been
described as a homodimeric protein by Wang et al (Wang, Zhang et al. 2006) and also
Kim et al (Kim, Lee et al. 2006) with respect to its enzymatic activity. Visfatin has two
active sites at the interface of the dimeric protein. This suggests that dimerisation is
essential for the catalytic activity visfatin.
FUNCTIONS OF VISFATIN
Catalytic mechanism:
Visfatin catalyses the rate limiting step in one of the key NAD+ salvage pathways in
mammals (Sommer, Garten et al. 2008). It converts nicotinamide to nicotinamide
mononucleotide (NMN) which is a key intermediate in nicotinamide adenine
dinucleotide (NAD). The catalytic activity was suggested on the grounds of its crystal
structure and the similarity between it and other type 2 phosphoribosyltransferases.
Both subunits of the visfatin molecule are involved in the catalytic mechanism and is
has been postulated that the Phe193 and the Tyr18 from the two subunits are framing
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the nicotinamide portion of the NMN molecule.
to nicotinamide and prevent
acid. It is the transfer of a phosphoribosyl residue 5
(prpp) to nicotinamide catalyzed by Nampt to produce NMN, which is finally converted
to NAD+ by NMN
hypothesized that NMN, a byproduct of
reaction exerts an autocrine/paracrine effect on target tissues
Figure 1.6 Cartoon demonstrating
from-Garten et al., 2008
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-
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regulated in certain cancers (Hufton, Moerkerk et al. 1999; Van Beijnum, Moerkerk et
al. 2002). This offers a potential mechanism whereby visfatin may be able to regulate
cell proliferation. As demonstrated above NMN is an intermediary product in NAD+
metabolism. NMN has independently been implicated to exert effects on tissue. This
has been demonstrated in Nampt+/- mice with insulin secretion defects being corrected
by the use of NMN. This is another mechanism by which extracellular visfatin may act
on cells i.e. by extracellular production of NMN. Revollo et al has also documented that
plasma NMN levels are regulated by e-visfatin independently of intracellular NMN
biosynthesis (Revollo, Grimm et al. 2007). This extracellular modulation of NMN by
visfatin suggests that NMN also offers a surrogate for visfatin’s mechanism of action
(Garten, Petzold et al. 2009).
Figure 1.7 Proposed modalities of extracellular visfatin (eNAMPT) action on cells
Adapted from-Garten et al., 2008.
The NAD+ salvage pathway is essential when the cellular level of NAD+ falls.
Examples of situations when NAD+ levels may become depleted would include poly
ADP ribosylation during DNA repair and NAD+ dependent protein deacetylase activity
(Zhang, Dawson et al. 1994; van der Veer, Nong et al. 2005). Visfatin has also been
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shown to regulate the function of the silent information regulator (SIR) 2 orthologue
SIRT1/SIRT2α in mammalian cells.  SIRT1/SIRT2α is implicated in the transcriptional 
regulatory activity of a variety of cellular processes, which include stress, cytokine
responses, differentiation and metabolism (Revollo, Grimm et al. 2004). Van der Veer
et al. further demonstrated that visfatin enhanced SIRT1 mediated p53 degradation in
human vascular smooth muscle cells which has the effect of delaying the senescence
phase and subsequently enhancing cell life (van der Veer, Ho et al. 2007).
Insulin-mimetic function:
In a paper that was subsequently retracted, Fukuhara et al (Fukuhara, Matsuda et al.
2005) suggested there was a role for visfatin as an insulin-mimetic. Subsequently no
further studies have reproduced these results; however there has been some data in
support of these interesting findings. Xie et al. demonstrated insulin-like effects with
visfatin in human osteoblasts (Xie, Tang et al. 2007). They found that visfatin
increased glucose uptake, stimulating the expression of osteogenic markers at both
gene and protein level. It was also shown to cause an increase of mineralisation of
osteoblasts similar to that of insulin. They also went on to show that when the insulin
receptor (IR) was specifically blocked by HNMPA-(AM) (cell permeable Hydroxy(2-
naphtyl)methyl]phosphonic acid) the insulin-like effects were also inhibited. These
results were at a visfatin concentration level similar to that initially reported by
Fukuhara.
Another group demonstrated, using in vitro studies in human SGBS adipocyte cells,
that in response to visfatin at 100nmol/L there was a 2 fold increase in glucose uptake
by the cells (Moschen, Kaser et al. 2007). Dahl and associates (Dahl, Yndestad et al.
2007) also published further evidence that visfatin acts via the IR. They showed that in
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THP cells visfatin mediated secretion of interleukin-8 (IL-8) and tumour necrosis factor-
alpha (TNF-α) as well as matrix metalloproteinase-9 (MMP-9) activity was abolished 
when the IR was inhibited by HNMPA-(AM).
There has been evidence to the contrary and Revollo et al. have shown that visfatin
does not exert insulin-mimetic effects in vitro or in vivo but does exhibit NAD
biosynthetic activity. It may be that there is a degree of cross talk between visfatin-
mediated and insulin signaling pathways in a cell specific manner. An alternative
theory is that it is the visfatin mediated NAD synthesis influences insulin signaling. With
this evidence it is easy to conclude that visfatin has insulin like effects however further
studies are warranted.
Immunomodulatory Functions:
Originally visfatin was termed PBEF and was thought to be a cytokine that increased
pre-B-cell colony forming activity (Samal, Sun et al. 1994) and was shown to have a
role in neutrophil maturation (Jia, Li et al. 2004). Visfatin has also been shown to be up
regulated in psoriasis (Dahl, Yndestad et al. 2007), acute lung injury (Garcia and
Moreno Vinasco 2006) and rheumatoid arthritis (Nowell, Richards et al. 2006; Otero,
Lago et al. 2006) which are all conditions associated with inflammation. Visfatin has
been demonstrated to activate human leucocytes and induce cytokine production
(Moschen, Kaser et al. 2007).
Apoptosis was earlier discussed on page 32. Interestingly visfatin has been shown to
be a cytokine with a role in inhibiting apoptosis. Jia et al. have demonstrated that in
human neutrophils, visfatin inhibits apoptosis in response to multiple inflammatory
stimuli (Jia, Li et al. 2004).
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In patients with inflammatory bowel disease, plasma levels of visfatin have been shown
to be elevated and the gene expression has been significantly elevated in colonic tissue
with inflammatory bowel disease compared to control.
Recently Oki et al. have demonstrated that serum visfatin is independently correlated
with C reactive protein (CRP) and IL-6 in a cohort of Japanese Americans however
there was no correlation between visfatin and markers of insulin sensitivity (Oki,
Yamane et al. 2007).
In the afore-mentioned studies it remains unclear whether it is the NAD biosynthetic
property of visfatin, either in isolation, in conjunction with or separable from the
proposed cytokine-like activity of circulating visfatin that drives these reported
inflammatory effects. These results infer that visfatin enzymatic activity is required for
the secretion of pro-inflammatory cytokines, however the question as to whether
visfatin acts as an inflammatory cytokine in its own right remains largely unanswered.
More recently, Li et al. published data showing that extracellular visfatin is protective in
macrophages in the face of endoplasmic reticulum stress-induced apoptosis. This was
demonstrated to be via non-enzymatic activity and this triggered IL-6 secretion and
consequentially activates the pro-survival pathways (Li, Zhang et al. 2008). In
conclusion it appears that visfatin may mediate inflammatory cytokines and is therefore
has an immunomodulatory function although the exact mechanism remains unclear.
VISFATIN AND ANGIOGENESIS
Angiogenesis is a crucial step in the progression of cancer and adipokines have been
shown to play a significant role in dysregulated angiogenesis (Lau, Schillabeer et al.
1996; Mohamed-Ali, Pinkney et al. 1998). Visfatin has been recently shown to induce
and up-regulate VEGF secretion and matrix metalloproteinases 2-&-9 (MMP-2/9)
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gelatinolytic activity, with angiogenesis occurring via the PI3K/Akt and MAPK signaling
pathways in human endothelial cells (Adya, Tan et al. 2008). The latter cascades are
crucial in cancer progression. Additionally, the same group has shown a role for the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling in
visfatin-induced up-regulation of MMP-2 and –9 activity (Adya, Tan et al. 2008). NF-kB
is a protein complex that is involved with DNA transcription. These observations are
pertinent given that NF-kB plays a vital role in anti-apoptosis, proliferation and
progression of CaP via MMP-9 activation (Suh and Rabson 2004).
VISFATIN AND CARCINOGENESIS
Visfatin has been described as a biosynthesiser of NMN which is a precursor for
Nicotinamide adenine dinucleotide (NAD+), a key metabolic coenzyme. Visfatin up-
regulation has been described in colorectal cancer cells, which have a high metabolic
rate and thus high NAD+ turnover (Hufton, Moerkerk et al. 1999; Van Beijnum,
Moerkerk et al. 2002). Visfatin expression has also been demonstrated in tumour
tissues (Bae, Kim et al. 2006), and has been implicated in chemo-resistance in breast
cancer patients (Folgueira, Carraro et al. 2005). Its role as an inhibitor of apoptosis in
cancer has not been elucidated; however, it is of interest and importance that inhibition
of visfatin by FK-866 induces apoptosis in tumours (Drevs, Loser et al. 2003; Hasmann
and Schemainda 2003; Khan, Tao et al. 2006; Kim, Lee et al. 2006).
More recently another visfatin inhibitor, CHS-828, has been identified and causes cell
growth inhibition in multiple tumour types but the mechanism for its action is unknown
(Ravaud, Cerny et al. 2005; Olesen, Christensen et al. 2008).
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IN VITRO CAP MODELS
Primary prostate epithelial cells have a finite life span and then senesce, making the
establishment of primary prostate cancer lines from tissue very difficult. Two commonly
published in vitro models are the LNCaP and PC3 human CaP cell lines. LNCaP cells
are androgen-receptor positive and PSA-secreting, which can be extrapolated to
represent an early stage or androgen sensitive model of CaP (Horoszewicz, Leong et
al. 1983) whilst PC3 cells exhibit low testosterone-5-alpha reductase activities, are non-
PSA-secreting and are androgen receptor negative and may provide a model for
advanced, androgen-insensitive CaP (Kaighn, Narayan et al. 1979). It should be noted
that these two cell types are from different origin and one cell type does not develop
into the other.
HYPOTHESIS AND AIMS
The association between obesity and CaP remains poorly understood, but evidence
suggests that obesity may adversely affect the risk of developing high grade disease.
Adipokines may contribute to the molecular basis for a link between obesity and CaP,
in particular, adiponectin and visfatin. The following broad hypothesis will be
investigated in this thesis:
 Visfatin is involved in the pathophysiology of CaP
AIMS
1. To demonstrate Visfatin in human prostate tissue and LNCaP and PC3 human CaP
cell lines.
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2. To determine the effects of and visfatin on LNCaP and PC3 CaP cell proliferation
both alone and in combination with other factors.
3. To investigate the effect of visfatin on the expression of key tumour suppressor
genes and oncogenes involved in CaP development and progression.
4. To identify the intracellular pathways activated by visfatin in CaP cells
5. To demonstrate a role for FK866 in regulation of prostate cancer growth
6. To measure levels of visfatin in human plasma as a potential biomarker.
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CHAPTER 2
MATERIAL AND METHODS
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CHAPTER 2: MATERIALS AND METHODS
MATERIALS
EQUIPMENT
‘Mr. Frosty’ cryo-freezing unit: Fisher Scientific, Loughborough, UK.
Bio-Rad IQ5 iCycler Real-Time PCR Detection System: Bio-Rad Laboratories Inc.
California, USA
Bio-Rad mini Protean II Gel system: Bio-Rad Laboratories, Hemel Hempstead, UK.
Cell culture flasks: BD Biosciences, Bedford, MA, USA
Digital microscope camera system: Olympus, Tokyo, Japan
DMRE laser-scanning confocal microscope: Leica, Milton Keynes, UK.
ELISA plate reader: EL800, Bio-Tek Instruments, Inc., Winooski, VT, USA
Fuji medical X-ray film: Fuji Photo Film Company, Tokyo, Japan.
Haemocytometer: Paul Marienfeld GmbH & Co. KG, Germany
Hot Block Techne TC-312: Geneflow
NanoDrop spectrophotometer: Labtech International, Ringmer, UK.
Roche Light Cycler™ system: Roche Molecular Biochemicals, Mannheim, Germany.
Spectrophotometer (Beckman DU640: Beckman Instruments Inc, California, USA.
63
BIOCHEMICAL REAGENTS AND KITS:
4'-6-diamidino-2-phenylindole (DAPI) nuclear marker: Invitrogen, Paisley, UK
Alexa Fluor® 488: Invitrogen, Paisley, UK
10X protein running buffer: Department of Biological Sciences, University of Warwick –
Media Preparation.
10X protein transfer buffer: Department of Biological Sciences, University of Warwick –
Media Preparation.
30% Acrylamide: Bisacrylamide (37.5:1): GENEFLOW, Fradley, UK.
Ammonium persulphate (APS): Sigma-Aldrich, Gwellingham, UK.
Bio-Rad DC Protein Assay: Bio-Rad Laboratories, Bio-Rad Laboratories Inc. California,
USA
Bovine serum albumin (BSA): Sigma-Aldrich, Gwellingham, UK.
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) kit: Promega, UK.
Cellular DNA fragmentation ELISA: Roche, Mannheim, Germany.
Complete mini protease inhibitor cocktail: Roche, Manheim, Germany
DNA ladder: Invitrogen, Paisley, UK.
ECL+: GE Healthcare, Amersham, UK.
Ethidium Bromide: Sigma-Aldrich, Gwellingham, UK.
Foetal Calf Serum (FCS): Invitrogen, Paisley, UK.
geNorm™™ Housekeeping Gene Selection Kit: Primer Design Ltd, Southampton
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Human VEGF duoset ELISA kit: R&D systems, Abingdon, UK
Human Visfatin ELISA: Phoenix Secretomics, California, USA
Light Cycler DNA Master SYBR® Green I: Roche, Manheim, Germany.
MgCl2: Biogene, Kimbolton, UK.
Moloney Murine Leukaemia Virus Reverse Transcriptase (MMLV): Fermentas, York,
UK.
N, N, N’, N’- tetramethylethylenediamine (TEMED): Sigma-Aldrich, Gwellingham, UK.
OptiMax Wash Buffer: BioGenex, San Ramon, CA, USA.
Penicillin: Department of Biological Sciences, University of Warwick – Media
Preparation.
pH 7.8 Tris-EDTA buffer: Sigma-Aldrich, Gwellingham, UK.
Phosphate Buffered Solution (PBS): Department of Biological Sciences, University of
Warwick – Media Preparation.
Phophotase Inhibitor Set 2, CalBiochem (Merck Chemicals Ltd), Nottingham, UK
PMSF: Sigma-Aldrich, Gwellingham, UK.
Poly-D-Lysine (Sigma, P7280-5MG)
Polyvinylidene difluoride (PVDF) membranes: Millipore, Billerica, MA, USA.
Precision Plus Protein Standard: Bio-Rad Laboratories, Hemel Hempstead, UK.
PrimerDesign Ltd Precision Reverse Transcription kit: Primer Design Ltd, Southampton
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Protease Inhibitor Cocktail: Sigma-Aldrich, Gwellingham, UK.
Protein gel running buffer: Department of Biological Sciences, University of Warwick –
Media Preparation
QIAquick Gel Extraction Kit: Qiagen, Crawley, UK.
Radioimmunoprecipitation lysis buffer (RIPA): Upstate, Lake Placid, NY, USA.
Reaction Buffer: Fermentas, York, UK.
RNase-free DNAse (Promega, Madison, WI, U.S.A)
SDS: Bio-Rad Laboratories Inc. California, USA.
SDS-sample buffer: Sigma-Aldrich, Gwellingham, UK.
Streptomycin: Department of Biological Sciences, University of Warwick – Media
Preparation.
SYBR® Green: Roche, Mannheim, Germany
TBE agarose gel running buffer- Department of Biological Sciences, University of
Warwick – Media Preparation.
TE (Tris-HCL/EDTA) buffer- Department of Biological Sciences, University of Warwick
– Media Preparation.
Tris Buffered Saline (TBS) containing 0.1% TIen-20: Department of Biological
Sciences, University of Warwick – Media Preparation.
Tris-HCL [tris (hydroxymethyl) aminomethane, pH adjusted with HCl]: Sigma-Aldrich,
Gwellingham, UK.
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Trypsin solution: Department of Biological Sciences, University of Warwick – Media
Preparation.
β-mercaptoethanol: Sigma-Aldrich, Gwellingham, UK. 
PEPTIDES AND INHIBITORS:
Camptothesin: BioVision, California, USA.
Fk866: Axon Medchem, Groningen, The Netherlands.
Human Insulin: Sigma-Aldrich, Gwellingham, UK
Human Recombinant Visfatin: Axxora Ltd, Nottingham, UK (ALX-201-336)
Human VEGF peptide: Calbiochem, UK.
NMN: Sigma Aldrich, Gwellingham UK
ANTIBODIES:
All secondary antibodies were purchased from DakoCytomation Ltd (Cambridge, UK)
Anti-Rabbit horseradish peroxidase-conjugated Ig (P0450): Dako, Ely, UK.
Human β-actin antibody (4967): Cell Signalling Technology, Beverly, MA, USA. 
MMP-2 antibody (ab2462), MMP-9 antibody (ab7299): ABCAM, Cambridge, UK.
Visfatin antibody: Universal Biologicals Cambridge, A300-778A
Human Phospho ERK1/2 (9106S) and p38 (4631) MAPK antibodies: Cell Signalling
Technology, Boston, MA, USA.
Human total ERK1/2 (4695) and p38 (9212) MAPK antibodies: Cell Signalling
Technology, Boston, MA, USA.
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CELL CULTURE MEDIA AND CELL LINES
Cell Culture Media (Department of Biological Sciences, University of Warwick – Media
Preparation supplemented as follows).
Hams-F12 (Kaighn’s modification) (F12K)
F12K growth medium F12K starvation medium
+Foetal Calf Serum 10%
+Penicillin/Strep 100 IU-100µg/ml +Penicillin/Strep 100
IU/100µg/ml
+L-Glutamine (200mM) 5ml + L-Glutamine (200mM) 5ml
RPMI 1640
RPMI growth medium RPMI starvation medium
+FCS 10%
+L-Glutamine (200mM) 5ml + L-Glutamine (200mM) 5ml
+Penicillin/Strep 100 IU-100µg/ml +Penicillin/Strep 100
IU-100µg/ml
PC3/ LNCAP FREEZING MEDIA
Dimethylsulfoxide (DMSO) 5 %
+FCS 95%
PROSTATE CANCER CELL LINES
PC3 cells: American Type Culture Collection (ATCC), Manassas, VA, U.S.A.
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LNCaP cells: American Type Culture Collection (ATCC), Manassas, VA, U.S.A.
Normal and tumour prostate tissue cDNA: BioChain Institute, Hayward, CA, U.S.A.
SOFTWARE
Scion Image™: Scion Corporation, Maryland, U.S.A
ADLab software: ADI instruments, UK.
EXPO 32 ADC software: Beckman Coulter, UK.
Gel Pro image analysis: Gel Pro 4.5, Media Cybernetics, USA.
GraphPad Prism 4: GraphPad Software, California, USA.
Image-Pro Plus software: Media Cybernetics Inc, Bethesda, USA.
METHODS
CELL CULTURE
LNCaP and PC3 cells were cultured, as per manufacturer’s instructions, in RPMI and
F12K media, respectively. Both media were supplemented with 10% FCS and cultured
in 75 cm2 cell culture flasks. Flasks were incubated at 37 °C and 5% CO2, with 100
µg/ml penicillin G and 100 µg/ml streptomycin sulphate. The cells were seeded at 3 x
106 cells per flask and maintained in 175cm3 vented tissue culture flasks in a humidified
incubator at 37oC in 5% CO2 and 95% air atmosphere and routinely passaged at
approximately 80% confluence (determined by microscopic inspection). Cells were
seeded onto 6/12/96-well plates and, cultured to pre-confluence prior to treatments.
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SUBCULTURE OF ADHERENT CELLS:
Culture medium from the flask was carefully aspirated and the cells were washed with
PBS. 2 ml of Trypsin EDTA solution was added to the flask (T75 cm2) and incubated at
37ºC for between 3-5 minutes or until the cells had detached. 8ml of fresh culture
medium was used to block further trypsinisation. A small amount of this cell solution
was taken and added into a new flask with fresh medium for culture.
MAINTAINING CELLS:
Following cellular attachment at 48 hours 15ml of the pre-incubated medium was added
to the flask (T75 cm2). The culture medium was refreshed every 2-3 days.
PRESERVATION OF CELLS:
Cells were prepared as described above as for splitting and then centrifuged at
1000rpm for 5 minutes. The cells were then re-suspended with cryo-protective culture
solution (5% DMSO, 95% FBS). 1 ml of the cell suspension was pipetted into a
cryogenic vial and stored at -80ºC. After 48 hours the cells were placed in liquid
nitrogen.
CELL COUNTS USING HAEMOCYTOMETER
A haemocytometer was used to determine the cell density (cells/ml) to allow accurate
plating of cells for optimising experiments. The haemocytometer was cleaned with a
70% ethanol solution and a cover-slip placed. The correct position of the coverslip was
noted by the presence of Newton’s rings, which are ‘rainbow-like’ interference patterns,
visible on holding the haemocytometer up to light. The cell suspension was agitated
and 100µl taken and added to the haemocytometer chamber. Low magnification
microscopy was then used to view the haemocytometer. The number of unstained cells
in at least two 1mm2 areas (more if low count was noted) were counted. Cells within the
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left and upper border markings were included whilst those in the right and bottom
markings were excluded. The calculation was as follows:
Total number of viable cells = Total cell volume (ml) x 104.
TOTAL RIBONUCLEIC ACID (RNA) EXTRACTION AND COMPLEMENTARY
DEOXYRIBONUCLEIC ACID (CDNA) SYNTHESIS
RNA extraction was carried out using Qiagen RNeasy™ Plus Mini-Kit as per
manufacturer’s guidelines. RNA samples were treated with RNase-free DNAse to
eliminate genomic DNA contamination and the concentration quantified using the
NanoDrop spectrophotometer and reverse-transcribed into cDNA using 1.0µg RNAA
primer design first strand cDNA synthesis kit (using random nonamer primers) was
used to reverse transcribe the RNA as follows:
Annealing step: the following was added to a 500µl eppendorf and heated to 65ºC for 5
mins using a heat block and then immediately cooled in ice without allowing them to
cool first:
RNA 0.5-1µg
RT Primer 1.0µl
dNTP mix 10mM 1.0µl
RNAse/DNAse free water to a total 10µl
Extension Step: 10µl of a master-mix containing the following was added to the
samples and then mixed thoroughly before incubating at 42ºC for 60 mins. The
subsequent cDNA samples were then stored at -20ºC until use.
Moloney Murine Leukaemia Virus (MMLV) 5X buffer 4µl
71
RNAse/DNAse free water 5.2µl
Moloney Murine Leukaemia Virus (MMLV) Reverse Transcriptase 0.8µl
REAL TIME POLYMERASE CHAIN REACTION (RT-PCR)
For in depth RT-PCR protocols see Chapter 3 and 5.
Figure 2.1 Primer Sequences
Gene/product
size
Sense primer Antisense primer
B-Actin (249bp)
5’-AAGAGAGGCATCCTCACCCT-
3’
5’-
TACATGGCTGGGGTCTTG
AA-3’
GAPDH (185bp)
5’-GAGTCAACGGATTTGGTCGT-
3′           
5’-
GACAAGCTTCCCGTTCTC
AG-3′ 
B-Actin,
GAPDH, 18S,
YWHAZ, UBC,
B2MG*
NOT SUPPLIED BY
MANUFACTURER1
NOT SUPPLIED BY
MANUFACTURER1
Insulin Receptor
(INSR) (97bp)*
5’-AGAGCAGGAGCGTCATCAG-
3’
5’-
CCCACTGTGAAGGAGAGA
AATG-3’
Insulin like 5’- 5’-
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growth factor
receptor (IGFR)
(98bp)*
TTAACAGATGGAAAGAACCTCAT
TG-3’
CCAGACCAATCAAGCCAG
ATG-3’
MMP2 (179 bp)
5′-TGGCAAGTACGGCTTCTGTC -
3′         
5′-
TTCTTGTCGCGGTCGTAG
TC-3′ 
MMP9 (200 bp)
5′-TGCGCTACCACCTCGAACTT-
3′         
5′-
GATGCCATTGACGTCGTC
CT-3′ 
Visfatin (228bp)
5’-AAGAGACTGCTGGCATAGGA
-3’
5’-
ACCACAGATACAGGCACT
GA -3’
P53 (102bp)*
5’-
GTGGAGTATTTGGATGACAGAA
AC-3’
5’-
GTAGTTGTAGTGGATGGT
GGTAC-3’
BCL2 (88bp)* 5’-GAGGTCACGGGGGCTAATT-3’
5’-
GAGGCTGGGCACATTTCT
G-3’
BAX (101bp)*
5’-ATGGAGCTGCAGAGGATGAT-
3’
5’-
CAGTTGAAGTTGCCGTCA
GA-3’
BCL2L1 (84bp)* 5’- 5’-
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CACTTACCTGAATGACCACCTA
G-3’
GCATTGTTCCCATAGAGT
TCCA-3’
MCL1 (104bp)*
5’-
CTGATTGTTCTGCTCCCTCTAC-
3’
5’-
GTTTCACAGTGCCAAAAT
CTAAAAG-3’
* Pre-validated primers purchased from PrimerDesign Ltd. 1Sequences not supplied for
housekeeping genes used in ‘GeNorm™’ analysis and subsequent RT-PCR from
PrimerDesign Ltd.
‘GENORM™’ ANALYSIS FOR OPTIMISATION OF HOUSE KEEPING GENES
To help optimise the results from my gene expression data it was important to identify
suitable housekeeping genes as a fixed point of reference. It is commonly accepted
that there is no one universal gene or genes that can be used in all cases. This is
based on a concept and software initially developed by Vandesompele et al
(Vandesompele, De Preter et al. 2002). We looked to identify the most suitable
housekeeping genes for use in the cell model I adopted for my project. cDNA was
prepared as described above with n=3 samples including basal and treated cells. 6
commonly selected housekeeping genes were selected and provided by PrimerDesign
Ltd as part of the geNorm™ kit. These were; B-Actin (ACTB), GAPDH, YWHAZ, 18S,
UBC and B2MG. RT-PCR was subsequently using the above protocol on the Biorad I-
cycler as described previously.
The data was then analysed using the supplied geNorm™ software. The aim of the
software is to firstly assess the gene-stability and rank the selected housekeeping
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genes and secondly use a normalization factor calculation based on the geometric
mean of multiple control genes to assess the optimal number of housekeeping genes to
generate the best quality data.
The concept is built on the principle that the expression ratio of two ideal internal
control genes is identical in all samples, irrespective of the conditions or cell type.
Vandesompele developed a calculation whereby for every control gene the pairwise
variation with all other control genes as the standard deviation of the logarithmically
transformed expression ratios, and defined the internal control gene-stability measure
M as the average pairwise variation of a particular gene with all other control
genes.(Vandesompele, De Preter et al. 2002) Genes with the lowest M values have the
most stable expression. To manage the calculations, they have developed a Visual
Basic Application (VBA) for Microsoft Excel - termed geNorm. In addition, the
systematic variation was calculated as the pairwise variation, V, for repeated RT-PCR
experiments on the same gene, reflecting the inherent machine, enzymatic and pipette
variation. (Vandesompele, De Preter et al. 2002) It is also widely accepted that to
optomise expression levels accurately, normalization with multiple housekeeping genes
instead of one is required. Consequently Vandesompele et al developed a
normalization factor based on the expression levels of the best-performing
housekeeping genes. A combination of these two concepts allows a second data set to
be generated again using the software programme to calculate the ideal number of
housekeeping genes to accurately quantify data
Practically speaking CT values were transformed into relative quantification data using
the ∆CT method.  Following this for each data point the equation 2(-deltaCt) is applied,
hence allowing all data to be expressed relative to the expression of the least
expressed gene. The data is then inserted into an excel spreadsheet with an inbuilt
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applet. The software allows for automated analysis and produces 2 charts displayed
below. Figure 2.2 shows which of the 6 genes are most stably expressed in my
system. In this case B-Actin (ACTB) and YWHAZ were the most stable and 18S the
least stable. Figure 2.3 reveals the ideal number of housekeeping genes against which
to normalise data based on a ‘pair-wise variation’ or ‘V score’. The manufacturers
suggest a V score of <0.15 as a cut off for optimal normalisation but stress this is only a
guide. For the purpose of the experiments undertaken 2 housekeeping genes were
used as standard.
Figure 2.2 Average expression stability values of remaining control genes
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Figure 2.3 Determination of the optimal number of control genes for normalisation
(Pairwise variation (Vn/n + 1) analysis between the normalization factors NFn and NFn
+ 1 to determine the number of control genes required for accurate normalization
(arrowhead = optimal number of control genes for normalization) (Vandesompele, De
Preter et al. 2002)
WESTERN BLOTTING
MAKING SDS-PAGE GEL
Using the Bio-Rad mini Protean II Gel system, 8% or 10% SDS-PAGE gel was made
up, as per the manufacturer’s protocol. The resolving gel was prepared using 30%
Acrylamide: Bisacrylamide (37.5:1), 1.5M Tris-HCL [tris (hydroxymethyl)
aminomethane, pH adjusted with HCl], pH 8.0) pH 8.8, 10% SDS, deionised water, 10%
ammonium persulphate (APS) and N, N, N’, N’- tetramethylethylenediamine (TEMED).
The mixture was carefully added into the casting system and allowed to set at room
temperature for approximately 30 minutes.
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The stacking gel was identically prepared aside from 1.5 M Tris-HCl, pH 8.8 being
substituted by 0.5 M Tris-HCl, pH 6.8. The mixture was then poured on top of the pre-
set resolving gel and a comb used for well formation. The gel was allowed to set at
room temperature for a further 20 minutes. The gel was placed into the electrophoresis
running system and copious protein gel running buffer was added to the tank.
SAMPLE PREPARATION AND WESTERN BLOTTING TECHNIQUE
Western blotting was used to assess protein levels in cell lysates from both treated and
untreated prostate cancer cell lines. All protein extraction was carried out on ice.
Protein lysates were prepared by lysing cells from tissue culture plates in
radioimmunoprecipitation lysis buffer (RIPA) containing (containing; 0.5M Tris-HCl, pH
7.4, 1.5M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA and 2µl of Protease
Inhibitor Cocktail and 2µl of Phosphatase Inhibitor). Protein concentrations were
determined colourimetrically using the Biorad DC Protein Assay Method which is a
modification of the Lowry method (Lowry, Rosebrough et al. 1951)
Protein lysates were mixed with equal amounts of sodium dodecylsulphate (SDS)-
sample buffer (5M urea, 0.17M SDS, 0.4M dithiothreitol, and 50mM Tris-HCl, pH 8.0)
and placed in a boiling water bath for 5 min, and then gently allowed to cool. Protein
lysates were separated by SDS-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride (PVDF) membranes using a protocol of; 100 V for one hour in
a transfer buffer containing 20mM Tris, 150mM glycine, and 20% methanol. To prevent
non-specific binding the membranes were ‘blocked’ by incubating in tris buffered saline
containing 0.1% Tween-20 (TBS-T) and 5% BSA for one hour at room temperature.
The PVDF membranes were incubated with the relevant primary antibodies for at least
12 hours at 4°C. Following overnight incubation, membranes were washed for 1 hour
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with TBS-T before addition and incubation with the required secondary antibody for one
hour at room temperature. Antibody complexes were demonstrated using
chemiluminescence ECL+ and autoradiography. Where necessary the appropriate
positive controls were used. The densities were measured using a scanning
densitometer coupled to scanning software.
STATISTICAL ANALYSIS
All of the data in the present study are expressed as mean ± SEM. Parametric
comparisons between groups were made by ANOVA. If significance (P<0.05) was
present, a post hoc Tukeys multiple-comparison test was performed. All statistical
analysis was performed using Graph Pad software (version 4.0) unless stated
otherwise in individual results chapters.
The ANOVA test was chosen based on the notion that performing multiple two-sample
t-tests would most likely result in type 1 error. ANOVA has also been shown to be an
established data analysis tool for RT-PCR (Pfaffl, Horgan et al. 2002; Brunner,
Yakovlev et al. 2004). It should be noted that parametric tests rely on the assumption
that the data is normally distributed. However, to prove or disprove this notion,
particularly in the context of gene expression data, can be difficult. On the other hand,
the use of non-parametric tests based on ranks (Mann-Whitney, Kruskal-Wallis, etc.)
suffer a significant reduction in power relative to parametric tests (t-tests, ANOVA, etc.).
Based on the above, it was the decision of the author to use the established test,
ANOVA, on the basis of Gaussian distribution of data..
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CHAPTER 3 THE IDENTIFICATION OF
INTRACELLULAR VISFATIN IN PROSTATE
CANCER CELL LINES AND TISSUE
INTRODUCTION
Obesity is well established as a risk factor for type 2 diabetes, cardiovascular disease
and cancer (Kershaw and Flier 2004). Specifically, visceral obesity is associated with
insulin resistance, hyperinsulinaemia and prothrombotic/proinflammatory states
(Kershaw and Flier 2004), and has also been identified as a risk factor for prostate
cancer (von Hafe, Pina et al. 2004). Evidence also suggests that the presence of
obesity increases the aggressiveness of the disease (Freedland and Platz 2007).
As commented on earlier adipose tissue has been documented as a metabolic organ
and not just a fat store. This encompasses the notion that adipose tissue is also the site
for the production of multiple biologically active peptides now termed ‘adipokines’
(Matsuzawa, Funahashi et al. 1999). Adipokines which include adiponectin, leptin,
TNF-α and IL-6 are not only produced by adipocytes but also by other stromal cells 
(Frayn, Karpe et al. 2003; Fain, Madan et al. 2004). Amongst the newly discovered
adipokines is Visfatin and this is the adipokine of interest to my thesis. Circulating
visfatin plasma concentrations as well as visceral adipose tissue visfatin mRNA
expression correlated with measures of obesity and visceral fat accumulation. (Berndt,
Kloting et al. 2005). Visfatin plasma concentrations have also been shown to be
markedly elevated in obese subjects ((0.037 +/- 0.008 mcg/ml) mean +/- SD),
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compared with controls ((0.001 +/- 0.000 mcg/ml mean +/- SD) (Haider, Schindler et al.
2006).
Visfatin has gained momentum as having a more multifunctional physiological role with
its identification as nicotinamide phosphoribosyltransferase (NMPRTase), an enzyme
involved in NAD+ biosynthesis (Rongvaux, Shea et al. 2002). NAD+ is an essential
metabolic co-enzyme and visfatin in its capacity as NMPRTase replenishes cellular
NAD+ by converting free nicotinamide (NM) to nicotinamide mononucleotide (NMN).
Intracellular visfatin expression has already been demonstrated in normal and inflamed
tissues (Bae, Kim et al. 2006). Cancer cells by virtue of their rapid cell division have a
naturally high NAD+ turnover and unsurprisingly therefore visfatin expression has been
shown to be up-regulated in certain cancers (Hufton, Moerkerk et al. 1999; Van
Beijnum, Moerkerk et al. 2002).
It is of note and importance that in obesity it has been reported that there are elevated
circulating visfatin levels in serum. However, there has been no study to date
evaluating the association between the level of exogenous or extracellular visfatin and
its impact on intracellular visfatin levels. This is important given the documented over-
expression of visfatin in certain cancers, most recently for example ovarian cancer
(Shackelford, Bui et al. 2010).
HYPOTHESIS
Visfatin is present intra-cellularly and can be identified in both in-vitro and in-vivo
models of prostate cancer.
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AIMS
 To identify and investigate the expression of visfatin in human prostate cancer
cell lines and tissue.
 To identify if visfatin plays a role in visfatin gene regulation.
METHODS
Methods were as outlined in the methods chapter. Following from work initiated by Tina
Mistry previously in the group, I looked to confirm her preliminary data with respect to
immunohistochemistry as a starting point to my thesis and overall hypothesis.
Therefore all experiments were performed as stated by Ms Mistry and completed in this
part of the study; subjects were identified and archived tissue used.
Following ethical approval, paraffin embedded sections (3μm thickness) were cut from 
archived prostate tissue obtained from patients undergoing transurethral prostatectomy
(n = 13; mean 75.1 years; range 57 – 92; SEM ± 2.6). Sections were floated onto 3-
aminopropyltriethoxy-silicane (APES) coated slides. All patients had histologically
diagnosed prostatic adenocarcinoma, and cut sections had foci of benign and
malignant tissue.
Gene expression was outlined using standard qualitative and quantitative PCR
techniques as described in the literature (Mistry, Digby et al. 2008).
Immunocytochemistry and immunohistochemistry were used as detailed below to
identify intracellular visfatin using cell lines and human tissue respectively. This was a
well established technique both in the group and in the literature (Mistry, Digby et al.
2006; Wang, Hasan et al. 2011).
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IMMUNOCYTOCHEMISTRY AND CONFOCAL ANALYSIS
COVERSLIP PREPARATION
Coverslips were prepared by placing them in a beaker with concentrated acetic acid for
30 mins. Then washed with distilled water and placed in 70% ethanol for 30 mins.
Then washed again in distilled water. They were then placed in a petri dish containing
200µl of APES and 10mls acetone in a fumigation hood for 5 mins until the acetone had
evaporated. Wash with distilled water thoroughly and then air dry on styrofoam blocks.
Once dry, place in 6 or 12 well plates as needed. Immediately prior to use they are
exposed to ultra violet (UV) light for 30mins to sterilize.
POLY-D-LYSINE COATING
Poly-D-Lysine (5mg) was diluted in 5ml of sterile PBS and stored in 500µl aliquots at -
20ºC. Each aliquot was further diluted 1:100 with PBS prior to use. When using a 12-
well plate, 100µl was added per well. The plate was incubated for 15mins and then
washed with PBS. Cells were cultured onto the poly-D-lysine-coated glass cover slips
for 48-hours.
FIXATION
The media was aspirated and the plate washed with sterile PBS. 400µl of 4%
paraformaldehyde (PFA) in PBS was added to each coverslip and left for 30mins. The
PFA was removed and the slips washed with PBS several times.
PERMEABILIZATION, BLOCKING AND ANTIBODY INCUBATION
Non specific binding was inhibited by incubating cells with 3% BSA in PBS-0.01%-
Triton x100 for 1 hour at room temperature. Cells were incubated with 100µL primary
rabbit anti-human visfatin antibody diluted in PBS-0.1% TRITON x100 (1:100) overnight
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at 4ºC. A blank with no antibody was used to check for non specific binding. After
washing with PBS-0.05%-Tween, cells were incubated in the dark with secondary
conjugated donkey anti-rabbit antibody, Alexa Fluor® 488. Following further washes
cover slips were mounted on slides with glycerol containing DAPI. Images were
acquired using a Leica SP2 confocal laser scanning microscope system linked to a
Leica DM RE7 upright microscope and an X40 oil immersion lens. Settings for aperture,
laser line and filters were set using the conditions detailed in Mistry et al (Mistry, Digby
et al. 2006). Images were acquired using an argon laser (excitation, 488 nm; emission,
UV excitation and a BP 385-470 nm emission filter for DAPI). The confocal aperture
was set to a pinhole diameter of 1 Airy unit.
IMMUNOHISTOCHEMISTRY
The paraffin embedded sections collected as described above were floated onto APES
coated slides. All patients had histologically diagnosed prostatic adenocarcinoma, and
cut sections had foci of both benign and malignant tissue. Each section of prostate
tissue had foci of both benign and adenocarcinomatous prostate glands. The benign
glands have tall columnar epithelial cells with well circumscribed lumens, whereas the
malignant glands are distinguishable by their variation in size, shape, prominent nuclei
and occlusive lumens.
Optimax Wash Buffer was used for all washes and dilutions. An immunoperoxidase-
based detection system (VECTASTAIN Elite ABC Kit (Universal), Vector Laboratories,
Peterborough, U.K.) and diaminobenzidine tetrahydrochloride (DAB) visualization agent
(Menarini Diagnostics, Florence, Italy) were used. All incubations were carried out at
room temperature.
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To revive the antigen heat-induction was used by incubating the mounted sections in
pH 7.8 Tris–EDTA buffer for 80 seconds in a pressure cooker. Endogenous peroxidise
activity was inhibited by incubating in 1.5% hydrogen peroxide (H2o2) solution for 20
mins. Then sections were blocked with BSA for 20 mins. Rabbit anti-human visfatin
primary antibody was used for 1 hour (1:200). Sections were washed with buffer for 10
minutes and incubated with secondary antibody for 30 minutes. Further wash was done
with buffer for 10 mins. Sections were incubated with the Avidin: Biotinylated Enzyme
Complex for 30 mins and then washed with buffer for 5 minutes. DAB was applied for 5
minutes and rinsed with de-ionised water. Sections were counterstained for 1 minute in
Mayers Haematoxylin, then blued in Scott’s tap water, dehydrated, cleared and
mounted. They were then examined under a microscope.
REAL TIME POLYMERASE CHAIN REACTION (RT-PCR)
Quantitative RT-PCR was performed using the Roche Light Cycler™ system. Reaction
mixtures contained SYBR® Green and 1.5μl cDNA. PCR conditions consisted of 
denaturation at 95°C for 1 min followed by 40 cycles of 95°C for 1 s, 59°C for 10 s and
72°C for 15 s, followed by melting curve analysis. Quantitative amounts of visfatin were
standardised against β-actin/GAPDH. For each sample, ∆CP (crossing point) values 
were calculated as the CP of the target gene minus the CP of the β-actin gene. The 
RNA levels were expressed as a ratio, using comparative “delta-delta method” for
comparing relative expression results between treatments in real-time PCR (Pfaffl et
al., 2001). and changes in gene expression expressed as x-fold over basal.
10μl of the PCR products were then electrophoresed on a 1% agarose gel and ethidium 
bromide used to identify the products. A 1kb DNA ladder was used to estimate the
band sizes. RNA was assayed from n ≥3 independent biological replicates. RT 
negatives were used throughout the study.
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RESULTS
VISFATIN MRNA EXPRESSION IN PROSTA
HUMAN PROSTATE
Using RT-PCR, visfatin mRNA was detected in both cell lines used in this study, with
agarose gel electrophoresis yielding an expected 249 base pair product. Visfatin gene
expression was also present in cDNA prepared from mRNA obtained from normal and
malignant human prostate tissue (Figure 3.1
identity of these products.
Figure 3.1 Visfatin mRNA expression in the LNCaP (LN) and PC3 (PC) prostate
cancer cell lines. Human fat (HF) cDNA was used as a positive control. Visfatin mRNA
was also detected in normal prostate tissue (NP) and prostate adenocarcinoma tumour
tissue (TT) cDNA. A no te
instead of cDNA and an RT was performed to confirm absence of genomic
contamination.
VISFATIN PROTEIN EXP
Expression of visfatin protein was demonstrated in LNCaP
immunocytochemistry and confocal analysis. The expression of visfatin in both cell
types showed a predominantly cytoplasmic distribution, although there was also
250 bp
TE CANCER CELL LINES
); sequencing analysis confirmed the
mplate negative control was also performed using water
RESSION IN PROSTATE CANCER CELL LINES
and PC3 cells using both
1kb
ladder LNCaP PC3 Fat NP
AND
TT
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evidence of nuclear staining in LNCaP cells (Figure 3.2 Arrow). Nuclear and
cytoplasmic staining was seen in all cells with a qualitative ratio of approximately 1:4.
VISFATIN PROTEIN EXPRESSION IN PROSTATE TISSUE.
Immunohistochemistry was used to study visfatin protein expression in human benign
and malignant prostate tissue (Figure 3.3). Visfatin staining was detected in both
benign and malignant tissue, with glandular epithelial cells showing high levels of
expression. Interestingly, visfatin demonstrated both nuclear and cytoplasmic staining
in both normal and malignant cells. Qualitative analysis revealed a ratio of 1:5
(nuclear:cytoplasmic).
REGULATION OF VISFATIN MRNA BY EXOGENOUS VISFATIN
Real time PCR was used to identify if exogenous visfatin plays a role in regulating
visfatin mRNA expression. PC3 cells showed down regulation in mRNA expression in
response to treatment with exogenous visfatin at dose ranges greater than 50ng/ml at 4
hours (figure 3.4a) and this appeared to be sustained at 24 hours although only
statistically significant at 200ng/ml at this time point (figure 3.4b). As visfatin appeared
to have no functional effect in LNCaP cells (see chapter 4) no further studies were
carried out using the LNCaP cell line with respect to visfatin.
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Figure 3.2 Immunocytochemical and confocal analysis were used to s
protein expression in LNCaP and PC3 prostate cancer cell lines. Visfatin protein was
detected in the cytoplasm of both cell lines (green), and following co
the DAPI nuclear marker (blue), nuclear staining for visfatin was a
LNCaP cells (arrowed).
tudy visfatin
-visualization with
lso detected in
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Figure 3.3 Immunohistochemical analysis of benign and adenocarcinomatous human
prostate cancer tissue. Visfatin expression was detected in the glandular epithelial cells
of both benign (i, ii) and malignant tis
nuclear staining. Visfatin stained brown.
Figure 3.4a Effect of Visfatin on PC3 cell gene activation using real time PCR: Effect of
visfatin [0– 400ng/ml] on PC3 cell Visfatin RN
are expressed as relative to basal proliferation; n = 3
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Figure 3.4b Effect Of Visfatin on PC3 cell gene activation using real time PCR: Effect
of visfatin [0– 400ng/ml] on PC3 cell Visfatin RNA expression at 24 hours. Data are
expressed as relative to basal proliferation; n = 3; * p < 0.01.
DISCUSSION
This initial part of the study was undertaken as a starting point to determine if there was
a detectable level of visfatin present in prostate cancer cells, and therefore could
visfatin be involved in the pathogenesis or aetiology of prostate cancer. Observations in
this area could therefore potentially lend support to visfatin as a mechanism in the
association between obesity and prostate cancer. Although Berndt et al (Berndt,
Kloting et al. 2005) has shown an inverse relationship between plasma visfatin levels
and levels in the subcutaneous fat suggesting visfatin auto-regulation there is no data
on the correlation in prostate cancer cells given the description of both an intracellular
and extracellular version of this interesting molecule.
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The result of this study demonstrates the novel expression of visfatin in LNCaP and
PC3 cell lines and human prostate tissue. It also describes the novel role of visfatin
auto-regulation in PC3 prostate cancer cell lines.
These data in prostate cells are consistent with previous findings of visfatin expression
in other normal tissues such as lymphocytes, bone marrow, liver and muscle (Samal,
Sun et al. 1994) and also malignant tissues such as breast and colorectal cancer
(Hufton, Moerkerk et al. 1999; Van Beijnum, Moerkerk et al. 2002; Folgueira, Carraro et
al. 2005). In my study, immunocytochemistry and immunohistochemical analysis of
prostate cancer cell lines and tissue, demonstrated cytoplasmic and nuclear staining for
visfatin. This is in keeping with the literature which has shown in the PC-12 (adrenal)
and Swiss 3T3 (fibroblast) cell lines the identification of visfatin in both nuclear and
cytoplasmic compartments and this is thought to be dependent on the stage of the cell
cycle (Kitani, Okuno et al. 2003). Immunohistochemical analysis did not suggest any
difference between cancerous and benign sections of tissue with respect to visfatin
staining. This was purely a qualitative rather than quantitative analysis and further
studies would be required to confirm this observation. This could be performed in the
future but would require a greater volume of tissue collection and new ethical approval
and analysis using techniques such as western blotting in the first instance.
Visfatin has been shown to act as a novel inhibitor of apoptosis in response to a variety
of inflammatory stimuli (Jia, Li et al. 2004). This is of significance with regards to
prostate cancer as low grade, chronic inflammation has been proposed as a risk factor
for prostate carcinogenesis (Palapattu, Sutcliffe et al. 2005); obesity itself is also
recognized as being a state of chronic low-grade inflammation (Visser, Bouter et al.
1999). The significance of these findings are supported by discovery of the function of
visfatin as NMPRTase (Rongvaux, Shea et al. 2002). Of even more importance is the
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finding that inhibition of visfatin by FK866 results in depletion of intracellular NAD+ and
the induction of apoptosis in tumour cells (Drevs, Loser et al. 2003; Hasmann and
Schemainda 2003; Khan, Tao et al. 2006). An interesting finding by the group Samal et
al 1994 was that the 3’ untranslated region of the mRNA has been shown to have
multiple TATT and message-destabilizing sequences that are usually found in the labile
mRNA of cytokines and oncogenes (Samal, Sun et al. 1994).
Visfatin expression and its subsequent activity may well represent a physiological
response to meet the increased demand for NAD in proliferating cells. It should also be
considered that increased visfatin expression in cancer cells with a high turnover rate
correlates to a pathological state and provides cancer cells with the capacity to fuel its
high metabolic rate.
I have commented on the compartmentalisation of visfatin into intra and extracellular
forms and this is corroborated by the detection of the peptide in the circulation. This
has raised the question that visfatin may function as a possible cytokine-like secreted
protein (Rongvaux, Shea et al. 2002) as well as its well documented enzymatic action.
This is still a hotly contested issue however and despite visfatin, under the guise of
PBEF, having been documented to have mRNA encoding the 52 kDa polypeptide it
lacks the typical signal sequence for secretion which makes it surprising that visfatin
secretion has been demonstrated from activated lymphocytes and HeLa cells (Samal et
al. 1994). One hypothesis regarding this surprising finding is that high circulating levels
of visfatin in obesity are secondary to visfatin release during adipocyte
necrosis/apoptosis, which occurs in obese states (Rongvaux, Shea et al. 2002;
Stephens and Vidal-Puig 2006). The presence of circulating visfatin is however
undisputed and the mechanism of its action remains unknown and may be via an
undiscovered receptor. It is interesting therefore that although obesity and elevated
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levels of various adipokines including visfatin are postulated to increase prostate
cancer risk high extracellular visfatin appears to have a negative feedback effect on
visfatin mRNA production in the prostate. This may simply be a protective mechanism
or suggest that intracellular visfatin has a less important role than extracellular visfatin.
Recent studies have suggested that this is not the case (Wang, Hasan et al. 2011). It
should also be heavily considered that an isolated effect does not represent the holistic
in-vivo environment.
CONCLUSION
This initial study provides novel data identifying visfatin in prostate cell lines and tissue
including prostate cancer. Concurrent high circulating visfatin, as occurs in obesity,
combined with increased intracellular prostatic visfatin expression may represent a
possible mechanism whereby these two disease states may be associated although the
above data implies each mechanism may exert separate effects that combine to
increase risk. The remainder of this thesis will look to identify the role that visfatin has in
prostate cancer biology and identify mechanisms of action.
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CHAPTER 4 FUNCTIONAL EFFECTS OF
VISFATIN ON PROSTATE CANCER CELL LINES
INTRODUCTION
It has been well documented that numerous adipokines can exert varying effects on
prostate cancer cell models Mistry, Digby et al. 2007). Prior to this study, there were no
published data with respect to visfatin and its effects in prostate cancer cells or tissue.
Visfatin has been documented to have elevated serum level in obese patients and it
would therefore be reasonable to postulate that it is a contributory factor in leading on
to aggressive prostate cancer (Haider, Schindler et al. 2006). In stark contrast the
serum levels of adiponectin (which is the most abundantly circulating adipokine) are
inversely correlated with visceral obesity (Arita, Kihara et al. 1999), adiponectin levels
also appear to be lower in prostate cancer patients, with levels being inversely
proportional to Gleason score (Freedland 2005; Goktas, Yilmaz et al. 2005).
Interestingly, adiponectin has been shown in its high molecular weight form (HMW) to
inhibit the proliferation of androgen dependent (LNCaP-FGC (fast growing colony)) and
androgen-independent (DU145 and PC-3) prostate cancer cell lines at sub-
physiological concentrations (Bub, Miyazaki et al. 2006).
The adipokine leptin is another molecule that has been studied in prostate pathology.
Leptin circulates in plasma levels that are proportional to visceral fat accumulation
(Considine, Sinha et al. 1996), and they have also been demonstrated to be
significantly higher in men with high grade, advanced prostate cancer (Chang, Hursting
et al. 2001; Saglam, Aydur et al. 2003). As well as the plasma correlation leptin
expression has also been observed in prostate cancer cell lines and human tissue
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(Cioffi, Shafer et al. 1996; Onuma, Bub et al. 2003). Leptin is also known to have a
proliferative effect in DU145 and PC-3 prostate cancer cells but not in androgen-
dependent LNCaP-FGC cells (Onuma, Bub et al. 2003; Somasundar, Yu et al. 2003;
Somasundar, Frankenberry et al. 2004).
During in vitro studies it is easy to fixate on solitary interactions of one cytokine either
elevating or decreasing the basal level and one should remain constantly aware that
there are multiple factors in-vivo that can account for changes in homeostasis. An
example of this is shown in the opposing actions and properties of adiponectin and
leptin. It has been demonstrated in breast cancer patients, where the serum
leptin:adiponectin ratio was found to be higher in cancer patients compared to controls
and displayed a positive correlation with tumour size (Chen, Chung et al. 2005).
Subsequently Mistry et al (Mistry, Digby et al. 2008) also demonstrated that leptin and
adiponectin interact causing a decrease in prostate cancer cell proliferation via the
regulation of p53 and bcl-2 gene expression. The group concluded that high leptin and
low adiponectin levels may be important in leading obesity-related prostate cancer
progression.
In human endothelial cells as well as vascular smooth muscle cells, incubation with
exogenous visfatin has been shown to stimulate cell proliferation (Adya, Tan et al.
2008; Wang, Xu et al. 2009). More recently it has also been shown to induce
proliferation in MCF-7 cells (human breast cancer cells) (Kim, Kim et al. 2010).
As described in the introduction, visfatin had also been identified as nicotinamide
phosphoribosyltransferase - Nampt, and this provides further intonation for the
multifunctional role for visfatin. It has been described as a vital rate limiting enzyme in
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nicotinamide adenine dinucleotide (NAD+) biosynthesis in particular the conversion of
nicotinamide to nicotinamide mononucleotide (NMN) (Rongvaux, Shea et al. 2002).
Thus far we have discussed the possible rationale for examining cell proliferation on
relation to visfatin. With respect to neoplastic states there is a state of flux between
dysregulated cell proliferation and apoptosis.
Apoptosis is an important physiological phenomenon that is a regimentally controlled
process of programmed cell death. It is involved in normal development and cell
biology and disruption to this process is highly significant in tumourogenesis (Kerr,
Wyllie et al. 1972; Thompson 1995). Any potential roles of visfatin as an inhibitor of
apoptosis in cancer are still as yet unclear and not defined; the compound (e)-n-[4-(1-
benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl) acrylamide (FK866) is a long established
very selective non-competitive inhibitor of visfatin (Hasmann and Schemainda 2003).
The compound interferes with NAD+ production and hence total cell reduction of NAD+
concentration. FK866 leads to an effect on pyridine nucleotide biosynthesis i.e. the
induction process and then disrupts the mitochondrial membrane potential i.e. the
effector process and finally leads to irreversible degradation via cellular caspases
(Holen, Saltz et al. 2008). It is therefore of great interest and importance that inhibition
of visfatin by FK866 induces apoptosis in tumours (Drevs, Loser et al. 2003; Hasmann
and Schemainda 2003; Khan, Tao et al. 2006; Kim, Lee et al. 2006). During this study
FK866 has been used to help evaluate the effect of visfatin in this prostate cancer
model. Given this potential therapeutic target clinical trials are currently in progress to
explore the role of FK866. (Holen, Saltz et al. 2008).
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HYPOTHESIS
Visfatin has functional effects on prostate cancer and these can be demonstrated using
in vitro models.
AIMS
 To identify if visfatin has proliferative effects on both LNCaP and PC3 cell lines
 To identify if visfatin is anti-apoptotic in LNCaP and PC3 cells
 To identify if visfatin alters the cellular migration of prostate cancer cells
METHODS
To assess cellular proliferation a MTS based proliferation assay was performed as
outlined below. This method is well established both in the group and in the literature
(Mistry, Digby et al. 2008; Wang, Hasan et al. 2011). A DNA fragmentation assay was
used a marker of late stage apoptosis to elucidate apoptosis. This was chosen as it
was consistent with the literature to date in particular with reference to the inhibitory
molecule FK866 (Hasmann and Schemainda 2003). As surrogate for cellular ‘invasion’
a wound scratch assay was performed. This assay was used in part due to limitations
with time and funding, however it has been well documented as a valid assay in CaP
models (Hermani, De Servi et al. 2006; Gkika, Flourakis et al. 2010)
All of the data in the present study are expressed as mean± SEM. Parametric
comparisons between groups were made by ANOVA in keeping with published work
from the group (Mistry, Digby et al. 2008; Patel, Mistry et al. 2010). The test was
chosen based on its established use, as well as the notion that performing multiple two-
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sample t-tests would be most likely result in type 1 error. For this reason, ANOVAs are
useful in comparing two, three or more means. If significance (P<0.05) was present, a
post hoc Tukeys multiple-comparison test was performed. All statistical analysis was
performed using Graph Pad software (version 4.0)
PROLIFERATION ASSAY
10,000 cells per well of LNCaP and PC3 cells were uniformly seeded onto 96-well
plates, cultured for 48 hours and incubated with serum-free media for 24 hours before
treatment with visfatin (0-400 ng/ml) and IGF-1 (10 ng/ml) for 24 or 48 hours. Cell
proliferation was assayed using CellTiter 96® AQueous One Solution Cell Proliferation
Assay according to manufacturer’s instructions by adding 20µl of 3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
MTS reagent was to 100µl of fresh culture medium in each well. This is an MTS-based
assay that quantifies the amount of formazan produced by metabolically active cells as
measured by absorbance at 490nm using a spectrophotometric plate reader following
an incubation period of 2 hours, which is directly proportional to the number of living
cells in culture (according to product literature). The percentage of the absorbance was
calculated against untreated cells.
This assay was used as it had already been well established within the group and has
been commonly used in this cell model as a surrogate for cell proliferation.
APOPTOSIS ASSAY
DNA Fragmentation ELISA (Roche):
A photometric enzyme linked immunosorbent assay (ELISA) was used for the detection
of 5’-Bromo-2’-deoxy-uridine (BrdU)-labelled DNA fragments in cell lysates as an
alternative to the [3H]-thymidine assay. BrdU is used as a metabolic labelling agent by
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the nuclear DNA of target cells. This can then be easily detected by using a
monoclonal antibody directed against the BrdU in an ELISA.
10000 cells were cultured to 80% confluent in 96 well plates. Following serum
depletion they were then batch labelled with BrdU [10µM]. After overnight incubation at
37ºC all BrdU containing media wash aspirated and washed off with PBS.
BrdU labelled cells were then incubated with visfatin [0-400ng/ml], NMN [100µM], or
FK866 [10µM] or a combination for 24 hours. At the end of the incubation all
supernatant is removed and 200µl of incubating solution was added and incubated for
30 mins to lyse the cells. The cells were then centrifuged and the supernatant
containing LMW-DNA of the cellular lysate was analyzed for apoptosis ELISA.
Camptothesin [2µM] was used as a positive control. To adsorb the Anti-DNA antibody
onto the wells of the 96 well plate 100µl of anti-DNA coating solution was added to
each well and left to incubate at 37ºC for 1 hour. After washing the plate to remove the
coating solution, NSB was prevented by adding 200µl of incubation solution and left for
30 mins and then washed. 100 µl of the supernatant of the cell lysates was added to
the microplate allowing BrdU-labeled DNA fragments in the sample bind to the
immobilized Anti-DNA antibody. This incubation was left for 90 mins at room
temperature after covering the plate. The plate was then washed several times with
wash solution. The final wash solution was then left in situ prior to irradiation in a
microwave oven for 5 mins to allow denaturing of the immunocomplexed BrdU-labeled
DNA-fragments. 100µl of Anti-BrdU antibody peroxidase conjugate (Anti-BrdU-POD)
was then added and incubated for 90 mins which reacts with the BrdU-labeled DNA to
form an immunocomplex. After this step the plate was washed and 100µl of substrate
solution was added to each well incubated in the dark for 20 mins before adding 20µl of
stop solution and incubating for a further minute and then reading the plate at 450nm.
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The absorbance was then calculated as values relative to basal and analyzed using
graphpad software for statistical significance.
WOUND SCRATCH ASSAY
A complicated and highly methodical process is required for tissue wound healing. The
processes required can include infiltration of inflammatory cells which is needed to
eradicate any necrotic tissue from the site, followed by a mechanism which increases
vascularization mediated via angiogenic factors, and increased cell proliferation and
extracellular matrix deposition. A method of estimating the migration as well as
proliferation of a cell type that has been used throughout the literature is the wound
healing assay and is a technique that can employ different cells and culture conditions.
The assays generally require the growing of a confluent cell monolayer. A small area
within the monolayer is then disrupted by scratching a line through the layer. The open
gap is then inspected microscopically over a defined time as the cells migrate in and fill
the ‘wound’. This “healing” can take from several hours to over a day depending on the
cell type, conditions, and the extent of the “wounded” region. The cells must be nearly
confluent (~90%) for this to work and all steps done in a sterile fashion. The protocol
used was similar to that described by Denker 2002 (Denker and Barber 2002).
PROTOCOL
Cells were cultured to confluence or near (>90%) confluence in 12 well plates. They
were then washed with PBS and serum depleted overnight.
On the day of the assay:
Using a sterile 200μl pipette tip, a ‘wound’ was scratched on to the plate and the cells 
were rinsed (very gently as sheets of the cells may lift off if you are not careful) with
PBS and replaced with 1.5 ml of media containing any additives (visfatin, FK866,
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NMN). Photos were taken via the microscope at time points 6, 12 and 24 hours at 10x
and 40x magnification. Measurements were taken in micrometers of the width of the
wound at each time point and compared to basal. All experiments were carried out to
n=3.
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RESULTS
VISFATIN REGULATION OF PROSTATE CANCER CELL PROLIFERATION
Incubation of cells with visfatin alone resulted in a significant concentration-dependent
increase in proliferation after 24-hours incubation in PC3 cells compared to control,
(p<0.001 at 200 and 400 ng/ml) (Figures 4.1a/4.1b). In contrast treatment with visfatin
alone had no significant effect on LNCaP cell proliferation at either 24 or 48 hours
(Figures 4.2a/4.2b) compared to control. Given that there was no functional proliferative
outcome in the LNCaP cell line no further studies were conducted in this cell line. IGF
was used as a positive control to optimise the assay and the results are seen in Fig
4.3a and 4.3b in both PC3 and LNCaP cells respectively.
EFFECTS OF VISFATIN INCUBATION ON PC3 CELL MIGRATION
Visfatin treatment alone resulted in a significant reduction of the wound distance at 24
hours as compared to basal (p<0.001 at 400 ng/ml). NMN also had a significant
decrease in wound distance but less so than visfatin alone (p<0.001 at 100µm). 10µm
FK866 partially inhibited the action of visfatin although there was still closure of the
wound distance. The addition of NMN further negated the effect of the FK866 on
inhibition of cell migration but it still did not revert to the same wound distance as
visfatin treatment alone. (Figure 4.4)
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Figure 4.1a Effect of visfatin on PC3 cell proliferation at 24 hours. Effect of visfatin
alone [0– 400ng/ml] on PC3 cell proliferation. Data are expressed as relative to basal
proliferation; n = 4 for all experiments, *p<0.05, **p<0.01, *** p < 0.001.
Figure 4.1b Effect of visfatin on PC3 cell proliferation at 48 hours. Effect of visfatin
alone [0– 400ng/ml] on PC3 cell proliferation. Data are expressed as relative to basal
proliferation; n = 4 for all experiments.
0 25 50 100 200 400
0
50
100
150
200
***
***
***
Visfatin [ng/ml]
%
of
B
as
al
0 25 50 100 200 400
0
50
100
150
200
Visfatin [ng/ml]
%
of
B
as
al
105
Figure 4.2a Effect of visfatin on LNCaP cell proliferation at 24 hours. Effect of visfatin
alone [0– 400ng/ml] on LNCaP cell proliferation. Data are expressed as relative to
basal proliferation; n = 4 for all experiments.
Figure 4.2b Effect of visfatin on LNCaP cell proliferation at 48 hours. Effect of visfatin
alone [0– 400ng/ml] on LNCaP cell proliferation. Data are expressed as relative to
basal proliferation; n = 4 for all experiments.
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Figure 4.3a Effect of IGF on PC3 cell proliferation. Effect of IGF alone [0–10ng/ml] on
PC3 cell proliferation. 24 hour data are expressed as relative to basal proliferation; n =
4 for all experiments, * p < 0.05.
Figure 4.3b Effect of IGF on LNCaP cell proliferation. Effect of IGF alone [0–10ng/ml]
on LNCaP cell proliferation. 24 hour data are expressed as relative to basal
proliferation; n = 4 for all experiments, * p < 0.05.
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Figure 4.4 Wound Scratch Assay demonstrating the effect of visfatin [400 ng/ml] and
NMN [100µM] and in combination with FK866 [10nM] on the PC3 cell migration across
an artificial wound. A) representative photographs of each treatment and B) graphical
representation of 24-hour data; n=3 for all experiments, *p<0.05, ***p< 0.001
EFFECTS OF VISFATIN ON APOPTOSIS
A DNA fragmentation assay was used to assess for apoptosis. Visfatin treatment did
not significantly alter apoptosis. The positive control using H2O2 confirmed that the
assay was successful although weakly so (p < 0.05). There was a positive result at
400ng/ml of visfatin although not statistically significant. Fig 4.5
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Figure 4.5 Effect of Visfatin [0– 400ng/ml] on PC3 cell apoptosis. Hydrogen Peroxide
(H2O2) [10mM] was used as a positive control. 24-hour data are expressed as relative
to basal; n = 4 for all experiments, * p < 0.05.
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DISCUSSION
This is the first study to report a proliferative effect of exogenous visfatin incubation on
prostate cancer cells. This study reports clear differences in the proliferative response
of two different prostate cancer cell lines to visfatin. Visfatin demonstrated an increase
cellular proliferation using the cell proliferation assay at 24 hours but not at the 48 hour
time point (Fig 4.1a/b). The assay used is a correlate for cell number and by inference
a surrogate for proliferation. The main limitation therefore, is that the assay is not a
direct measure of cellular proliferation or apoptosis. At 48 hours the assay suggests
the proliferation of cells returned to baseline levels following an initial increase at 24
hours. Examining the result more closely with respect to this assay one could conclude
the cell number had actually reduced i.e. undergone rapid apoptosis/necrosis or the
rate of proliferation had declined rapidly relative to basal levels. One explanation for
this may be that the initial increase in cell number over the first 24 hours allowed the
cells to reach full confluence in the treated cells and prevent further increase in cell
numbers. Further correlation with DNA quantification assays may increase the validity
of these results and help answer the above discrepancy. The SYBR-DNA labelled
assay has been shown to be more accurate in quantifying cell number, proliferation and
cell cycle arrest as analyzed by DNA content in other cancer models (McGowan, Alling
et al. 2011). Visfatin-induced increases in cell proliferation were observed in the
androgen-independent PC3 cells, but not the androgen-dependent LNCaP cells. This
suggests that visfatin can exert differing effects based on characteristics of the cell
exposed to it. One of the key differences in the characteristics of the two cell lines used
is the androgen status of these cells. PC3 cells represent an in vitro model for
androgen-insensitive prostate cancer, and thus do not express the classical intracellular
androgen receptor (AR) as compared to the androgen sensitive LNCaP cells. The
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difference in response to visfatin between the two cell lines raises the possibility of
androgen or androgen receptor status being of potential significance in the modulation
of prostate cancer cell biology by visfatin. It is also a possibility that the absence of
additional androgen in the treatment media may have influenced the results seen in the
‘androgen sensitive’ LNCaP cell line. Future studies to strengthen these findings in this
cell line could therefore involve comparing visfatin exposure in the presence and
absence of androgen. The possibility of an interaction between AR and visfatin in
prostate cancer cells is also an area for future research but fell beyond the remit of this
thesis.
The effect on proliferation was demonstrated in a concentration-dependent manner (Fig
4.1a) and perhaps more importantly at levels of visfatin similar to those that have been
demonstrated in the obese population (Haider, Schindler et al. 2006). This provides
novel evidence that elevated levels of circulating visfatin may influence the growth of
prostate cancer tissue. As touched on in the introduction, in addition to being present
intracellularly, visfatin has also been detected in the circulation, suggesting that it may
function as a cytokine as well as/or an enzyme. However, having said this there is
some debate with regards to the function of visfatin as a cytokine-like secreted protein
(Rongvaux, Shea et al. 2002; Fukuhara, Matsuda et al. 2005). One of the theories as to
why visfatin was thought to not be an extracellular or circulating cytokine was based on
the fact that although visfatin cloning and characterization studies have found visfatin
mRNA to encode a 52 kDa polypeptide, it was found to lack a typical signal sequence
for secretion; despite this theory it has, however, been shown to be secreted from
activated lymphocytes and HeLa cells (Samal, Sun et al. 1994). In vivo however as is
often the case, multiple factors can contribute to altered homeostasis and thus it was
postulated that the high circulating levels of visfatin associated with obesity may be due
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to visfatin release during adipocyte necrosis/apoptosis, which occurs in obese states,
rather than true secretion by adipocytes (Rongvaux, Shea et al. 2002; Stephens and
Vidal-Puig 2006). The presence of visfatin in the circulation cannot be disputed despite
the theory, and therefore it is possible that it may exert biological effects via an
unknown receptor. In chapter three we have demonstrated that exogenous visfatin
down regulates visfatin mRNA expression and the mechanism of action by which
exogenous visfatin induces its proliferative effects remains to be elucidated. It may be
via the surrogate action of NMN by extracellular production and action by a secondary
mechanism. This is a well documented effect in pancreatic islets as demonstrated by
Revollo et al (Revollo, Korner et al. 2007) and the theory well described by Garten et al
(Garten, Petzold et al. 2009).
Having shown that visfatin up-regulates proliferation I looked to identify a more
functional assay to demonstrate the effect of visfatin on PC3 cells. To do this we used
a wound scratch assay. This assay demonstrated that an artificially created ‘wound’
was bridged much faster under the influence of visfatin compared to without (Fig 4.4).
Although this assay has been previously cited in the literature, in particular in cancer
models (Gkika, Flourakis et al. 2010), it is only a surrogate for migration as the assay
does not control for cellular proliferation as a mechanism of bridging the wound. The
migratory characteristics of cancer cells is a target of therapeutics and can also serve
as an indicator of tumour aggressiveness and malignancy (Gkika, Flourakis et al.
2010). Within the limits of this experiment as described above, this assay gives slightly
more insight into functional assessment as it demonstrates the more natural
proliferative behaviour of malignant cells to invade and grow into space. It should be
commented that the technique is semi-quantitative and not without its flaws and there
are more quantitative methods available such as in vitro cell invasion chamber assays
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(Wang, Hasan et al. 2011). Due to resource and time constraints I did not proceed to
these. We demonstrated that visfatin was more ‘proliferative’ than NMN. FK-866 did
inhibit proliferation; however the effect was partially reversed by visfatin.
FK866 is a long established very selective non-competitive inhibitor of Nampt
(Hasmann and Schemainda 2003). The compound interferes with NAD+ production
and hence total cell reduction of NAD+ concentration. It was also of interest that FK866
did reduce cell migration however not completely in the presence of visfatin. In this
study a dose of 10nM was used in keeping with concentrations used by Hasmann et al
in their paper examining apoptotic effects of FK-866 in HepG2 cells. It would be
anticipated that FK866 should induce apoptosis of the cells and therefore no migration
would be anticipated in its presence and in fact cell death would be observed.
Interestingly Hasmann et al found that cell viability based on a tetrazolium salt assay
was reduced early after incubation with FK-866 and cell proliferation was still noted up
to day 3 and apoptosis followed at a much more delayed time point of around day 4
onwards. This supports the theory that FK-866 induces apoptosis via NAD+ depletion
at a delayed state and if NAD+ production/levels are preserved i.e. by the use of
exogenous visfatin viability can be preserved. Using the wound scratch assay, it serves
as a semi-quantitative assay of cell migration. Accepting these limitations it was noted
that visfatin’s effect on enhancing cell migration clearly can, in part, be reduced from as
early as 24 hours. This effect is enhanced by using NMN as demonstrated in the final
wound scratch assay. This corroborates the suggestion that it is indeed the rate
limiting step catalysed by visfatin that is of importance. Replenishment of the
intermediary product, NMN, can to some extent recover the inhibition of FK-866 lending
further support to Garten et al’s theory i.e. by replenishing the exogenous NMN its
action via an unknown mechanism allows intracellular NAD+ replenishment (Garten,
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Petzold et al. 2009). This would explain why a combination of visfatin and NMN
incubation closes the wound distance significantly more than visfatin alone in the
presence of FK-866. It can be speculated that should a viability study be done in the
same population as per Hasmann’s findings then it would probably decreased and
apoptosis would be noted. This would certainly be a future study.
As part of the functional spectrum of visfatin this part of the study also looked at the
effect of visfatin on apoptosis. As discussed neoplasia is a balance between apoptosis
and proliferation. The literature suggests that visfatin is a proliferative agent however
little is documented as to whether it has a mechanism of action via anti-apoptosis. A
study by Kendal-Wright et al suggested that over-expression of visfatin in the amniotic
sac cells in response to stretch was anti apoptotic (Kendal-Wright, Hubbard et al.
2008). Jia et al (Jia, Li et al. 2004) demonstrated that in sepsis visfatin secretion by
activated neutrophils can also inhibit apoptosis. They suggested that visfatin may
inhibit the activity of caspase-8, which suggests the possibility that visfatin acts directly
at the cell membrane, possibly via a membrane-associated inhibitor of apoptosis such
as FLICE-like inhibitory protein (FLIP) or through regulatory phosphatases in the
plasma membrane. Visfatin has also been demonstrated to have anti apoptotic effects
in human umbilical vein endothelial cells (HUVECs) (Adya, Tan et al. 2008). I therefore
looked to identify whether an anti-apoptotic effect was a potential mechanism for the
increased migratory capacity of PC3 cells under the influence of exogenous visfatin.
Using the PC3 cell line no significant effect was identified with regards to apoptosis. In
this particular experiment it was difficult to obtain good optimization as demonstrated by
the use of H2O2 although it was weakly significant suggesting the assay itself worked.
The findings have confirmed the absence of a significant effect on apoptosis of visfatin
however at the maximum dose there is a suggestion that it had some apoptotic effect
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≈40% increase.  This was not statistically significant however due to the error involved.  
One explanation could be the onset of apoptosis due to prolonged starvation of the
cells for the assay coupled with high dose visfatin treatment. This is an unusual finding
as the proliferation assay performed earlier in the study suggested maximal proliferative
effect at this concentration. The apoptosis assay used was a DNA fragmentation
ELISA. The Cellular DNA Fragmentation ELISA measures apoptosis, necrosis, or cell
mediated cytotoxicity by quantifying the fragmentation and/or release of BrdU-labeled
DNA. This is a late stage of apoptosis and often referred to as the hall mark of
apoptosis as opposed to necrosis. As a marker of late stage apoptosis it could be
inferred that the cells may be in early stage apoptosis and either using an alternative
assay to capture this event such as a caspase cascade detection assay or simply
performing the study at varying time points may be a better option. As the literature
suggests that visfatin was a proliferative agent further functional assays were not
undertaken with respect to visfatin and apoptosis.
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CHAPTER 5 MECHANISMS OF ACTION OF
VISFATIN ON PROSTATE CANCER
INTRODUCTION
Carcinogenesis is a multi-step process which results in deregulation of cellular
homeostasis, allowing premalignant lesions to develop into invasive tumors (Gorgoulis,
Vassiliou et al. 2005). Detailed mechanisms pertaining to the cell cycle, apoptosis and
angiogenesis have been laid out in chapter 1 pages 31-35. It is therefore imperative
that multiple avenues are explored to examine the mechanisms of functional effects of
agents suspected of being involved in the carcinogenic process.
Visfatin has been shown to elicit a variety of effects in different cell lines through
several second messenger systems. This chapter focuses upon the potential
mechanisms through which visfatin may elicit its functional effects on PC3 cells. The
specific aim for this part of the study was to identify second messengers and
angiogenic mechanisms. Given that adipokines, in particular leptin and adiponectin,
have been shown previously to influence oncogenes in prostate cancer models (Mistry,
Digby et al. 2008) the study also looked at onco- and tumour suppressor genes that
may be regulated by exposure to visfatin.
Given that visfatin has been postulated to have insulin-mimetic effects initially thought
to be mediated via the insulin receptor, an evaluation of visfatin’s effects on gene
expression of IGF-1R was performed.
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HYPOTHESIS
Having demonstrated the functional effects of visfatin on PC3 cells it is suggested that
visfatin exerts its functional effects on prostate cancer cell models via various
mechanisms including MAP-kinases, MMPs and BCL-2, BCL2-L1, MCL-1, BAX, IGF-R,
gene over/under expression. Thus this study hypothesizes that visfatin modulates
MAPK and also effects MMP-2/-9 activity and may therefore effect CaP evolution. It is
also hypothesized that visfatin modulates oncogenes as a mechanism of CaP
neoplasia.
AIMS
 To identify if visfatin activates common MAPKs in PC3 cell lines
 To identify if visfatin activates MMPs in PC3 cells
 To identify if visfatin alters the expression of various tumour suppressor and
oncogenes
METHODS
Methods are detailed below. Protein data was measured by standard western blotting
technique and MMP activity was detailed using gelatin zymography. RT-PCR was
undertaken to evaluate gene expression data.
MAPK- ERK 1/2 AND P38 MAPK ACTIVATION, MMP-2/9 EXPRESSION
The effect of visfatin on activation of the MAPK (ERK-1/2 and p38) as well as MMP-2
and MMP-9 protein expression in PC3 cells was studied using Western blotting
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analysis as per Patel et al and Adya et al (Adya, Tan et al. 2008; Patel, Mistry et al.
2010). Following treatment with visfatin at times points between 0-60 mins for MAPK
activity and at 24-hours for MMP analysis), cells were lysed with RIPA buffer. Samples
were centrifuged and quantified and subsequently boiled prior to use.
For MAPK analysis 40 µg of each sample was loaded; for MMP analysis 80 µg was
used. Samples were separated by 10% sodium dodecyl sulphate (SDS)-polyacrylamide
gel electrophoresis (SDS-PAGE), and electro-blotted onto a polyvinylidene fluoride
(PVDF) membrane. The PVDF membrane was then blocked by incubating with 5 %
bovine serum albumin in TBS-T, pH 7.4 for 1-hour at room temperature. Membranes
were then incubated with primary antibody phosphorylated ERK1/2, phosphorylated
p38 (rabbit polyclonal 1:2000 diluted in 5% BSA/TBS-T), MMP-2 or MMP-9 (mouse
monoclonal 1:400 diluted in 5% BSA/TBS-T) overnight at 4 °C. Membranes were then
washed thoroughly for 1 hour at room temperature with TBS-T (0.1%) followed by
incubation with a secondary anti-mouse horseradish-peroxidase-conjugated secondary
antibody (1:2000 dilution) for 1-hour at room temperature. Antibody complexes were
demonstrated using a chemiluminescence detection reagent kit (ECL+). To determine
MAPK activity the membranes were stripped by submerging in stripping buffer [10%
SDS, 1M Tris-HCl pH 6.8, β-mercaptoethanol and incubated at 50oC for 30 minutes
with occasional agitation followed by washing with TBS-T at room temperature (10
minutes – twice) and PVDF membranes were blocked in TBS-T and 5% BSA for one
hour at room temperature. The membranes were re-probed with primary rabbit-anti-
human antibody for total ERK1/2 /p38 MAPK [1:1000 dilution] overnight at 4 °C. The
following day, membranes were washed with TBS-T for 1 hour and then incubated with
the secondary anti-rabbit horseradish peroxidase-conjugated Ig [1:2500 dilution] for one
hour at room temperature.
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In addition to quantitative loading of gels, the MMP membranes were also re-probed
with -actin antibody (1:10,000 dilution) to determine equal protein loading. With
respect to MMP analysis IGF [10ng/ml] was used as a positive control. Studies have
demonstrated a role for IGF in in vitro prostate cancer models with respect to MMP-
2/9.(Saikali, Setya et al. 2008). Band densities were measured using a scanning
densitometer coupled to scanning software Scion Image™.
To calculate potential MAPK activation the band densities (calculated using Scion
image) of phosphorylated MAPK in the different treatment groups were normalized by
dividing with the band intensity of total MAPK detected with an antibody that detects
both phosphorylated and un-phosphorylated forms of the enzyme. This corrected for
any differences in protein loading. Fold induction is calculated as normalized band
intensity relative to basal. For MMP expression a similar calculation was performed
however the band intensity was normalised to -actin.
GELATIN ZYMOGRAPHY
The gelatinolytic activity of MMP-2 and MMP-9 secreted into culture supernatants
following treatment with 0 – 800 ng/ml visfatin was measured by gelatin zymography.
10µl zymography sample buffer was mixed with 10 µl of culture supernatant and
resolved in 10% SDS-PAGE containing 1 mg/ml of gelatin (Sigma, St. Louis, USA)
under non-reducing conditions. After electrophoresis at 4º C, gels were washed twice
for 30 mins with renaturation buffer (2.5% Triton X-100) at room temperature, and then
incubated overnight in incubation buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM
CaCl2, 1 µM ZnCl2) at 37º C. MMP activity was determined by inhibition with 10 mM
EDTA. Following incubation, gels were stained for 1-hour using a buffer of 0.25 %
coomassie brilliant blue R-250 (in 45% methanol and 10% acetic acid), and then
destained in the same buffer minus coomassie. Following de-staining, gelatinolytic
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activity of secreted MMP was observed as white bands against a blue background,
which were quantified by measuring the band intensity (Gel Pro image analysis). IGF
[10ng/ml] was used as a positive control.
REAL TIME POLYMERASE CHAIN REACTION (RT-PCR)
For quantitative RT-PCR the BioRad IQ5 I-cycler system with 96 well plates was used.
Reaction mixtures contained 10µl PrimerDesign 2X PrecisionTM Mastermix (2x
reaction buffer, 0.025 U/>l Taq Polymerase, 5 mM MgCl2, dNTP Mix
(200>M each dNTP), 1µl primer (300nM in a 20μl reaction) and 4 µl RNAse/DNAse free 
water and 5µl of diluted cDNA (5ng/<l). The final volume in each well was 20µl.
Quantitative amounts of the genes of interest were standardized against 2
housekeeping genes as per geNorm™ analysis (see page 75). For each sample, ∆CT 
(crossing point) values were calculated as the CT of the target gene minus the CT of
the β-actin gene. The RNA levels were expressed as a ratio, using “Delta-delta method” 
for comparing relative expression results between treatments in real-time PCR (Pfaffl et
al., 2001). and changes in gene expression expressed as x-fold over basal.
Thermal cycling conditions were:
Cycle 1: (1X)
Step 1: (enzyme activation) 95.0 °C for 10:00.
Cycle 2: (40X)
Step 1: (denaturation) 95.0 °C for 00:15.
Step 2: (data collection) 60.0 °C for 01:00.
Cycle 3: (1X)
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Step 1: 95.0 °C for 01:00.
Cycle 4: (1X)
Step 1: 55.0 °C for 01:00.
Cycle 5: (81X)
Step 1: 55.0 °C-95.0 °C for 00:10.
All samples were analysed in triplicate and n=3-5 were used for all treatments. To
identify cDNA cross contamination between wells or contamination of one or more
reagents ‘no template controls’ were used where the cDNA was replaced with
RNAse/DNAse free water. To identify for genomic DNA contamination ‘RT-negative’
controls were used with the equivalent concentration of RNA is added minus the
reverse transcription step. With respect to MMP analysis IGF [10ng/ml] was also used
as a positive control.
All primers were designed using the reference sequence in the NCBI Nucleotide
sequence database or pre-validated primers were purchased from PrimerDesign Ltd.
Specificity of all primer sets were confirmed using melt-curve analysis and sequencing
where appropriate. Figure 2.1 shows the primers used.
RESULTS
THE EFFECT OF VISFATIN ON MAPK ACTIVITY IN PC3 CELLS
Incubation of PC3 cells with visfatin resulted in a significant activation of ERK 1/2 after
10 minutes at a treatment dose of 400ng/ml which corresponded to the maximal
proliferative effect of visfatin (p<0.05) (Figure 5.1). A significant increase in p38
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phosphorylation was also observed after 2 min
(p<0.05) with a subsequent rapid return to basal levels after 10 min
Figure 5.1 The effect of visfatin on MAP
A: Representative western blot showing changes in p
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B: Bar chart showing quantification of chang
represent means +/-
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Figure 5.2 The effect of visfatin on MAP-K (p38) activity in PC3 cells
A: Representative western blot showing changes in p-p38/t-p38 expression following
treatment with 400 ng/ml visfatin at varying time points of incubation 0-30 mins; lanes
correspond to bar chart
B: Bar chart showing quantification of changes in p38 activation in PC3 cells. Data
represent means +/- SEM of 3 experiments; * p < 0.05 compared to basal expression.
THE EFFECT OF VISFATIN/IGF-1 ON MMP-2 AND MMP-9 MRNA AND
PROTEIN EXPRESSION AND SECRETED ACTIVITY IN PC3 CELLS
mRNA expression of both MMP-2 and MMP-9 was significantly increased following
treatment with all doses of visfatin studied (p ≤ 0.05); the greatest increases were seen 
p-p38
t-p38
A
B
38 KD
38 KD
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in MMP-9 expression. Addition of 10 ng/ml IGF-1 alone also significantly increased both
MMP-2 and MMP-9 expression (Figure 5.3).
The effect of visfatin on MMP-2 and MMP-9 protein expression was studied using
Western blotting. We found that the changes in mRNA expression of these MMPs were
also associated with corresponding significant increases in protein expression (p ≤0.05) 
(Figure 5.4).
The effect of visfatin +/- IGF-1 on the activity of secreted MMP-2 and MMP-9 by PC3
cells was studied using gelatin zymography. Visfatin induced a concentration-
dependent increase in MMP-2 activity that was significant at concentrations over 400
ng/ml (p ≤ 0.05); 10 ng/ml IGF-1 alone also significantly induced MMP-2 activity (p < 
0.001) (Figures 5.5). MMP-9 also showed a dose-dependent increase in activity
following treatment with visfatin which was significant at concentrations over 400 ng/ml
(p< 0.001). IGF-1 alone also significantly increased MMP-9 activity (p < 0.001) (Figure
5.5).
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Figure 5.3 The effect of visfatin/IGF-1 on MMP-2 and MMP-9 mRNA expression in
PC3 cells. Bar chart showing quantification of changes in MMP-2/-9 mRNA expression
in PC3 cells. Data represent means +/- SEM of 3 experiments; * p < 0.05, ** p < 0.01,
*** p < 0.001, compared to basal expression.
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Figure 5.4 The effect of visfatin/IGF-1 on MMP-2/9 protein expression in PC3 cells.
A. Representative western blot showing changes in MMP-2/-9 expression following
treatment with 0 – 800 ng/ml visfatin or 10 ng/ml IGF-1; lanes correspond to bar chart.
B. Bar chart showing quantification of changes in MMP-2/-9 expression in PC3 cells.
Data represent means +/- SEM of 3 experiments; * p < 0.05, ** p < 0.01, *** p < 0.001,
compared to basal expression.
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Figure 5.5 The effect of visfatin/IGF-1 on MMP-2 /-9 activity in PC3 cells.
C. Representative zymography gel showing changes in MMP-2/-9 activity following
treatment with 0 – 800 ng/ml visfatin or 10 ng/ml IGF-1; lanes correspond to bar chart.
D. Bar chart showing quantification of changes in MMP-2/-9 activity in PC3 cells. Data
represent means +/- SEM of 3 experiments; * p < 0.05, ** p < 0.01, *** p < 0.001,
compared to basal expression.
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EFFECT OF VISFATIN ON PC3 CELL ONCOGENE EXPRESSION USING
REAL TIME PCR
Incubation with visfatin had no significant effect on the level of BCL-2 expression at all
concentrations and at both time points used (Figure 5.6).
mRNA expression of BAX was significantly decreased at both 4 and 24 hours following
treatment with 50 ng/ml of visfatin studied (p ≤ 0.05); (Figure 5.7). The trend suggested 
that there is a consistent fall in BAX expression at all concentrations.
mRNA expression of BCL2-L1 was significantly decreased following treatment with 25
and 50 ng/ml of visfatin (p ≤ 0.05 and p <0.01 respectively) at 4 hours before returning 
to basal at higher concentrations. Although statistically not significant the trend
appeared consistent at 24 hours (Figure 5.8).
mRNA expression of MCL-1 showed no significant change at 4 hours at any
concentration of visfatin. At 24 hours there was a significant decrease in mRNA
expression from concentrations of visfatin at 50 ng/ml and upwards (p <0.01) however
this was not dose dependent (Figure 5.9).
mRNA expression of IGF-R demonstrates a significant up-regulation from 50 ng/ml
visfatin (p<0.01) and peaks at a treatment concentration of 100 ng/ml (p <0.001) at 4
hours. The levels then begin to fall towards basal at higher concentrations. There was
no significant change at 24 hours although at concentrations ≥100ng/ml there was a 
trend to increase IGF-R gene expression (Figure 5.10).
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Figure 5.6 Effect of visfatin [0– 400ng/ml] on PC3 cell BCL-2 RNA expression. 4 and
24-hour data are expressed as relative to basal; n = 3.
Figure 5.7 Effect of visfatin [0– 400ng/ml] on PC3 cell BAX RNA expression. 4 and 24-
hour data are expressed as relative to basal; n = 3 * p < 0.05.
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Figure 5.8 Effect of visfatin [0– 400ng/ml] on PC3 cell BCL2-L1 RNA expression. 4 and
24-hour data are expressed as relative to basal; n = 3 * p < 0.05, **p<0.01.
Figure 5.9 Effect of visfatin [0– 400ng/ml] on PC3 cell MCL-1 RNA expression. 4 and
24-hour data are expressed as relative to basal; n = 3, *p<0.05, ** p < 0.01.
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Figure 5.10 Effect of visfatin [0– 400ng/ml] on PC3 cell IGF-R RNA expression. 4 and
24-hour data are expressed as relative to basal; n = 3 * p < 0.05, ***p<0.001
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DISCUSSION
Given that exposure to exogenous visfatin increased cell proliferation, it reasonably
followed that MAPKs may be implicated in this observation. ERK1/2 is broadly
associated with mitogenesis and therefore inversely related to apoptosis (Cross TG
2002). The results reported here demonstrate a small yet significant increase in
ERK1/2 activity after 10 mins using the maximal proliferative concentration of visfatin
which was determined with the cell proliferation studies (Fig 5.1). ERK activation has
been previously demonstrated in PC3 cells following incubation with leptin, also an
adipokine (Deo, Rao et al. 2008). Other groups have also demonstrated visfatin as an
activator of ERK1/2 in other tissues including endothelial and smooth muscle cells
(Kim, Bae et al. 2007; Wang, Xu et al. 2008). The Ras/Raf/MEK/ERK cascade is known
to act as a second messenger pathway from cell surface mitogens via transcription
factors ultimately regulating gene expression and this signalling cascade also regulates
the activity of many proteins involved in apoptosis (McCubrey, Steelman et al. 2007).
Increased expression of this complex Ras/Raf/MEK/ERK pathway is well established in
metastatic CaP, androgen independent states and poor outcome (Abreu-Martin, Chari
et al. 1999; Gioeli, Mandell et al. 1999; Bakin, Gioeli et al. 2003). This pathway has also
been shown to have notable effects on apoptosis regulatory molecules including the
BCL2 family members such as MCL-1 (Steelman, Pohnert et al. 2004; McCubrey,
Steelman et al. 2007). It was noted in this study that the level of ERK activation was
relatively low compared to that seen in the other aforementioned studies in other cell
types. This could be attributed to the finding that androgen independent cell line like
DU145 and including PC3 tend to express low levels of activated ERK (McCubrey,
Steelman et al. 2007). The most widely reported effect of ERK activation in a prostate
cancer model is to promote cell proliferation, although some studies have demonstrated
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ERK dependent apoptosis in prostate cancer cell lines (Maroni, Koul et al. 2004;
Ghosh, Malik et al. 2005). This was the first study to demonstrate ERK phosphorylation
in response to visfatin in prostate cancer cell lines. Undoubtedly the conclusion from
review of the literature is that ERK activity is implicated in CaP. However, although I
present novel data one needs to be cautious in extrapolating these results to be
biologically significant as the majority of studies demonstrate a much higher degree of
ERK phosphorylation.
Various groups have reported the activation of p38 by agents which include IL-1, TNF-
α, EGF, fibroblast growth factor (FGF) IL-6 and vitamin D, all of which have been 
related to prostate carcinogenesis (Mehta, Robson et al. 2001; Tuohimaa, Lyakhovich
et al. 2001; Culig, Bartsch et al. 2002). Ricote et al have also shown that p38 can be
induced by provoking a stress response in tissue via UV light and also osmotic
changes. They also noted that the activation of p38 pathways can regulate gene
expression by modulation of activating transcription factor-2 (ATF-2) and nuclear factor-
κB (NF- κB) (Ricote, Garcia-Tunon et al. 2006). p38 has been broadly associated with
apoptosis induction (Cross TG 2002). Prostate cancer cells with active p38 have been
shown to be highly sensitive to the chemotherapy agent, cisplatin, triggering increased
apoptosis (Skjoth and Issinger 2006). Newer data has opposed the above theory
proposed by Cross et al and suggested that p38 may indeed have pro-carcinogenic
effects in some cell types, conferring protection against apoptosis instead (Luschen,
Scherer et al. 2004), an example of this is found in melanoma cells whereby the
p38/ATF-2 pathway has been shown to mediate proliferation signals. The precise
effects of p38 activation in prostate carcinogenesis are poorly understood at present.
Interestingly we have novel data showing significant increased phosphorylation in p38
activation after 2 mins at visfatin concentrations of 400ng/ml (Fig 5.2). Given that the
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earlier functional data demonstrated proliferative effects of visfatin as opposed to
apoptotic it is likely that in this cell model activation of p38 has a proliferative nature
rather than apoptotic. Furthermore p38 has also been shown to play an important role
as a mediator in the up regulation of MMP-2 in prostate cancer (Huang, Chen et al.
2005). Our data lends support to the existing data that p38 activation may have
proliferative effects dependant on the stimulant applied, in this case visfatin, and also
that it may play a role in mediating factors responsible for prostate cancer progression.
The literature certainly suggests a significant role for p38 in CaP biology but the exact
role is still debated. The data presented here is again in keeping with the literature and
serves only to lend support. Ideally the use of a p38 inhibitor such as SB203580 would
help demonstrate and verify the true significance of this result and may have a place in
future studies.
MMP-2 and -9 are important proteases that are involved in the breakdown of the
extracellular matrix under both physiological and pathological conditions (Saarialho-
Kere, Chang et al. 1992; Adya, Tan et al. 2008). More specifically, they degrade type IV
collagen, the major structural component of basement membranes and are crucial to
the process of cell migration, invasion and metastasis. Both MMP -2 and -9 have been
shown to play an important role in advanced CaP (Wilson, Gallagher et al. 2004;
Incorvaia, Badalamenti et al. 2007). Not only were the effects of visfatin notable in the
PC3 prostate cancer cell line, but they also induced significant increases in MMP-2 and
-9 expression and gelatinolytic activity. In conjunction with their aforementioned effects
on proliferation and apoptosis, it is of great interest that both ERK 1/2 and p38 have
been implicated in the regulation of MMP-2 and -9 (Adya, Tan et al. 2008). Visfatin
induced ERK 1/2 phosphorylation has been shown to regulate the production and
activity of MMPs and play a role in dysregulated angiogenesis (Adya, Tan et al. 2008)
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while p38 has also been shown to influence MMP-2 in prostate cancer (Huang, Chen et
al. 2005). The data is strong when relating to MMPs to CaP and this novel data
supports the current published data. These data allow one to comment on a possible
mechanism by which visfatin influences prostate cancer progression i.e. via an increase
in MMP production and activity.
The multistep theory of metastatic spread proposed by Liotta et al is helpful in
understanding the rational for examining the MMP axis. The three steps are: (1) the
adhesion of tumor cells to basement membrane; (2) local proteolysis that leads to the
invasion of cancer cells into stroma; and (3) tumor cell proliferation (Liotta 1993). From
the above it can be inferred that step 2 is a key factor in prostate cancer progression.
This involves the disruption of the basement membrane components such as type IV
collagen, laminin, fibronectin, and proteoglycans (Mignatti and Rifkin 1993). MMPs are
an important part of this cascade (Liotta 1993) and our novel finding that visfatin
upregulates MMP-2/-9 at all levels and most importantly activity is dramatically
increased suggests that obese patients with elevated levels of visfatin may in fact have
a more aggressive form of the disease capable of metastasis. Studies have shown an
association of increased production of MMPs (MMP-2, -3, -7 and -9) with malignant
progression of prostate cancer (Nunn, Gibson et al. 1997). The above evidence lends
support to metastatic disease although as described in chapter 1 (introduction) the
Gleason score is largely thought to represent a key feature in grading CaP into
aggressiveness. Stearns et al (Stearns and Stearns 1996) have reported that, MMP-2
expression is associated with ≥ Gleason 7 i.e. high grade disease. In keeping with the
present study thus far one study has also shown that in normal prostate tissue and low
grade disease as per the Gleason score MMP-2/-9 display low levels as compared to
high grade tumours (Wood, Fudge et al. 1997).
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The findings reported here, particularly the increased gelatinolytic activity seen with
visfatin treatment, allows us to tentatively speculate that the elevated circulating visfatin
levels associated with obesity may promote prostate cancer progression by enhancing
the capability of metastasis via MMP regulation.
Finally, the effect of visfatin on gene expression levels of various oncogenes was
measured. As discussed in chapter 1 (p 34-35) adipokines have been shown to
regulate oncogenes and tumour suppressor genes but no data exists for gene
modulation by visfatin and the BCL family of genes in prostate cancer. It was therefore
decided to run a pilot study at this stage to try and establish if this was a novel
mechanism by which visfatin may influence CaP pathogenesis. Through-out the PCR
analysis it was noted that there was significant variance in the data presented, and to
further elucidate this relationship, a formal powered study would be needed with the
appropriate number of replicates. Strict post–hoc analysis to compare the data in the
presence of large standard error can also influence the likely hood of significance within
the data. Given the nature of the results seen graphically in Figs 5.6-5.10 the statistical
analysis was reviewed and confirmed. Both the ANOVA and unpaired t-test assume
Gaussian or parametric distribution and this is often difficult to confirm in RNA data and
a non-parametric test can be an acceptable alternative (Yuan, Reed et al. 2006). These
factors have been accounted for in discussing the data.
Although in the past adipokines have been shown to modulate BCL-2 in CaP cell lines
(Mistry, Digby et al. 2008) we did not show any similar findings with respect to visfatin.
The BCL-2 family have been documented to be expressed in both primary and
metastatic CaP (Hughes, Murphy et al. 2005). BCL-2 is anti-apoptotic (Bubendorf,
Sauter et al. 1996) and it is therefore unsurprising that given the lack of effect of visfatin
on apoptosis that an effect on this key anti-apoptotic gene was not discovered.
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We did however note an effect of down regulation of BAX mRNA at both 4 and 24 hr
time points following incubation with 50ng/ml visfatin. BAX has the opposite action to
BCL-2 and has the effect of permeabilizing the outer mitochondrial membrane which
results in apoptosis via caspase release (Wolter, Hsu et al. 1997). From this isolated
result it is difficult to discern its significance when applied to the overall picture. The
concentration of visfatin exhibiting this effect is close to physiological levels in the
obese population and down regulation of BAX at this level of visfatin may therefore be
of relevance. The down-regulation of an apoptotic gene provides an isolated
mechanism of action of tumour aggressiveness. This result can provide a further
mechanism of action of visfatin in increasing tumour aggressiveness as decrease in
this pro-apoptotic gene expression would encourage cellular proliferation. A further way
of revisiting this finding in the future would have been to examine the ratio of BCL-
2:BAX as it has been the balance of the two that has proposed to regulate apoptosis
(Kyprianou, King et al. 1997; Johnson, Robinson et al. 1998).
MCL-1 was originally described as an early gene that was induced during differentiation
of ML-1 myeloid leukemia cells (Kozopas, Yang et al. 1993). MCL-1's role in the
regulation of cell death has been mostly investigated in myeloma cells in which it
mediates ‘pro-survival’ i.e. promotion of cell viability via the action of IL-6 (Jourdan,
Veyrune et al. 2003) as do BCL2, BCL2-L1, and other anti-apoptotic members of this
family (Craig 2002). MCL-1 has been demonstrated to have variable expression from
prostate cancer specimens compared to benign tissue (Krajewski, Bodrug et al. 1995;
Krajewska, Krajewski et al. 1996) which suggests a role for MCL-1 in prostate cancer
although data has been sparse since this discovery. It should be noted however that
the increase cell viability has been found to be short lived with the MCL-1 conferring an
advantage for only several days longer than controls as found in murine myeloid
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progenitor cells (Zhou, Qian et al. 1997). A common thread that should be considered
and is expressed in the literature is that control of apoptosis via the BCL-2 family is a
complex set of interactions within the family. Given that the adipokine IL-6 is reported
as a mediator in BCL-2 family mediated apoptosis it seemed feasible that visfatin would
play a similar role. This is novel data and the kinetics of these genes and there
expression in response to visfatin has not been elucidated until this study. This is
particularly difficult to explain given the knowledge that MCL-1 and BCL2-L1 have been
shown to be linked to MAP kinase mediated pathways (either MEK/ERK or p38)
(Boucher, Morisset et al. 2000). We have demonstrated that visfatin may regulate both
these pathways. The complex interplay is well illustrated by using the Raf/MEK/ERK
pathway.
Overall, although I have shown that visfatin treatments at a variety of concentrations
and time points appears to modulate these various BCL2 family oncogenes, the data is
not in keeping with the literature and the findings presented thus far. These data
therefore have to be reviewed with caution. Much of the data is novel yet within the
confines of the experiments (in particular low ‘n’ numbers) and incongruity with
published literature significant conclusions cannot necessarily be drawn.
The final result in this chapter showed an increase in IGFR mRNA at 4 hours. This may
prove to be highly significant finding. In a paper that was subsequently retracted,
Fukuhara et al (Fukuhara, Matsuda et al. 2005) suggested there was a role for visfatin
as an insulin-mimetic. Subsequently no further studies have reproduced these results;
however there has been some data in support of these interesting findings. Xie et al.
demonstrated insulin-like effects with visfatin in human osteoblasts (Xie, Tang et al.
2007). They found that visfatin increased glucose uptake, stimulating the expression of
osteogenic markers at both gene and protein level. It was also shown to cause an
139
increase of mineralisation of osteoblasts similar to that of insulin. They also went on to
show that when the insulin receptor (IR) was specifically blocked by HNMPA-(AM)
(Cell-permeable analogue of HNMPA (Hydroxy(2-naphtyl)methyl]phosphonic acid) that
yields the parent compound from cleavage by cytosolic esterases and inhibits tyrosine
autophosphorylation of the human insulin receptor). the insulin-like effects were also
inhibited. Dahl and associates (Dahl, Yndestad et al. 2007) also published further
evidence that visfatin acts via the IR. They showed that in THP cells visfatin mediated
secretion of interleukin-8 (IL-8) and tumour necrosis factor-alpha (TNF-α) as well as 
matrix metalloproteinase-9 (MMP-9) activity was abolished when the IR was inhibited
by HNMPA-(AM)
There has been evidence to the contrary and Revollo et al. have shown that visfatin
does not exert insulin-mimetic effects in vitro or in vivo but does exhibit NAD
biosynthetic activity. It may be that there is a degree of cross talk between visfatin-
mediated and insulin signalling pathways in a cell specific manner. An alternative
theory is that it is the visfatin mediated NAD synthesis influences insulin signalling. With
this evidence it is easy to conclude that visfatin has insulin like effects however further
studies are warranted. IGFs are structurally similar to pro-insulin. In prostate epithelial
cells, IGFs display significant mitogenic and anti-apoptotic effects, and are
hypothesised to be causal in prostate carcinogenesis and progression (Cohen, Peehl et
al. 1991; Cohen, Peehl et al. 1994). The IGF ligand family include IGF-I, IGF-II, insulin,
as well as several non-classical ligands of which the roles are not fully elucidated
(Werner and LeRoith 1996). The IGF receptors display a similar affair and comprise of
the insulin receptor (IR), IGF-1R, IGF-IIR, and several atypical receptors, (Nakae, Kido
et al. 2001). IR has been shown to have high homology with the to the insulin-like
growth factor receptor (IGF-1R) ranging between 45-65% homologous in the ligand
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binding site (Ullrich, Gray et al. 1986; Yip, Hsu et al. 1988; Andersen, Wiberg et al.
1995; Mynarcik, Williams et al. 1997). It is therefore unsurprising that cancer cells have
an amazing ability to respond to circulating insulin a situation that becomes extremely
important in the obese population suggesting further evidence between aggressive CaP
and obesity. These findings lend support to other epidemiological data confirming that
obesity and a hyperinsulinaemic state are associated with a variety of cancers such as
breast, prostate, colon and kidney carcinomas (Bray 2002; Calle and Thun 2004).
Further evidence to the importance of IGF-1R to this system can be found in data from
Chan et al who found that IGF-1 serum levels are positively correlated with CaP
development risk (Chan, Stampfer et al. 1998). Further studies have also found similar
results (Mantzoros, Tzonou et al. 1997; Wolk, Mantzoros et al. 1998). Furthermore it
been has shown that prostate cancer cell lines form both androgen sensitive and
insensitive lineage show an increase in proliferation in response to IGF-1 (Semjonow,
Brandt et al. 1996). All of the above lend support to the significant finding
demonstrated in this study that the upregulation of IGF-1R mRNA levels in response to
visfatin exposure is a significant finding in potentially explaining a mechanism by which
visfatin modulates aggressive disease. There is also evidence in the literature that
IGF-1R is involved with CaP directly. Both protein and mRNA for IGF-1R have been
found to have altered expression in tissue samples of prostate cancer and benign
prostate epithelium (Tennant, Thrasher et al. 1996), and even more significant is the
finding by Burfeind et al that antisense RNA to IGF-1R suppresses tumour growth and
prevents invasion by rat prostate cancer cells in vivo (Burfeind, Chernicky et al. 1996).
With respect to IGF-1R there is a wide evidence base as discussed above as to the
role in prostate cancer. The data presented is in keeping with the published literature
to date and provides novel mechanisms linking visfatin and prostate cancer.
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CONCLUSION
In this study it has been demonstrated with novel data that there are multiple potential
mechanisms by which visfatin may modulate CaP further studies inhibiting these
pathways would further delineate which second messenger systems are implicated with
any significance. The finding that visfatin upregulates MMP levels and activity is highly
significant in explaining a mechanism of increased aggressiveness as is the increase in
mRNA levels if IGF-1R.
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CHAPTER 6
THE INVESTIGATION OF NMN
AND FK866 IN PC3 CELLS
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CHAPTER 6 THE INVESTIGATION OF NMN AND
FK866 IN PC3 CELLS
INTRODUCTION
Visfatin is the rate-limiting step in NAD biosynthesis and therefore becomes a highly
important part of normal energy homeostasis, including metabolism and also plays a
role in immunity and neoplasia (Galli, Van Gool et al. 2010). The concept of
extracellular and intracellular visfatin has already been discussed in chapter 4 (p81-81)
and the compartmentalization of visfatin in this fashion becomes of increasing
importance when discussing the role of nicotinamide mononucleotide (NMN).
NMN is a by-product of the action of extracellular visfatin in NAD metabolism. This ‘by-
product’ has been suggested to have the capacity to behave in an autocrine and even
paracrine fashion on tissue (Garten, Petzold et al. 2009). In addition it has been shown
in visfatin knockout mice that the insulin secretion dysfunction is reversible with the
addition of extracellular NMN (Revollo, Korner et al. 2007). This finding suggests a role
for NMN as a surrogate for extracellular visfatin. Of further interest is that plasma NMN
levels have been found to be regulated by extracellular visfatin and that this is
independent of intracellular NMN levels and biosynthesis (Revollo, Korner et al. 2007).
The role of circulating NMN levels in prostate cancer and neoplasia still remains
unexplored and therefore the purpose of this study was to try and elucidate this role in
PC3 cancer cells. It would seem logical that cancer cells with high metabolic demand
require high levels of both visfatin but also the intermediary products of this metabolic
reaction and hence a role for NMN as a neoplastic molecule.
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Looking through the literature it becomes apparent that in the past 7 years there has
been a renewed interest in the NAD axis as a novel target for an anti-cancer agent. As
mentioned above it would be logical that interfering with NAD levels in cells that have a
high metabolic requirement, secondary to high proliferative rates may induce tumour
cell death following an associated fall in the levels of the pyridine nucleotide. The knock
on effect of lowering NAD levels would not only affect the reactions requiring NAD+ as
a cofactor but may hamper other cell signaling processes. An example of this scenario
can be found in the modulation of sirtuins and mono- and poly-ADP ribosylating
enzymes (PARP). NAD is a substrate for the sirtuin subclass of histone deacetylases
as well as PARP and the extremely high level of PARP activity of cancer cells should
make them more prone to NAD level manipulation (Pollak, Dolle et al. 2007).
Typically human cells have multiple ways of replenishing their NAD levels. Two of
these pathways are salvage or recycling pathways and a third involves de novo
synthesis from the amino acid tryptophan (Magni, Amici et al. 2004). The pathway that
is of particular interest to this study is the pathway that involves visfatin. As we know
this co-enzyme controls the rate-limiting step of nicotinamide conversion to NMN, which
is then converted further to NAD by NMN adenylyltransferase (NMNAT). Visfatin is the
target of the inhibitor molecule FK866 (Hasmann and Schemainda 2003). FK866
induces apoptosis and also lowers NAD levels (Drevs, Loser et al. 2003; Hasmann and
Schemainda 2003). The in-vitro results relating to FK866 have been promising and it
has indeed reached phase 2 clinical trials (Khan, Forouhar et al. 2007; Holen, Saltz et
al. 2008).
FK866 (also known as APO866 or WK175) is a highly specific non competitive-inhibitor
of visfatin NAPRT (nicotinamidephosphoribosyl-transferase), which causes a reduction
of NAD levels (Wosikowski, Mattern et al. 2002) and thus induces apoptosis
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independent of the stage of the cell cycle. Visfatin is known to form a homodimer before
it exerts its enzymatic action with FK866, binding at the interface between the two
subunits with partial overlap of the NMN binding site (Bae, Kim et al. 2006). FK866 is
known to lead to apoptosis via all three phases of the apoptotic pathway as
demonstrated in in-vitro studies as follows; It manipulates the induction process via its
effect on reducing NAD levels; the effector process via the disruption of the
mitochondrial membrane potential; and finally the irreversible degradation process via
the manipulation of cellular caspases (Holen, Saltz et al. 2008). In-vitro studies have
demonstrated that FK866 has had anti-tumour activity in multiple solid human tumours
(Hasmann and Schemainda 2003), leukaemia’s and also human tumour xenografts
including prostate cancer in mice (Wosikowski, Mattern et al. 2002). We wished to use
this compound to assess its action on PC3 cells and identify mechanisms by which
FK866 may act. Furthermore we used this compound to try and elucidate the role on
NMN in these cell lines.
Figure 6.1 Chemical Structure of FK866 (Bae, Kim et al. 2006)
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Figure 6.2 figure illustrating the visfatin dimer in complex with FK866; the two
monomers are shown in slate and green (subunit A) and pale blue and green (subunit
B), respectively. The two FK866 molecules are shown in red. (Bae, Kim et al. 2006)
HYPOTHESIS
NMN is a mechanism by which PC3 cell activity can be modulated as delineated by
proliferation and apoptosis. FK866 a potent visfatin inhibitor will act as an anti-tumour
agent and its action can be reduced by the use of NMN.
AIMS
 Identify the proliferative and apoptotic effects of both FK866 and NMN in the PC3
cell lines
 To identify if FK866 and NMN alter the expression of various oncogenes in PC3 cell
lines
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METHODS
Methods were as outlined in the methods chapter and with respect to cell proliferation
assay and apoptosis assays see chapter 4 for further details.
Statistical analysis was as described in chapter 4.
RESULTS
FK866 REGULATION OF PROSTATE CANCER CELL PROLIFERATION
Incubation of cells with FK866 alone resulted in a significant decrease in proliferation
after 24-hours incubation in PC3 cells compared to control, (p<0.001 at 1, 10 and 100
nM) (Figure 6.3). As discussed in chapter 4 (pages 97 and 107) this particular
proliferation assay is a surrogate for cellular proliferation based on cellular number
derived from metabolic activity and does not take into account cellular proliferation
directly or apoptosis. It is also discussed in the literature as cell viability (Hasmann and
Schemainda 2003). For the purpose of this chapter in the context of published data we
have elected to discuss cell viability/proliferation. The effect appeared to show a dose
dependent decrease aside from an aberrant result at 50 nM concentration showing no
significant fall in viability.
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Figure 6.3 The Effect of FK866 [0-100nM] on PC3 cell viability. 24 hour data expressed
as relative to basal viability. n = 4 for all experiments, *** p < 0.001.
NMN REGULATION OF PROSTATE CANCER CELL PROLIFERATION
Incubation of cells with NMN alone resulted in a significant increase in proliferation after
24-hours incubation in PC3 cells compared to control, (p<0.01 at 50 and 100 µM)
(Figure 6.4). The effect appeared to show a dose dependent increase before starting
to fall to basal at 200µm concentration which still showed a significant increase in
viability (p <0.05)
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Figure 6.4 The Effect of NMN [0-200µM] on PC3 cell viability. 24 hour data expressed
as relative to basal viability. n = 4 for all experiments, *p < 0.05, ** p < 0.01.
NMN AND FK866 REGULATION OF PROSTATE CANCER CELL
PROLIFERATION
Incubation of cells with FK866 demonstrated a significant fall in cell viability at 10nM
concentration (p<0.01). This was consistent at 1, 10 and 100nM FK866 and the
addition of NMN at the maximum proliferative concentration of 100 µM did not rescue
PC3 cell viability. (Figure 6.5)
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Figure 6.5 The Effect of FK866 alone and in combination with NMN on PC3 cell
viability. 24 hour data expressed as relative to basal viability. n = 4 for all experiments,
**p < 0.01, *** p < 0.001.
VISFATIN AND FK866 REGULATION OF PROSTATE CANCER CELL
PROLIFERATION
Incubation of cells with FK866 demonstrated a significant fall in cell viability at 10nM
concentration (p<0.01). The addition of visfatin at the maximum proliferative
concentration of 400 ng/ml did not rescue PC3 cell viability (Figure 6.6).
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Figure 6.6 The Combination Effect of FK866/Visfatin on PC3 cell Viability. 24 hour data
expressed as relative to basal viability. n = 4 for all experiments, ** p < 0.01.
FK866 REGULATION OF PROSTATE CANCER CELL APOPTOSIS
Incubation of cells with FK866 alone resulted in a significant increase in apoptosis after
24-hours incubation in PC3 cells compared to control, (p <0.01 at 10 nM) and sustained
increase at 50 nM (p<0.05) (Figure 6.7) There appears to be a sustained increase in
apoptosis although not statistically significant at 100 nm FK866 (Figure 6.8).
Camptothesin was used as a positive control at a concentration of 2 µM. This was not
only an established positive control within the group, it is also an established agent of
apoptosis in androgen insensitive prostate cancer cells (Chatterjee, Schmitz et al.
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2001). At 48 hours there was no significant change in apoptosis in PC3 cells following
incubation with FK866 at all concentrations.
Figure 6.7 The Effect of FK866 on PC3 cell Apoptosis using DNA fragmentation
ELISA. 24 hour data expressed as relative to basal apoptosis. n = 4 for all experiments,
* p <0.05 ** p < 0.01.
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Figure 6.8 The Effect of FK866 on PC3 cell Apoptosis using DNA fragmentation
ELISA. 48 hour data expressed as relative to basal apoptosis. n = 4 for all experiments,
*** p < 0.001.
THE INTERACTION BETWEEN FK866, NMN AND VISFATIN REGULATION
OF PROSTATE CANCER CELL APOPTOSIS
Incubation of cells with FK866 10nM alone resulted in a significant increase in
apoptosis after 24-hours incubation in PC3 cells compared to control, (p <0.001 at 10
nM). Camptothesin was used as a positive control at a concentration of 2 uM (p<0.05).
The addition of NMN at 100 µM significantly rescued apoptosis at 24 hours and the
addition of visfatin 400ng/ml did not enhance this further. Visfatin alone at 400 ng/ml
did not significantly rescue apoptosis, although the result appeared to show a slight
reduction in apoptosis from 170%-130% of the control level. Figure 6.9
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Figure 6.9 The effect of FK866, NMN and visfatin on PC3 cell apoptosis using DNA
fragmentation ELISA. 24 hour Data expressed as relative to basal apoptosis. n = 4 for
all experiments, *p <0.05, ** p <0.001 *** p < 0.001.
EFFECT OF VISFATIN ON PC3 CELL GENE ACTIVATION USING REAL
TIME PCR
NMM 100µM and FK866 10nM both significantly reduce visfatin mRNA expression
relative to basal (p<0.001) (Figure 6.10)
mRNA expression of IGF-1R demonstrates a non-significant up-regulation following
incubation with 100µm of NMN. No change is demonstrated with FK866 at 4 hours
(Figure 6.11).
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mRNA expression of MCL-1 showed no significant change at 4 hours after incubation
with either NMN or FK866 (Figure 6.12).
NMN 100µM has no significant effect on the level of BCL-2 expression. FK866 10 nM
has a dramatic and significant effect in reducing BCL-2 mRNA expression at 4 hours (p
<0.001) (Figure 6.13).
mRNA expression of BAX was significantly decreased at 4 hours following treatment
with 100µM of NMN (p ≤ 0.05); (Figure 6.14). At 4 hours however FK866 had no 
significant effect on BAX mRNA expression.
mRNA expression of BCL2-L1 was not significantly changed following treatment with
either FK866 or NMN after 4 hours (Figure 6.15)
Figure 6.10 Effect of NMN and FK866 on PC3 cell visfatin mRNA expression activation
using real time PCR at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell
visfatin RNA expression. Data are expressed as relative to basal; n = 3 *** p < 0.001.
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Figure 6.11 Effect of NMN and FK866 on PC3 cell IGF-1R mRNA activation using real
time PCR at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell IGF-1R
RNA expression. Data are expressed as relative to basal; n = 3 *** p < 0.001
Figure 6.12 Effect Of NMN and FK866 on PC3 cell MCL-1 mRNA expression using
real time PCR at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell
MCL1 RNA expression. Data are expressed as relative to basal; n = 3 *** p < 0.001.
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Figure 6.13 Effect of NMN and FK866 on PC3 cell Gene activation using real time
PCR at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell BCL2 RNA
expression. Data are expressed as relative to basal; n = 3 * p < 0.05.
Figure 6.14 Effect of NMN and FK866 on PC3 cell Gene activation using real time PCR
at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell BAX RNA
expression. Data are expressed as relative to basal; n = 3 * p < 0.05.
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Figure 6.15 Effect of NMN and FK866 on PC3 cell Gene activation using real time PCR
at 4 hours: Effect of NMN [100 µM] and FK866 [10 nM] on PC3 cell BCL2L1 RNA
expression. Data are expressed as relative to basal; n = 3 * p < 0.05.
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DISCUSSION
This study elucidated the effect of FK866 on PC3 cells and tried to identify its effect on
some of the oncogenes already discussed. Unsurprisingly, FK866 reduced the cell
viability at 24 hours of PC3 cells as demonstrated using a MTS cell proliferation/viability
assay by 42% at the maximum dose of 100 nM and 27% at 10 nM (p<0.001). This is in
keeping with other in-vitro studies in other human cell types that have also shown that
cell viability reduced at 24 hours. It was noted in a study by Hasman et al that after 24
hours of incubation with FK866 HepG2 cells were noted to have reduced cell viability
using a similar assay to the one used in this study (Hasmann and Schemainda 2003).
They noted a decreased WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate) reaction (another form of tetrazolium salt reaction measuring
metabolic activity as a correlate for viability (Hasmann and Schemainda 2003). During
this study it was also noted that FK866 induced apoptosis at all concentrations at 24
hours (70% increase in apoptosis at 24 hours with 10nM FK866 p<0.01, using a DNA
fragmentation assay). However, no significant increase was seen at 48 hours. Again
this is in keeping with published results e.g. in a study by Wosikowski et al using THP-1
cells, they have demonstrated apoptosis using a flow cytometric assay following 28
hours of incubation with FK866. Of interest in this study was the relatively rapid
decrease in NAD concentration, with levels falling as early as 2 hours after WK175
(FK866) was added to the cell culture media and had fallen undetectable levels by 24
hours. These findings suggest that there is a lag period between the primary apoptotic
trigger and the initiation of programmed cell death. The observation of a lag period was
noted in the Human acute monocytic leukemia cell line (THP-1) cells but also human
hepatocellular carcinoma (HepG2) cells and chronic myelogenous leukemia (K562)
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cells (Wosikowski, Mattern et al. 2002). From these data it is concluded that the NAD
levels need to reach a critical level prior to acting as a trigger for apoptosis.
As it was not within the confines of this project to measure NAD levels we looked to
identify alternative mechanisms of action in the PC3 cell line. The study then looked to
examine if FK866 had any effect on various mRNA gene expression. It was found
during this study that FK866 significantly reduced visfatin gene expression (p<0.001)
and also significantly reduced BCL-2 expression (p<0.001). The above theory of NAD
depletion is now well established in the literature (Wosikowski, Mattern et al. 2002;
Hasmann and Schemainda 2003) and it has been suggested that FK866 has no DNA-
damaging effect and has been shown not to alter p53 or p21 expression (Wosikowski,
Mattern et al. 2002). It was therefore surprising that FK866 had any gene expression
effects, in this case BCL-2 expression.
Intuitively one would anticipate that a non-competitive inhibitor of visfatin, which acts by
complexing itself with visfatin, would in turn reduce the amount of active visfatin and
thus trigger a stimulus for de-novo visfatin production via a putative positive feedback
loop. In this study it was discovered that visfatin gene expression is significantly
reduced at 4 hours, which is the opposite effect to that was expected. It is feasible that
the effect of visfatin up-regulation is of delayed onset and therefore longer time points
than 4 hours would be necessary to examine in future studies to answer this question
further. It is also possible to hypothesise that this represents another mechanism of
action of not yet reported.
With respect to BCL-2 this is a novel finding in keeping with the expected results. As
discussed in chapter five BCL-2 is not expressed in the normal prostate and the family
of genes are commonly expressed in both primary and metastatic CaP (Hughes,
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Murphy et al. 2005). Various evidence in the literature, as discussed in chapter 5 (p
129), has demonstrated that adipokines influence BCL-2. It has been established that
BCL-2 exerts its anti-apoptotic effect via modulation of the mitochondrial membrane
potential and cytochrome c release (Kluck, Bossy-Wetzel et al. 1997). The down-
regulation of BCL-2 gene expression by FK866 would lead to an increase in apoptosis
and thus this study has demonstrated a further novel mechanism of apoptosis by
FK866 which is unreported.
Further mRNA studies exploring the influence of FK866 on PC3 cell gene expression
revealed no effect on MCL-1, BCL2-L1, BAX or the IGFR genes.
The effects on NMN were then elaborated in this cell model. NMN has been shown to
increase cell viability at all concentrations in a dose dependent fashion till 100 µM and
then begins to decrease in effect at higher doses Fig 6.4. The effect was demonstrated
at 24 hours (p<0.01). This effect is anticipated based on the theory proposed by
Garten et al (Garten, Petzold et al. 2009). One anticipated that bypassing the rate-
limiting step modulated via visfatin and with the addition of NMN in the culture media
cell viability will inherently be improved. This theory is in keeping with work described
by Revollo et al (Revollo, Korner et al. 2007) and the notion that extracellular visfatin
acts as an NAD biosynthetic enzyme. It is however distinctly possible that NMN
modulates via alternative mechanisms in addition to this and to that effect the study
looked at the modulation of tumour genes by NMN.
NMN was found to reduce visfatin mRNA gene expression at similar levels to FK866
Fig 6.10. This was highly significant and is a logical outcome. With excessive levels of
NMN one would anticipate that both gene and protein expression of visfatin would
reduce as high levels of visfatin would be unnecessary in this scenario. Slightly
162
unexpected however was the effect of FK866 on visfatin gene expression. One would
anticipate that an inhibitor of visfatin would reduce the bioavailable concentration and
prompt further gene expression. This is a novel finding and would merit further
investigation as no explanation can be offered at this juncture. Furthermore I showed
that NMN significantly reduced the mRNA expression of BAX (p<0.05) at 4 hours. BAX
is a pro-apoptotic protein that is part of the BCL-2 family. By switching off the gene for
BAX it provides a mechanism by which NMN can increase cell viability and proliferative
response. It has been demonstrated that control of membrane channels BAX can
control levels of apoptosis via cytochrome c levels (Shimizu, Narita et al. 1999). Further
mRNA studies exploring the influence of NMN on PC3 cell gene expression revealed
no significant effect on MCL-1, BCL2-L1, BCL-2 or the IGFR genes.
In chapter four the study touched on the functional interaction of FK866 and NMN using
the wound scratch assay. During this chapter the study looked to evaluate if NMN
could salvage the effect of FK866 with respect to cell viability and apoptosis. In this
experiment it was shown that FK866 reduced the cell viability of PC3 cells. This effect
was not negated or reduced by the addition of NMN. This is another surprising outcome
as one would expect NMN to rescue visfatin inhibition by bypassing the visfatin driven
step. This would be via the same theory described earlier on page 157. However,
when the effect of NMN and FK866 in combination on apoptosis was evaluated the
results were far more rewarding. As expected FK866 induces significant apoptosis at
24 hours and this effect was significantly reduced by the addition of extracellular NMN
(10µM p<0.001). Interestingly visfatin did not enhance this effect further nor did it have
the same effect in isolation. These findings are in keeping with Wosikowski and
Hasmann who suggested that NMN is required to reach a critical level prior to the
induction of the apoptotic process. By replacing NMN, the primary mechanism of
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action of FK866 is negated and apoptosis averted. The apoptotic effect demonstrated
in Fig 6.7 was highly significant and was approximately 70% greater relative to basal.
This in itself in not surprising, however in Fig 6.5 we noted that viability/proliferation
only reduced by 25% at the same concentrations. This discrepancy can be accounted
for when considering the assays involved. The proliferation assay monitors metabolism
and correlates with cell number. It does not account for necrosis or apoptosis. The
combination of the two assays and their respective results suggest that FK866
mechanism of action is primarily apoptotic and not anti-proliferative.
CONCLUSION
This study has shown novel mechanisms for the action of FK866 and NMN in PC3 cell
lines via the modulation of BCL-2 and BAX. The study also supports the findings in the
literature with respect to NMN and FK866 with respect to apoptosis. This study also
supports the theory of critical NMN levels precipitating apoptosis. By elucidating these
effects these novel data with respect to the prostate cell model could assist with the
therapeutic potential of FK866.
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CHAPTER 7
HUMAN PLASMA VISFATIN
LEVELS IN PROSTATE
CANCER
165
CHAPTER 7 HUMAN PLASMA VISFATIN LEVELS
IN PROSTATE CANCER
INTRODUCTION
Visfatin (also known as Pre-B cell colony enhancing factor/PBEF and nicotinamide
phosphoribosyltransferase - Nampt) is a 52kDa protein highly expressed in visceral
adipose tissue, and in other tissues such as liver, muscle and bone marrow cells.
Circulating visfatin levels have been shown to be increased proportionally with visceral
fat accumulation (Berndt, Kloting et al. 2005; Sandeep, Velmurugan et al. 2007) and
pro-inflammatory states (Moschen, Kaser et al. 2007). The results of epidemiological
studies have shown a correlation between obesity and solid cancers such as prostate,
breast and colorectal (Nishii, Kono et al. 2001; Wolk, Gridley et al. 2001; Calle and
Thun 2004). A topic of interest in the literature over the past decade has been the
investigation of adipokines as biomarkers for a variety of pathological states such as
endothelial dysfunction and chronic kidney disease (Bessa, Hamdy et al. 2010), and
including various cancers and logically these have been those cancers for which
obesity has been positively correlated as detailed above. Nakajima et al have
demonstrated using a case control study that visfatin may be a good marker of
colorectal malignancy independent of BMI and also stage progression of the disease
(Nakajima, Yamada et al. 2009). The same group had also earlier demonstrated a
similar finding in gastric cancer (Nakajima, Yamada et al. 2009). During this study it has
been demonstrated that visfatin is expressed in prostate cancer tissue and cell lines. It
has also been demonstrated that it promotes cell viability and cell migration in the PC3
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cell line. It has also been shown to activate the MAPK pathways specifically p38 and
ERK 1/2 and also cause dramatic up-regulation of MMP-2/-9 expression and more
importantly their activity. These novel findings have since been corroborated by a
recent study by Wang et al who have shown that visfatin promotes prostate cancer cell
growth, survival via regulation of SIRT1 functions (Wang, Hasan et al. 2011). The same
group also demonstrated that visfatin expression was up-regulated in multiple solid
cancers including prostate, colon, brain and lung as well as lymphoma when compared
with their benign equivalents. Given the above evidence from other solid tumours and
the in-vitro functional as well as tissue findings in prostate cancer the final part of this
thesis looked to evaluate if human plasma visfatin levels correlated with prostate
cancer and therefore whether there is a role for visfatin as a biomarker in prostate
cancer.
As stated above and in chapter 1 (pages 41-49) several studies have correlated obesity
with prostate cancer and in particular the incidence of high grade or aggressive
disease. On review of the evidence this is conclusive. Furthermore adipokines have
been associated with prostate cancer as described and the body of evidence is growing
in particular in relation to visfatin and prostate cancer (Wang, Hasan et al. 2011). The
literature remains unclear when linking conclusively a single mechanism or cytokine as
the mechanism by which obesity is linked with prostate cancer. Levels of visfatin have
been documented to be elevated in obesity as have other adipokines. This may be one
mechanism by which obesity is linked with prostate cancer, but, I cannot stress enough
that it is highly unlikely to be the only mechanism.
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HYPOTHESIS
Plasma visfatin levels are correlated with prostate cancer and can potentially be used
as a novel biomarker in prostate cancer.
AIMS
 To determine if levels of human plasma visfatin levels are positively correlated with
CaP compared to benign prostate disease.
 To identify if human plasma visfatin levels correlate with gleason grade of prostate
cancer
METHODS
Methods were as outlined in the methods chapter. This part of the study was
performed in collaboration with Dr Andrew Blann (University Hospital Birmingham and
City Hospital Birmingham). For human plasma samples, following ethical approval,
patients were identified from 3 groups; healthy controls, histologically proven benign
prostatic hypertrophy (BPH) or histologically proven prostate adenocarcinoma (CaP).
Venous blood was obtained by uncomplicated venepuncture into sodium citrate and
was immediately placed on ice before centrifugation at 3000 r.p.m. (1000 g) at 4 °C for
20 min. Citrated plasma samples were then aliquotted into clean tubes and stored at
−70 °C until the time of analysis. Serum from the patients was passed to the routine 
hospital Biochemistry Department for measurement of prostate-specific antigen.
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A visfatin ELISA was used to determine plasma visfatin concentrations. This was
based on published data (Tan, Chen et al. 2006; Reddy, Umesh et al. 2008) and the
ability to process significant sample numbers efficiently. The details are below.
In addition to univariate parametric analysis, results were evaluated between groups by
using ANOVA, with significance determined at the level of P < 0.05. Spearman rank
correlation (non-parametric) was used for calculation of associations between variables
(e.g. BMI, visfatin and cancer status) using SPSS version 18.0 (SPSS, Chicago, USA)
software and multivariate regression analysis was performed where appropriate.
VISFATIN ELISA
Human plasma samples were collected as described above. A human visfatin ELISA kit
was purchased from Phoenix Secretomics and used as per manufacturer’s protocol.
The assay employs a quantitative sandwich enzyme immunoassay technique.
Visfatin standards were prepared in advance by reconstituting visfatin in 1000µl of
reagent diluents. This gives a stock solution of 1000ng/ml. 7 Serial dilutions were then
made giving concentrations ranging from 0.78ng/ml-1000ng/ml. 100µl of reagent
diluents was used as blank. 100µl of standards were added to each well as were the
samples and supplied positive control. All samples were added in duplicate. The plate
was sealed and then incubated for 2 hours.
Aspiration and wash of the plate was done 5 times using 250µl per well of assay buffer.
100µl of detection antibody was added to each well the plate sealed and incubated for
2 hours. The aspiration and wash step was then carried prior to adding 100µl per well
of secondary antibody horse raddish peroxidase conjugate solution. The plate was
again resealed and incubated for 1 hour. Following plate washing 100µl of substrate
solution was added to each well for 30 mins avoiding exposure to light. 100µl of stop
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solution was then added directly and mixed thoroughly using a plate rocker. The
absorbance O.D. was then measured at 450nm.
To calculate the results graphpad software was used to generate a log-log curve fit of
the standards. To determine the visfatin concentration data was extrapolated from the
standard curve generated using a cubic spline regression. The minimal detectable
concentration is reported at 0.78 ng/ml. The manufacturer states an intra-assay
precision of 4% and an inter-assay precision of 10%.
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RESULTS
N=78 n
Age
(Yrs)
Visfatin
(ng/ml) BMI
PSA
(ng/ml)
Gleason
Grade
CONTROLS 25 Median 68 2.38 27.7 1.1 n/a
Mean 67.76 2.60 27.08 1.82 n/a
Sdev 6.76 1.65 3.84 2.27 n/a
BPH 23 Median 69 2.75 25.5 3.8 n/a
Mean 69.35 3.14 27.17 5.07 n/a
Sdev 5.97 1.81 5.15 6.51 n/a
PROSTATE
CANCER 30 Median 71.5 2.53 26.3 5.7 7
Mean 69.27 2.85 27.25 50.06 7.14
Sdev 8.46 1.84 4.92 149.57 1.17
Figure 7.1 A table summarising the results with respect to plasma visfatin levels
(ng/ml), prostate specific antigen (PSA/ng/ml), BMI, gleason grade and age.
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With respect to age and BMI all three groups were well matched with no significance
between them. Figs 7.2a/b
Figure 7.2a Graphical representation of BMI variation between the three groups of
patients. (BMI calculated as mass (kg)/ (height (m))2 )
Figure 7.2b Graphical representation of age (years) variation between the three groups
of patients.
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Using a human visfatin ELISA (Phoenix secretomics) the group of patients as a whole
did not demonstrate a significant correlation with BMI and visfatin (Figure 7.3). Using
univariate analysis, in the overweight category (BMI 25-29.9) there appears to a slight
increase in visfatin levels compared to basal with a mean level of 3.31 ng/ml as
compared to 2.94 ng/ml in the normal BMI population. With respect to those that were
obese based on BMI alone, there was no statistical difference and the trend appeared
to show a decrease in visfatin levels.
Figure 7.3 Graphical representation of visfatin levels (ng/ml) relative to BMI levels
categorised as per WHO guidelines on obesity. 18.5-24.99 normal (n=30); 25-29.99
overweight (n=35); 30-34.99 obese I (n=7); 35-39.99 obese II (n=6); ≥40 obese III 
(WHO 2004).
Using the spearman rank correlation it was noted that within the control group, there
was a significant positive bi-variate correlation between plasma visfatin levels and BMI
(r=0.416, P=0.043). No other significant bi-variate correlations with plasma visfatin
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levels were noted. In the other groups, no significant bi-variate correlations were noted
between plasma visfatin levels and variables. Multiple regression analyses with plasma
visfatin as the dependent variable against the other variables was also performed and
this did not yield any significant results.
Plasma visfatin levels were analysed with respect to disease state irrespective of other
variables. There was no significant difference between the three groups compared. It
was noted however the BPH group appeared to have a higher mean level of visfatin
3.14 ng/ml as compared to the control 2.60 ng/ml and the CaP group 2.85 ng/ml
Figure 7.4 Graphical representation of visfatin levels (ng/ml) in disease free control
groups, benign prostatic enlargement (BPH) and CaP.
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A further subset analysis of patients that were overweight was conducted based on
disease state. Although there was statistically significant difference between the three
groups interestingly the data suggests that when accounting for BMI >25 i.e. overweight
and obese visfatin levels are lower in the BPH group and marginally elevated in the
CaP group when compared to the normal weight category (Figure 7.5).
Figure 7.5 Graphical representation of visfatin levels (ng/ml) in disease free control
groups, benign prostatic enlargement (BPH) and CaP in the cohort of overweight and
obese patients.
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Data pertaining to gleason score was available from case note review in 14/30 patients.
The median gleason grade was 7 with standard deviation of 1.17. Although there was
no statistically significant difference between the varying grades it appears that visfatin
levels may show a trend to increase with increasing tumour grade.
Figure 7.6 Graphical representation of gleason grade vs. visfatin concentration (ng/ml)
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DISCUSSION
Based on the previous discovery of visfatin as a novel biomarker in various cancers to
date such as glioblastoma, colon cancer and gastric carcinoma (Reddy, Umesh et al.
2008; Nakajima, Yamada et al. 2009) this study tried to elucidate a relationship
between plasma visfatin and CaP. Thus far it has been demonstrated that visfatin has a
role in prostate cancer and it the effect appeared to be mediated by exogenously
applied visfatin. It was logical therefore to explore the levels of circulating plasma
visfatin to identify if indeed patients with CaP have higher levels of visfatin than their
non-affected counterparts and then to evaluate its potential as a potential biomarker.
This study used age and BMI matched cohorts and looked to primarily evaluate plasma
visfatin levels using ELISA methods. The study showed that there was a significant
difference in plasma visfatin levels with varying BMI levels within the control group only.
Overall in the population group studied no significant correlation was observed between
visfatin plasma concentrations and obesity. At face value this would be congruent with
some of the studies listed below and perhaps indicate that it is not elevated levels of
visfatin that mediate obesity related CaP risk. It should be noted that this study was not
matched for obese vs non obese and sample numbers particularly of those in the
obese category were small. These data therefore have to be observed with care.
Overall the literature reports conflicting results with respect to visfatin levels in obesity.
Several studies have concluded that visfatin levels are elevated with respect to obesity
(Berndt, Kloting et al. 2005; Filippatos, Derdemezis et al. 2007; Sandeep, Velmurugan
et al. 2007). However other studies have been to the contrary (Axelsson, Witasp et al.
2007) and some have in fact reported lower levels of visfatin in relation to obesity
(Pagano, Pilon et al. 2006).
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Furthermore no significant difference was noted between the control group, BPH and
CaP with respect to visfatin. The trend suggested that visfatin levels were elevated in
the control group with respect to the CaP group. Interestingly this was reversed when
looking at the overweight and obese population, where there was a suggestion that the
visfatin levels were highest in the CaP group. It is of note that our population group
demonstrated a comparable serum visfatin level compared to that published in the
literature (Haider, Schindler et al. 2006).
In a breakdown of Gleason grade the trend suggests that there may be a relationship
between visfatin levels and Gleason score. The numbers in the study however are low
and they do therefore do not reach any statistical significance. Further future studies
would involve a higher sample size in an effort to identify statistically significant results.
The differences in outcomes of the various clinical studies may be in part due to the
postulated multifactorial regulation of visfatin (Prieto-Hontoria, Perez-Matute et al.
2011) as well as discrepancies between the obesity measurements and also lack of
concordance between commercially available visfatin assays.
Visfatin can be measured by three readily commercially available techniques. These
immunoassays include Enzyme immunoassay (EIA), Enzyme linked immunoassay
(ELISA) and Radio immunoassay (RIA). A study by Korner et al involving 30 patients
forming 3 groups (visceral obese, subcutaneous obese and control group) evaluated
the three different assays and found absolutely no correlation between them and
showed the ELISA was the most specific assay (Korner, Garten et al. 2007). At the time
of the Korner study the EIA was the most commonly employed assay and they
suggested that a reason for the lack of sensitivity of the assay may be due to the
interference by proteins other than the visfatin monomer or dimer in human serum
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(Korner, Garten et al. 2007). A significant difference between the EIA and ELISA
method is that the EIA detects the C-terminal visfatin compared to ELISA which detects
the full length visfatin (Mahmood, Jamal et al. 2010). Pitfalls of the ELISA techniques
are that despite a wide overall range there is a narrow linear detection range (1.85-
19.5ng/ml) on the standard fit curve in which results are most accurate. Other possible
pitfalls with ELISA techniques and the discrepancies of varying studies include different
sample additives, storing conditions and times, and other pre-analytical conditions
(Nusken, Nusken et al. 2007). In our study venous blood was obtained and placed
directly into blood tubes supplemented with sodium citrate (for plasma). Plasma was
obtained by immediate placement on ice prior to centrifugation at 3000 rpm (1000g) at
4 C for 20 min, before being aliquotted into clean tubes and stored at -70 C until the
time of analysis (Blann, Li et al. 2001). It has been found that the use of citrate
additives can influence the protein concentrations as well generate highly variable
results (Nusken, Nusken et al. 2007). For future studies EDTA appears to be a more
stable additive with respect to visfatin. The trend demonstrated a possible correlation of
visfatin with gleason grade of prostate cancer. This is only a trend and to draw any
significant conclusions increasing the sample size may yield more robust and
statistically significant results.
This study was a longitudinal observation study and to that effect it was not necessary
to perform a formal power calculation. To confirm the findings a formal powered study
with the appropriate sample size would be needed to formally confirm or refute and
correlations observed here.
ELISA assay methods typically exhibit experimental variability at intra- and inter-assay
levels. Increased variability can increase the sample size necessary or generate
inaccurate conclusions secondary to significant undetected bias. Therefore, variability
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and bias effects impact the system. Although the identification of potential sources of
error may be possible eradication of these are difficult because they arise from
numerous sources and impact the bioassay process at many levels.
There is conflicting published data with respect to serum visfatin levels in particular
relating to obesity. The data presented in this chapter relates to a small sample size
and various pitfalls have been discussed when reviewing both the literature and study
design. Overall the data suggests trends only with no definitive correlations identified..
CONCLUSION
The results of this study suggest that there is no statistically significant correlation
between plasma visfatin levels and CaP. Furthermore this study did find a correlation
between obesity and plasma visfatin levels within the population studied.
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The literature is inconsistent with respect to obesity and its link to prostate cancer
incidence and is largely based on epidemiological studies. The literature does however
suggest that obesity is positively correlated with prostate cancer mortality as opposed
to incidence itself (Andersson, Wolk et al. 1997; Calle, Rodriguez et al. 2003; Wright,
Chang et al. 2007). The inconsistency in the epidemiological data could be attributed to
multiple factors such as the interaction between obesity and age, or the differing effects
of obesity on varying histological grades of CaP (Freedland, Giovannucci et al. 2006).
Obesity and prostate cancer prevalence appear to be on the increase. Both also are a
significant contributor to morbidity and mortality (Adams, Schatzkin et al. 2006).
Coupled with this growing health concern is the knowledge that advanced prostate
cancer has considerable therapeutic limitations and therefore a greater understanding
of any mechanisms responsible for high risk CaP would indeed be of value in
developing treatment modalities.
The concept of adipose tissue as a endocrine organ along with a wide body of evidence
linking obesity related cytokines or ‘adipokines’ to CaP models via a variety of
mechanisms lends support to the hypothesis that obesity is linked to CaP. The varying
circulating levels of some of these in states of obesity also lend further support to their
role in mediating prostate cancer.
This study has explored the mechanisms involved with a single adipokine, visfatin, and
its by- product NMM using in-vitro studies. It is duly noted that these studies will
inherently have limitations, most notably, the isolated pathways and interactions do not
necessarily translate to the circulating in-vivo environment and multiple factors can
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influence the final outcomes. For the purpose of this study LNCaP and PC3 prostate
cancer cell lines were used as surrogates for CaP rather than in-vitro cultures of human
prostatic cells. The cell lines are immortalised cell cultures derived from metastases of
advanced CaP with hormone refractory disease representing both androgen sensitive
and androgen insensitive disease respectively. One possible pitfall of using
immortalised cell lines is that repeat passage and culture of these cells may affect their
biological properties. Where possible, passage of the cells was kept to a minimum and
fresh batches used whenever possible. Despite these efforts however it should be
noted that these cell lines do not address the wide range of CaP phenotypes nor are
they representative of primary adenocarcinoma of the prostate (Peehl 2005). Despite
these limitations that are widely accepted these cell lines provide valuable in-vitro
models upon which to base preliminary studies and have been heavily validated by
extensive use in the literature (Kaighn, Narayan et al. 1979; Horoszewicz, Leong et al.
1983). Technical advances have provided the use of primary prostatic epithelial cells to
be used but malignant cell models of this nature are still limited (Peehl 2004).
One of the key biological differences between the two cell lines is the androgen
receptor (AR) status. LNCaP cells are also known to have oestrogen receptors and are
PSA producing cells in contrast to the PC3 cells. (Kaighn, Narayan et al. 1979;
Horoszewicz, Leong et al. 1983).This significant biological difference may be
responsible for the absence of the effect of visfatin in LNCaP cells compared to the
PC3 cells. There is some data showing that adipokines do indeed interact with steroids,
for example testosterone has been shown to reduce adiponectin secretion from
adipocytes however there are no studies looking at the links between visfatin and
androgen or androgen receptors.
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Since visfatin was first described by Samal et al with respect to B-cell differentiation
(Samal, Sun et al. 1994) the function of visfatin has been the interest of many studies.
Intracellularly, visfatin has been described as modulating inflammatory responses and
innate immunity (Moschen, Kaser et al. 2007; Luk, Malam et al. 2008) in different cell
types. It also functions intracellularly with a key role in the biosynthesis of NAD (see
chapter 1 and 4). This role with respect to NAD production not only serves great
importance with respect to energy homeostasis but also is highly significant in NAD-
dependent enzymes such as sirtuins (Wang, Zhang et al. 2006). Following on from the
controversy of Fukuhara et al whom first described visfatin as an adipokine with insulin-
mimetic properties further studies have since supported this notion (Xie, Tang et al.
2007), but none have reproduced the findings. Revollo et al and also suggested a key
role in insulin secretion via NAD biosynthesis (Revollo, Korner et al. 2007). Visfatin has
also been shown to have significant roles in cancer (Garten, Petzold et al. 2009).
Extracellularly visfatin has been implicated in multiple inflammatory processes such as
sepsis, arthritis and atherosclerosis (Jia, Li et al. 2004; Moschen, Kaser et al. 2007).
The anti-apoptotic action of visfatin has also been described in relation to neutrophils
and endothelial cells (Jia, Li et al. 2004; Adya, Tan et al. 2008)
During this study several aspects of visfatin with respect to prostate cancer were
investigated. The first step was to identify visfatin in the prostatic cell lines as well as
human prostate cancer tissue as well as benign prostatic tissue. The novel discovery of
visfatin gene expression as well as protein in both the prostate cancer cell lines studied,
as well as in benign and malignant prostate cancer tissue, generated a starting point for
the study as its presence suggested a role for visfatin in both normal and pathological
prostate physiology (Chapter 3 Pages 85-88). The next logical step would have been
to identify the receptor however to date a visfatin receptor has not been discovered and
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the mode of action of visfatin is the topic of much debate and ongoing research.
Interestingly it was also shown that exogenous visfatin reduces visfatin gene
expression as early as 4 hours after exposure and levels remain low up to 24 hours
(Chapter 3 Page 88). This suggests a feedback loop for the regulation of visfatin as
well as the implication that prostate cancer cells lines respond to extracellular visfatin
levels.
Functionally, it was clearly demonstrated that visfatin has differential effects on differing
prostate cancer cell lines e.g. had no effect on the LNCaP cell line as compared to the
PC3 cell lines, which clearly responded to exogenous visfatin in a proliferative fashion.
The differential effect may be due to the different androgen sensitivities of the two cell
lines and a hypothetical link between steroids and visfatin and investigating this was
beyond the scope of the thesis. It was also noted that visfatin was neither pro- nor anti-
apoptotic in the PC3 cell line. It is of great interest with particular reference to cancer
that visfatin when exogenously applied to PC3 cells causes a significant migration of
cells across a wound relative to basal and this action is opposed with the addition of
FK866. It was also noted that NMN was able to reverse this effect. Given there were
no significant effects in the LNCaP cell line with respect to functional studies further
experiments were not undertaken in this cell model as it was concluded that without
functional outcome dissecting signalling pathways and gene regulation would serve no
further purpose. (Chapter 4 pages 102-106)
The third facet to the study (Chapter 5 pages 118-127) looked to identify whether
visfatin modulated the phosphorylation of some key signalling molecules known to be
involved in the pathology of prostate cancer, namely p38 and ERK 1/2. This study
showed that visfatin significantly activated the p38 and ERK MAPKs at levels consistent
with those found to be proliferative in the cell lines. Further studies using specific
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inhibitors of these MAPKs, especially in relation to the functional effects of visfatin,
would help elucidate with much more certainty the relationship between visfatin and
MAPK related cell proliferation. Immunohistochemistry has been used to demonstrate
the distribution of ERK1/2 in prostate tissue (Royuela, Arenas et al. 2002). They have
shown that ERK 1/2 is predominantly localised to the cytoplasm of prostatic cells and is
not particularly active in the epithelial layer of normal prostatic tissue where the vast
majority of prostate adenocarcinomas originate, whereas 80% of stromal and basal
cells are positive for pERK 1/2 staining. Gioelli et al demonstrated that the identification
of activated ERK 1/2 in prostate tissue is directly related to poor histological and
prognostic factors as well as demonstrating that pERK 1/2 staining has been found in
normal tissue directly adjacent to CaP tissue (Gioeli, Mandell et al. 1999). With this
evidence from the literature and the novel findings presented in this study thus far;
visfatin having been demonstrated in prostate cancer tissue and exogenous visfatin
leading to ERK phosphorylation in-vitro, it lends further weight to the hypothesis that
visfatin is implicated in CaP progression.
The effects of visfatin on ERK activity in prostate cancer cells have not previously been
reported. In this study, visfatin increased ERK 1/2 phosphorylation in the PC3 prostate
cancer cell line. This is a significant finding as it has been suggested that ERK
signalling mediates some key mitogenic molecules such as endothelial derived growth
factor (EGF), transforming growth factor-α (TGF-α) and IGF (Maroni, Koul et al. 2004).
Further importance can be ascribed to this finding with the knowledge that cellular
proliferation induced by EGF and other EGFR ligands can be prevented by inhibition of
the ERK signaling pathway (Guo, Luttrell et al. 2000). ERK has also been put forward
as a mediator of IL-6 AR activation and the subsequent development of hormone
refractory prostate cancer (Culig, Bartsch et al. 2002; Heinrich, Behrmann et al. 2003).
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The role of ERK signaling in CaP has not been definitively identified and its role is still
debated. Most commonly ERK 1/2 is reported to lead to cell proliferation or an increase
in cell viability, however there are also studies that have shown ERK to be implicated in
an apoptotic role (Maroni, Koul et al. 2004; Ghosh, Malik et al. 2005). It was also
demonstrated that the levels of ERK 1/2 and related kinases showed low expression in
the same cell types as used in this study i.e. LNCaP and PC3 during normal cell culture
conditions, however MAPK signalling was increased in response to cellular stress and
in particular when exposed to chemotherapy agents (Lee, Steelman et al. 2005). A
specific example of this was demonstrated with the use of the chemotherapy agent
Docetaxel, which demonstrated increased ERK expression in androgen insensitive
cells following treatment (Zelivianski, Spellman et al. 2003). These findings suggest that
ERK activation by visfatin or other agents may be a stress response, which would be in
keeping with the cell viability studies. This would be in keeping with studies by Koul et
al who demonstrated that the ERK 1/2 signaling pathway has only a small part to play
in PC3 cell proliferation but was highly integral to cell migration and invasion (Koul,
Huang et al. 2004). Further studies that would help delineate this theory would be
demonstrable using the wound scratch assay or an invasion assay in PC3 cells
following treatment with visfatin and in the presence of an ERK inhibitor. It would
therefore be of interest in future studies to try and elucidate the true role of ERK
pathways in prostate cancer cell models using ERK inhibitors and cell invasion studies
to try and identify if ERK activation by visfatin is a more important pathway in prostate
cancer invasion than simply cell proliferation. It is also of interest that in pancreatic
cancer cells it has been shown that ERK 1/2 inhibition causes cell cycle arrest and
down-regulation of the expression of the anti-apoptotic genes BCL-2, MCL-1, and BCL-
XL suggesting that activation of the ERK pathway functions to protect pancreatic
cancer from apoptosis as well allowing cell cycle advancement (Boucher, Morisset et
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al. 2000). During this study it was found that BAX, BCL2-L1 and MCL1 genes were all
down regulated in response to visfatin exposure. This would suggest that the visfatin
induced ERK activation is unlikely to be related to gene manipulation in this model.
The study also looked at p38 phosphorylation by visfatin in PC3 cells (page 124). A
significant increase in p38 phosphorylation was seen after 2 minutes and then a
gradual reduction. p38 has been shown to be phosphorylated by a number of different
triggers including IL-1, TNF-α, EGF, fibroblast growth factor (FGF), IL-6 and vitamin D, 
all of which have been shown to play a role in CaP (Mehta, Robson et al. 2001;
Tuohimaa, Lyakhovich et al. 2001; Culig, Bartsch et al. 2002). As well as direct ligand
activation, p38 is also activated by physical stressors such as ultraviolet light and
osmotic stress.(Ricote, Garcia-Tunon et al. 2006). p38 has been largely thought to be a
mediator in cell apoptosis and in prostate cancer p38 activity has been shown to
sensitize cells to cisplatin based chemotherapeutics (Skjoth and Issinger 2006).
However there is now evidence to suggest that p38 activity may indeed be carcinogenic
and in fact protect against apoptosis and this has been shown in murine fibroblasts
(Luschen, Scherer et al. 2004) and melanoma cells.
Overall the role of MAPK activation in prostate cancer is debated with evidence
suggesting both pro- and anti-apoptotic mechanisms. Given the data presented in this
study it is tempting to speculate that visfatin activation of these two MAPKs may be
implicated in proliferative effects on PC3 cells or in the manipulations of anti-apoptotic
genes. Future studies with the use of specific inhibitors would be needed to elucidate
these speculative links further.
This study clearly showed that visfatin modulated MMP with a significant up-regulation
at both RNA and protein level and also caused a highly significant up-regulation of
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zymographic activity in a dose dependent fashion. Neovascularisation, which is a form
of dys- or unregulated angiogenesis, is a highly important part of solid tumour
progression and as discussed in chapter five MMP-2/-9 have been heavily implicated in
prostate cancer. The findings of this study are in keeping with that in the literature.
This novel data is of great interest in the quest to find a reliable marker for prostate
cancer and more importantly a marker of aggressive disease. A study by Di Carlo et al
has suggested promising data suggesting the potential use of MMP zymography in
concentrated urine samples to identify CaP patients (Di Carlo, Mariano et al. 2010).
The findings during this study are in keeping with the published literature and also
suggest a strong mechanism by which visfatin may be linked to prostate cancer. I have
discussed in chapter 7 the data obtained with respect to human plasma concentrations
of visfatin. These data imply that it is not elevated levels of visfatin that are responsible
for obesity related CaP. This would go against the published literature. Furthermore it
would go against a hypothesis detailing elevated visfatin levels in obesity as the
mechanism linking obesity and CaP. It was discussed however, that the strength of
these findings must to be viewed with caution as sample size was low and the study
was not powered to identify this relationship. One therefore needs to address the study
based on the original findings outlined in the literature to date.
Interestingly visfatin has been heavily implicated as a mediator of inflammation (Busso,
Karababa et al. 2008) as well as an angiogenic factor and promotes cell survival (Jia, Li
et al. 2004; Moschen, Kaser et al. 2007; Adya, Tan et al. 2008). It is also well reported
that elevated levels of visfatin have been found in chronic inflammatory states such as
arthritis (Nowell, Richards et al. 2006; Otero, Lago et al. 2006). This is of great interest
when attempting to identify links between obesity and prostate cancer risk in particular
the role of visfatin. The chronic inflammatory effect that obesity has may be in part due
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to elevated visfatin levels and it is of great interest that chronic inflammation is a known
risk factor for CaP with population studies, epidemiological genetics and molecular
pathologies all lending evidence to this hypothesis (Palapattu, Sutcliffe et al. 2005).
This may well be a further mechanism by which visfatin is implicated in CaP.
As well as some of the signalling pathways seen during this study other possible
mechanisms by which visfatin may modulate CaP and provide an insight in to the role
of obesity in CaP may be found in the link between obesity and insulin resistance and
the ensuing compensatory chronic hyperinsulinaemia. This hyperinsulinaemia state
leads to reduced IGF binding protein (IGFBP) and a theoretical increase in the
bioavailability of free IGF (Renehan, Frystyk et al. 2006). There is also a reported
lower level of IGF-1 production by the liver. Overall it is suggested that the alteration in
IGF biology is enough to influence cancer risk (Calle, Rodriguez et al. 2003; Renehan,
Frystyk et al. 2006). This study discovered that visfatin leads to a highly significant up
regulation of IGFR at four hours with exogenous visfatin treatments and this appeared
to be sustained at 24 hours although not statistically found to be significant. Given that
visfatin levels are postulated to be elevated in obesity this is further novel data that
lends support to the link between obesity and CaP via the IGF axis. Insulin has also
been shown to up-regulate fatty acid synthase (FAS) expression in hepatocytes
(Claycombe, Jones et al. 1998). FAS is a key enzyme involved in mammalian energy
homeostasis by converting surplus dietary carbohydrates to fat. FAS is also over
expressed in prostate carcinomas and is associated with an aggressive phenotype
(Baron, Migita et al. 2004), but whether hyperinsulinaemia stimulates an increase in
FAS expression in CaP cells or is linked with visfatin is as yet undocumented.
Nonetheless, this could be another feasible mechanism to link obesity/metabolic
syndrome and CaP.
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With regards to growing obesity levels worldwide it has been long publicized in the
media that increasing physical activity and dietary modifications are highly important
and can lead to dramatic improvement in obesity related morbidity and mortality with
emphasis being played on cardiovascular disease and diabetes (WHO 2000). It is
however also highly likely to reduce the risk of a variety of cancers by modulating the
many mechanisms discussed in this study including CaP. A study has shown that
physical exertion has a reduced risk of advanced prostate cancer and cancer death
(Nilsen, Romundstad et al. 2006). The evidence with respect to physical activity and
prostate cancer is very difficult to confidently discern as one cannot conclusively say
that the beneficial effects are not due to simple weight loss and to date there are no
studies showing weight loss effects on prostate cancer risk and progression.
CONCLUSIONS
In conclusion, this study has shown that visfatin may well have a role in prostate cancer
and supports the hypothesis linking obesity and prostate cancer and this has been
demonstrated by in-vitro in PC3 cells. Thus this study has provided evidence that
visfatin is proliferative in androgen insensitive cells models as well as providing
potential mechanism by which it may modulate aggressive disease by virtue of its
action on MAPKs, MMPs, and oncogenes. It has also provided some supporting
evidence that the effects of visfatin may be primarily mediated via its relevance to NMN
production. Finally it has been concluded that although this study has not confirmed a
link between obesity and circulating levels and visfatin nor increased levels in prostate
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cancer it has suggested preliminary evidence that levels may be elevated in relation to
grade of disease.
These data presented here are by in large preliminary studies. However that being
said, study has shown significant novel data and provides a basis for further
investigation into prostate carcinogenesis. It would also not be unfair to suggest that
these data have predominantly looked at prostate cancer cells lines and investigation
into visfatin and normal prostate physiology would yield helpful information into the role
visfatin may play in the development and progression of prostate cancer.
When evaluating the effects of visfatin in cell models it has been done for the most part
in isolation using an in-vitro model and needless to say, this is a far cry from the in-vivo
environment in which pathology normally ensues. Investigation using in-vivo models as
would yield more accurate data in the future. A greater insight into the mechanisms
linking obesity to cacner is important as it would allow the further development of new
therapeutic markers and prognostic indicators. It may also lend greater emphasis to
lifestyle modification and weight loss as adjuvant therapies for prostate cancer
prevention and treatment.
FUTURE STUDIES
 Objective quantification of visfatin levels in prostate cancer tissue compared to
benign prostatic tissue.
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 Use of specific MAPK inhibitors to identify if visfatin mediates its proliferative
effects via MAPK activity and also its MMP activity.
 Further studies looking at visfatin plasma and or serum levels to identify if there
is significant difference in the levels between prostate cancer patients and
benign controls and further correlations with MMP as potential biomarkers for
aggressive disease.
 To ascertain whether visfatin modulates androgen receptor status in prostate
cancer cells or vice versa to indentify if androgen status is a defining factor in
visfatin mediated effects.
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1. Introduction
Prostate cancer is the third most common male cancer world-
wide [21] and treatment modalities for advanced disease remain
limited. Early prostate cancer growth is dependent on the presence
of androgens, with androgen ablation therapy the mainstay of
treatment; however, many men fail this therapy and develop
androgen-independent disease [8]. Progression of established
prostate cancer has been associated with obesity and its metabolic
sequelae. Both tumor aggressiveness and mortality from prostate
cancer are correlated positively with body mass index (BMI) [5].
Obesity is becoming one of the most signiﬁcant and growing public
health concerns and has reached epidemic proportions with a
prevalence of 60% ormore in someWestern societies [26]. Obesity is
well established as a risk factor for type 2 diabetes, cardiovascular
disease and cancer. Speciﬁcally, visceral obesity is associated with
insulin resistance, hyperinsulinaemia and prothrombotic/proin-
ﬂammatory states [16], has also been identiﬁed as a risk factor for
prostate cancer [27]. Evidence also suggests that obesity increases
the aggressiveness of the disease [10].
Recent studies have investigated the role of adipokines as
potential mediators of molecular association between these two
disease states [20].
Pre-B cell enhancing factor (PBEF), was originally isolated from
peripheral blood lymphocytes, and described as a secreted growth
factor for early B cell proliferation [25]. More recently, however,
PBEF has also been characterized as an adipokine, being highly
expressed in and secreted by visceral adipose tissue, and has
subsequently been termed visfatin [30].
Circulating visfatin plasma concentrations as well as visceral
adipose tissue visfatin mRNA expression correlated with measures
of obesity and visceral fat accumulation [3]. Visfatin plasma
concentrations have also been shown to be markedly elevated in
obese subjects (0.037  0.008 mg/ml), compared with controls
(0.001  0.000 mg/ml) [11].
Intracellular visfatin expression has been demonstrated in
normal, inﬂamed and tumor tissues [2], and has been implicated in
chemo-resistance in breast cancer patients [9]. In human
endothelial cells, incubation with exogenous visfatin has been
shown to stimulate cell proliferation as well as inducing matrix
metalloproteinases 2-&-9 (MMP-2/9) expression and gelatinase
activity via the PI3K/Akt and mitogen-activated protein kinase
(MAPK) signaling pathways [1]. These latter cascades are crucial to
carcinogenesis.
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Use of the visfatin inhibitor, FK-866, has been shown to induce
apoptosis in tumors [12]. This further suggests that visfatin has a
signiﬁcant role to play in cancer biology.
We propose a potential role for the circulating adipokine
visfatin in prostate cancer within the obese population. To do
this we used LNCaP (androgen-sensitive) and PC3 (androgen-
insensitive) human prostate cancer cell lines as well as human
prostate tissue.
2. Materials and methods
2.1. Reagents
Recombinant human visfatin was purchased from Axxora
(Nottingham, UK). Visfatin primary antibody was purchased from
Bethyl Inc. (Montogomery, TX, USA). MAPK, b-actin primary
antibodies were purchased from Cell Signaling Technology Inc.
(Beverly, MA, USA). MMP-2 and MMP-9 primary antibodies were
purchased from Abcam plc (Cambridge, UK). All secondary
antibodieswere purchased fromDakoCytomation Ltd. (Cambridge,
UK). Normal and tumor prostate tissue cDNAwere purchased from
BioChain Institute (Hayward, CA, USA).
2.2. Subjects
Following ethical approval, parafﬁn embedded sections (3 mm
thickness) were cut from archived prostate tissue obtained from
patients undergoing transurethral prostatectomy (n = 13; mean
75.1 years; range 57–92; SEM 2.6). Sections were ﬂoated onto 3-
aminopropyltriethoxy-silicane coated slides. All patients had histo-
logically diagnosed prostatic adenocarcinoma, and cut sections had
foci of benign and malignant tissue.
2.3. Cell culture
LNCaP and PC3 cells (ATCC, Manassas, VA, USA) were cultured
as previously described [19]. Cells were seeded onto 6-well plates
and cultured to pre-conﬂuence prior to treatments. Cells were
allowed to attach for 24 h and subsequently were incubated with
visfatin at varying concentration ranges and time points to analyze
MAPK and MMPs. For proliferation assays cells were uniformly
seeded into 96-well plates cultured for 24 h and incubated with
serum-free media for 16 h before treatment with visfatin.
2.4. RNA extraction and quantitative RT-PCR
RNA was extracted using Qiagen RNeasyTM Plus Mini-Kit
(Crawley, UK) and RNA was reverse-transcribed into cDNA using
500 ng RNA, random hexamers and 200 units RevertAid H minus
M-MuLV Reverse Transcriptase. RT-PCR of visfatin was performed
using the Roche Light CyclerTM system (Roche, Mannheim,
Germany). Reaction mixtures contained SYBR1 Green (Roche,
Mannheim, Germany) and 1.5 ml cDNA. PCR conditions consisted
of denaturation at 95 8C for 1 min, 40 cycles of 95 8C for 1 s, 59 8C
for 10 s and 72 8C for 15 s, followed by melting curve analysis. The
primers used were: visfatin (forward: 50-AAGAGACTGCTGGCA-
TAGGA-30, reverse: 50-ACCACAGATACAGGCACTGA-30); b-actin
(forward: 50-AAGAGAGGCATCCTCACCCT-3, reverse: 50-TACATGG-
CTGGGGTCTTGAA-30). With regards to PCR for MMP analysis,
protocol conditions consisted of denaturation at 95 8C for 15 s,
followed by 40 cycles of 94 8C for 1 s, 60 8C for 5 s, and 72 8C for
12 s, followed by melting curve analysis. For analysis, quantitative
amounts of MMP-2, MMP-9 were standardized against the
housekeeping gene GAPDH. The primers used were: MMP-2
forward: 50-TGGCAAGTACGGCTTCTGTC-30, reverse: 50-TTCTTGTC-
GCGGTCGTAGTC-30; MMP-9 50-TGCGCTACCACCTCGAACTT-30,
reverse: 50-GATGCCATTGACGTCGTCCT-30. For all reactions a no
template control and also RT-negative was used as standard. With
respect to MMP analysis IGF [10 ng/ml] was also used as a positive
control.
2.5. Immunocytochemistry and confocal analysis
Cells were cultured onto poly-L-lysine-coated glass cover slips
for 48 h and ﬁxedwith 4% paraformaldehyde. Non-speciﬁc binding
was inhibited by incubating cells with 3% BSA in PBS–0.01% Triton
X-100 for 1 h at room temperature. Cells were incubated with
primary rabbit anti-human visfatin antibody (1:100) overnight at
4 8C. After washing with PBS–0.05% Tween, cells were incubated
with secondary conjugated donkey anti-rabbit antibody, Alexa
Fluor1 488 (Invitrogen, Paisley, UK). Following further washes
cover slips were mounted on slides with glycerol containing 40-6-
diamidino-2-phenylindole (DAPI) nuclear marker (Invitrogen,
Paisley, UK). Images were acquired using a Leica SP2 confocal
laser scanningmicroscope system linked to a Leica DMRE7 upright
microscope and a 40 oil immersion lens.
2.6. Immunohistochemical analysis
Prostate tissue sections were prepared and immunohistochem-
istry performed as previously described [19]; 1:200 primary rabbit
anti-human visfatin antibody was used.
2.7. Proliferation assay
Cells were treated with visfatin [0–400 ng/ml] for 24 and 48 h.
Cell proliferation was assayed using CellTiter 961 AQueous One
Solution Cell Proliferation Assay (Promega,Madison,WI, USA). This
is a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS)-based assay that quantiﬁes
the amount of formazan produced by metabolically active cells as
measured by absorbance at 490 nm using a spectrophotometric
plate reader, which is directly proportional to the number of living
cells in culture (according to product literature).
2.8. Western blot analysis
The effect of visfatin on activation of the MAPK (ERK-1/2 and
p38) as well as MMP-2 and MMP-9 protein expression in LNCaP
and PC3 cells was studied using Western blotting analysis.
Following treatment with visfatin at times points between 0
and 60 min for MAPK activity and at 24 h for MMP analysis, cells
were lysed with Ripa buffer (containing; 0.5 M Tris–HCl, pH 7.4,
1.5 M NaCl, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA).
Samples were centrifuged and quantiﬁed and subsequently boiled
prior to use.
For MAPK analysis 40 mg of each sample was loaded; for MMP
analysis 80mg was used. Each sample were separated by 10%
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(SDS-PAGE), and electro-blotted onto a polyvinylidene ﬂuoride
(PVDF) membrane (Millipore, Bedford, MA, USA). The PVDF
membrane was then blocked by incubating with 5% bovine serum
albumin (BSA; Sigma–Aldrich, Gillingham, UK) in 1 M Trizma/base,
1.54 M NaCl, 0.05% Tween 20 (tris-buffered solution (TBS) plus
Tween 20 (TBS-T), pH 7.4) for 1 h at room temperature.
Membranes were then incubated with primary antibody phos-
phorylated ERK 1/2, phosphorylated p38 (rabbit polyclonal 1:2000
diluted in 5% BSA/TBS-T), MMP-2 or MMP-9 (mouse monoclonal
1:400 diluted in 5% BSA/TBS-T) overnight at 4 8C. Membranes were
thenwashed thoroughly for 60 min at room temperaturewith TBS-
T (0.1%) followed by incubation with a secondary anti-mouse
horseradish-peroxidase-conjugated secondary antibody (1:2000
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dilution) for 1 h at room temperature. Antibody complexes were
visualized using chemiluminescence (ECL; GE Healthcare, Little
Chalfont, UK). To determine MAPK activity the membranes were
stripped and re-probed with primary antibody for total MAPK.
Band densities were measured using a scanning densitometer
coupled to scanning software Scion ImageTM (Scion Corporation,
Maryland, USA). In addition to quantitative loading of gels, the
MMPmembranes were also re-probed with b-actin antibody (Cell
Signaling Technology Inc., Beverly, MA, USA; 1:10,000 dilution) to
determine equal protein loading.With respect toMMP analysis IGF
[10 ng/ml] was used as a positive control. studies have demon-
strated a role for IGF in in vitro prostate cancermodels with respect
to MMP-2,-9 [24].
2.9. Gelatin zymography
The gelatinolytic activity of MMP-2 and MMP-9 secreted into
culture supernatants following treatment with 0–800 ng/ml
visfatin was measured by gelatin zymography. 10 ml of culture
supernatant was mixed with 10 ml zymography sample buffer and
Fig. 1.Visfatin expression in LNCaP and PC3 humanprostate cancer cell lines and humanprostate tissue. (A) VisfatinmRNA expression in the LNCaP (LN) and PC3 (PC) prostate
cancer cell lines. Human fat (HF) cDNA was used as a positive control. Visfatin mRNA was also detected in normal prostate tissue (NP) and prostate adenocarcinoma tumor
tissue (TT) cDNA. (B) Immunocytochemical and confocal analysis were used to study visfatin protein expression in LNCaP and PC3 prostate cancer cell lines. Visfatin protein
was detected in the cytoplasm of both cell lines (green), and following co-visualization with the DAPI nuclear marker (blue), nuclear staining for visfatin was also detected in
LNCaP cells (arrowed). (C) Immunohistochemical analysis of benign and adenocarcinomatous human prostate cancer tissue. Visfatin expressionwas detected in the glandular
epithelial cells of both benign (i and ii) and malignant tissue (iii and iv), with evidence of cytoplasmic and nuclear staining. Negative controls shown.
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resolved in 10% SDS-PAGE containing 1 mg/ml of gelatin (Sigma, St.
Louis, USA) under non-reducing conditions. Following electro-
phoresis at 4 8C, gels were washed twice for 30 min with
renaturation buffer (2.5% Triton X-100) at room temperature,
and then incubated overnight in incubation buffer (50 mM Tris–
HCl pH 7.5, 200 mM NaCl, 10 mM CaCl2, 1 mM ZnCl2) at 37 8C.
Characterization of MMP activity was determined by inhibition
with 10 mM EDTA. Following incubation, gels were stained for 1 h
buffer 0.25% Coomassie Brilliant Blue R-250 (in 45% methanol and
10% acetic acid), and then destained in the same buffer without
Coomassie. Following de-staining, gelatinolytic activity of secreted
MMP was observed as white bands against a blue background,
which were quantiﬁed by measuring the band intensity [Gel Pro
image analysis (Gel Pro 4.5, Media Cybernetics, USA)]. IGF [10 ng/
ml] was used as a positive control.
2.10. Statistical analysis
Data are shown asmean  SEM. Repeatedmeasures ANOVAwith
post hoc Tukey’s multiple comparison test was employed to calculate
the signiﬁcance of differences in themeans between different groups;
signiﬁcance was determined at p < 0.05.
3. Results
3.1. Visfatin mRNA expression in prostate cancer cell lines and
human prostate
Using RT-PCR, visfatin mRNA was detected in both cell lines
studied, with agarose gel electrophoresis yielding an expected 249
base pair product. Visfatin gene expression was also present in
cDNA prepared from mRNA obtained from normal and malignant
human prostate tissue (Fig. 1A); sequencing analysis conﬁrmed the
identity of these products (data not shown).
3.2. Visfatin protein expression in prostate cancer cell lines and
prostate tissue
Visfatin staining was demonstrated in LNCaP and PC3 cells
using immunocytochemistry and confocal analysis (Fig. 1B).
Visfatin staining showed a predominantly cytoplasmic distribu-
tion, although there was also evidence of nuclear staining in LNCaP
cells (Fig. 1Bii arrow).
Immunohistochemistry was used to study visfatin expression
in human benign and malignant prostate tissue (Fig. 1C). Visfatin
Fig. 2. (A and B) Effect of visfatin on LNCaP and PC3 cell proliferation. Effect of visfatin alone [0–400 ng/ml] on (A) PC3 and (B) LNCaP cell proliferation. 24 h data are expressed
as relative to basal proliferation; n = 4 for all experiments, *p < 0.05, **p < 0.01, ***p < 0.001 (C–F) The effect of visfatin on MAPK (ERK 1/2 and P38) activity in PC3 cells. (C)
Representative western blot showing changes in pERK/tERK expression following treatment with 400 ng/ml visfatin at varying time points of incubation 0–30 min; lanes
correspond to bar chart. (D) Bar chart showing quantiﬁcation of changes in ERK activation in PC3 cells. Data represent means  SEM of three experiments; *p < 0.05 compared
to basal expression. (E) Representative western blot showing changes in p-p38/t-p38 expression following treatmentwith 400 ng/ml visfatin at varying time points of incubation 0–
30 min; lanes correspond to bar chart. (F) Bar chart showing quantiﬁcation of changes in p38 activation in PC3 cells. Data represent means  SEM of three experiments; *p < 0.05,
**p < 0.01, ***p < 0.001 compared to basal expression.
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staining was detected in both benign and malignant tissue, with
glandular epithelial cells showing high levels of expression.
Interestingly, visfatin demonstrated both nuclear and cytoplasmic
staining in both normal and malignant cells.
3.3. Effect of visfatin on LNCaP and PC3 cell proliferation
Visfatin treatment alone resulted in a signiﬁcant concentra-
tion-dependent increase in proliferation after 24 h incubation
in PC3 cells (p < 0.001 at 200 and 400 ng/ml) (Fig. 2A). In
contrast treatment with visfatin alone had no signiﬁcant effect
on LNCaP cell proliferation (Fig. 2B). Given that there was no
functional outcome in the LNCaP cell line no further studies
were conducted.
3.4. Effect of visfatin on MAPK activity
Visfatin treatment of PC3 cells resulted in a signiﬁcant
activation of ERK1/2 after 10 min at a treatment dose of
400 ng/ml which corresponded to the maximal proliferative
effect of visfatin (p < 0.05) (Fig. 2D). There was also a signiﬁcant
increase in p38 activity after 2 min incubation with visfatin
[400 ng/ml] (p < 0.05) and subsequently rapidly returning to
basal levels after 10 min (Fig. 2F). We observed no signiﬁcant
effect of visfatin on MAPK activity in the LNCaP cell line (data not
shown).
3.5. Effect of visfatin/IGF-1 on MMP-2 and MMP-9 expression
mRNA expression of both MMP-2 and MMP-9 was signiﬁcantly
increased following treatment with all doses of visfatin studied
(p  0.05); the greatest increases were seen in MMP-9 expression.
Addition of 10 ng/ml IGF-1 alone also signiﬁcantly increased both
MMP-2 and MMP-9 expression (Fig. 3).
The effect of visfatin on MMP-2 and MMP-9 protein expression
was studied using Western blotting. We found that the changes in
mRNA expression of these MMPs were also associated with
corresponding signiﬁcant increases in protein expression
(p  0.05) (Fig. 4A and B).
No signiﬁcant effects on MMP-2 or MMP-9 mRNA or protein
expression were detected in LNCaP cells following treatment with
visfatin or IGF-1 (data not presented).
3.6. Effect of visfatin on secreted MMP-2 and MMP-9 activity
The effect of visfatin  IGF-1 on the activity of secreted MMP-2
and MMP-9 by PC3 cells was studied using gelatin zymography.
Visfatin induced a concentration-dependent increase in MMP-2
activity that was signiﬁcant at concentrations over 400 ng/ml
(p  0.05); 10 ng/ml IGF-1 alone also signiﬁcantly induced MMP-2
activity (p < 0.001) (Fig. 4C and D). MMP-9 also showed a dose-
dependent increase in activity following treatment with visfatin
which was signiﬁcant at concentrations over 400 ng/ml (p < 0.001).
IGF-1 alone also signiﬁcantly increased MMP-9 activity (p < 0.001)
Fig. 3. The effect of visfatin/IGF-1 on MMP-2 and MMP-9 mRNA expression in PC3
cells. Bar chart showing quantiﬁcation of changes inMMP-2/-9mRNA expression in
PC3 cells. Data represent means  SEM of three experiments; *p < 0.05, **p < 0.01,
***p < 0.001, compared to basal expression.
Fig. 4. The effect of visfatin/IGF-1 on MMP-2 protein expression and secreted MMP-2 activity in PC3 cells. (A) Representative western blot showing changes in MMP-2/-9
expression following treatment with 0–800 ng/ml visfatin or 10 ng/ml IGF-1; lanes correspond to bar chart. (B) Bar chart showing quantiﬁcation of changes in MMP-2/-9
expression in PC3 cells. Data represent means  SEM of three experiments; *p < 0.05, **p < 0.01, ***p < 0.001, compared to basal expression. (C) Representative zymography gel
showing changes in MMP-2/-9 activity following treatment with 0–800 ng/ml visfatin or 10 ng/ml IGF-1; lanes correspond to bar chart. (D) Bar chart showing quantiﬁcation of
changes in MMP-2/-9 activity in PC3 cells. Data represent means  SEM of three experiments; *p < 0.05, **p < 0.01, ***p < 0.001, compared to basal expression.
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(Fig. 4C and D). Again, visfatin had no signiﬁcant effect on LNCaP cell
MMP activity (data not shown).
4. Discussion
Obesity is gaining recognition as an important risk factor for
high grade prostate cancer and also an increased risk of prostate
cancer mortality compared to the non-obese population [4]. There
is growing evidence to suggest that adipokines may play an
important role in mediating this association, and we have
investigated the possible role of the adipokine visfatin on prostate
cancer progression.
In addition to its identiﬁcation as a circulating adipokine,
visfatin has been identiﬁed as an intracellular enzyme (NMPRTase)
and thus we investigated the expression of visfatin in the
established prostate cancer cell lines LNCaP and PC3 and human
prostate cancer tissue. This is the ﬁrst study to demonstrate
visfatin expression in these prostate cancer cell lines and tissue,
however, its expression in both normal and tumor tissues other
than the prostate [9,14,25] has been demonstrated. Previous
studies have shown nuclear and cytoplasmic staining for visfatin in
both adrenal cells and ﬁbroblastswhich is thought to be dependent
on the stage of the cell cycle [18]. In our study, we detected both
cytoplasmic and nuclear staining for visfatin which is in
accordance with these ﬁndings. Immunohistochemical analysis
did not identify any signiﬁcant difference between cancerous and
benign sections of tissue. Further quantitative studies are needed
to assess the importance of this observation. Although we
demonstrated comparable gene expression as well as intracellular
visfatin protein levels in this study, we report clear differences in
the proliferative response of the two different prostate cancer cell
lines to visfatin. Visfatin-induced increases in cell proliferation
were observed in PC3 cells but not LNCaP cells, suggesting that
circulating visfatin can exert differing effects based on cell
characteristics. One of the key differences in the characteristics
of the two cell lines used is the androgen status of these cells. PC3
cells represent an in vitromodel for androgen-insensitive prostate
cancer, and thus do not express the classical intracellular androgen
receptor (AR) as compared to the androgen-sensitive LNCaP cells.
The difference in response to visfatin between the two cell lines
raises the possibility of androgen or androgen receptor status being
of potential signiﬁcance in the modulation of prostate cancer cell
biology by visfatin. It is also a possibility that the absence of
androgen in the treatment media may have inﬂuenced the results
seen in the ‘androgen-sensitive’ LNCaP cell line. Future studies to
strengthen these ﬁndings in this cell line could therefore involve
comparing visfatin exposure in the presence and absence of
androgen. The possibility of an interaction between AR and visfatin
in prostate cancer cells is also an area for future research but falls
beyond the remit of this paper.
The effect on proliferation was demonstrated in a concentra-
tion-dependent manner and perhaps more importantly at levels
of visfatin similar to those that have been demonstrated in the
obese population [11]. This provides novel evidence that elevated
levels of circulating visfatin may inﬂuence the growth of prostate
cancer tissue.
Given that visfatin treatments increased cell proliferation, we
investigated two common MAPKs implicated in cell viability/
apoptosis. ERK1/2 is generally associated with mitogenesis and
therefore inversely related to apoptosis [6]. We demonstrate an
increase in ERK1/2 activity after 10 min which is consistent with
our functional studies. In keeping with our results, ERK activation
has been previously demonstrated in PC3 cells following incuba-
tion with leptin, also an adipokine [7]. Other groups have also
demonstrated visfatin as an activator of ERK1/2 in other tissues
including endothelial and smooth muscle cells [17,28].
Interestingly we also found a signiﬁcant increase in p38
activation after 2 min. p38 has been broadly associated with
apoptosis induction [6]. There is alsoevidence thatp38 increases cell
proliferation in prostate cancer in response to external stimuli and
also its over-expression is implicated in increased cell proliferation
[22]. Furthermorep38hasalsobeenshown toplayan important role
as amediator in the up regulation ofMMP-2 in prostate cancer [13].
Our data lends support to the existing data that p38 activation may
haveproliferative effects dependant on the stimulant applied, in this
case visfatin, and also that it plays a signiﬁcant role in mediating
factors responsible for prostate cancer progression.
MMP-2 and -9 are important proteases that are involved in the
breakdown of the extracellular matrix under both physiological
and pathological conditions [1,23]. More speciﬁcally, they degrade
type IV collagen, the major structural component of basement
membranes and are crucial to the process of cell migration,
invasion and metastasis. Both MMP-2 and -9 were highly
expressed in prostate cancer tissue [29] and circulating levels of
MMP-2 and -9 have also been correlatedwith bonemetastases and
tumor grade in prostate cancer patients [15]. Not only were the
effects of visfatin more notable in the PC3 prostate cancer cell line,
but they also induced signiﬁcant increases in MMP-2 and -9
expression and gelatinolytic activity. In conjunction with their
aforementioned effects on proliferation and apoptosis, it is of great
interest that both ERK 1/2 and p38 have been implicated in the
regulation of MMP-2 and -9. Visfatin induced ERK 1/2 phosphor-
ylation has been shown to regulate the production and activity of
MMPs and play a role in dysregulated angiogenesis [1] while p38
has also been shown to inﬂuence MMP-2 in prostate cancer [13].
One can speculate from these ﬁndings that a possible mechanism
by which visfatin inﬂuences prostate cancer progression may be
via an increase inMMP production and activity via visfatin induced
MAPK phosphorylation.
Our ﬁndings, particularly the increased gelatinolytic activity
seen with visfatin treatment, allows us to tentatively speculate
that the elevated circulating visfatin levels associated with obesity
may promote prostate cancer progression by enhancing the
capability of metastasis. The apparent increase in metastatic
sensitivity of the PC3 cell line supports to the theory that obesity is
an important risk factor for prostate cancer disease progression
and mortality. Further investigation of visfatin in prostate cancer
biology and investigation into the mechanisms by which visfatin
drives cell proliferation is required before any pathological or
therapeutic conclusions can be drawn.
In conclusion our novel data have demonstrated a clear
difference between androgen-sensitive and androgen-insensitive
prostate cancer cell lines with regards to visfatin induced cell
proliferation, metastatic and angiogenic potential. This potential
role for visfatin in prostate cancer may well be a signiﬁcant
contributory factor in the increased aggression of prostate cancer
in obese individuals.
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